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CHAPTER I 
GENERAL INTRODUCTION 
1.1. Hemopoietic stem cells and progenitor cells. 
Peripheral blood cells have a limited life span. Therefore, to sustain life it is 
necessary to have a continuous production of new blood cells. Hemopoiesis is 
maintained from a small population of pluripotential hemopoietic stem cells. 
Those cells, defined as PHSCs, have the capacity of both self-renewal and dif-
ferentiation into specific lineages of committed hemopoietic progenitor cells, 
which eventually differentiate into mature blood cells. This concept, depicted in 
Figure 1.1, has experimentally been substantiated by a number of observations: 
Bone marrow (BM) cells, and in mice also spleen cells, protect lethally ir-
radiated animals against death from BM failure1,2,3. Protection is due to the 
production of donor derived peripheral blood cells4,5,6. Only a small proportion 
of the injected cells contributes to production of blood cells. Transplantation of a 
small number of syngeneic BM cells following lethal irradiation results in the 
appearance of a small number of macroscopically visible colonies of hemopoietic 
cells in the spleen?. Such a colony, which is the progeny of one single cellS 
termed spleen colony forming unit (CFU-S), may grow out to a complete 
hemopoietic system9, including lymphocyteslO,II. Thus such a CFU-S has 
some characteristics of the putative PHSC. However, CFU-S have also been 
shown to be a heterogeneous group of cells 12, which are not all capable to 
repopulate a lethally irradiated recipient. Roughly, two major populations of 
CFU-S can be distinguished, one producing colonies around day 8, and the other 
13 
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Figure 1.1 Schematic representation of blood cell formation. 
around day 12. Although these populations partially overlap, a number of dif-
ferences between the two populations are generally accepted: Injection of day 12 
spleen colonies into irradiated secondary recipients results in larger numbers of 
daughter CFU-S than injection of day 8 CFU-S, indicating that the day 12 CFU-S 
have a higher self-renewal capacity B. Furthermore, day 8 CFU-S can be distin-
guished from day 12 CFU-S by differences in cell surface antigens14,15,16, in 
physical parameters, and in cell cycle status and metabolism17.18.19.20.21. Both 
populations have been demonstrated to be heterogeneous for those parameters. 
Analysis of BM regeneration following BM transplantation with grafts from 5-
14 
fluorouracil treated donor mice have indicated the existence of a more primitive 
HSC (i.e. a pre-CFU-S)17 which may give rise to CFU-S in irradiated recipients 
(marrow repopulating ability, MRA). 
Hemopoietic progenitor cells have been studied extensively in vitro using semi-
solid colony culture systems. In such cultures, individual progenitor cells of a 
particular lineage proliferate and differentiate into a clone of mature cells, which 
can be detected as a colony. Such a progenitor cell is defined as a colony-
forming unit in culture (CPU-C). Initially, only colonies, composed of 
granulocytes and macrophages have been described22,23, but more recently, 
other culture systems have been developed for progenitor cells of erythrocytes24, 
eosinophils25, megakaryocytes26,2 7, and for colonies composed of 
lymphocytes28,29. The nomenclature of all these colony forming cells has been 
described in an UICC-ICREW Report30: An affix added to the term CPU-
indicates the cells present in such a colony, for instance GM for granulo-
cyte/macrophage and Meg for megakaryocytes. A CPU-mix forms multilineage 
colonies in vitro31. 
Recent data suggest, that the capacity for self-renewal is not strictly limited to 
pluripotent cells, but is shared by committed progenitor cells and even more 
differentiated cells32. 
The current concept is that of a PHSC which is a resting, metabolically 
inactive, primitive cell. This cell can be triggered into cell cycle, thereby having 
a probability (p) of self-renewal and a probability (1-p) of maturation. 
Following one or more maturation divisions, lineage commitment occurs, which 
is irreversible. In this concept, a p-value of 0.5 in steady state implies, that the 
number of PHSCs is constant throughout life, whereas a p-value < 0.5 results in 
exhaustion of the PHSC pool. The extreme possibility, that p = 0 in steady state 
would implicate, that either the number of PHSCs at birth, or the number of cell 
divisions between PHSCs and mature cells is extremely high33,34,35. The 
evidence for the capacity of PHSC self replication, summarized above, argues 
against a p-value being 0. 
It is poorly understood, ho.w PHSCs become committed to restricted pathways 
of differentiation. Restriction in differentiation potentials could be intrinsically 
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determined either in a stochastic36 or in an hierarchically branched manner37. 
Alternatively, restriction in differentiation potentials could be determined by 
external influences, such as stromal cells and cytokines38,39. Generally, the 
probability of self renewal is considered to be lower in more mature progenitor 
cells as compared to more primitive cells32. The precise relationships between 
the various committed lineages remain unresolved, and different hierarchical 
orders can be argued40. 
The process of hemopoiesis is tightly regulated, so that functional end cells are 
produced in response to peripheral demands. In this process, hemopoietic growth 
factors play a role, which will be discussed in the next section. 
Characterization of HSCs is essential for the development of methods to 
eliminate unwanted cells, such as T lymphocytes or malignant cells from BM 
grafts without loss of the critical HSCs. Furthermore, characterization and 
purification of HSCs is of importance for investigations concerning the influence 
of hemopoietic growth factors (see section 1.3) on self replication and/or 
differentiation of HSCs. In addition. characterization and purification of HSC is 
necessary for studies on the genetic control of stem cell differentiation, which 
needs to be elucidated to make gene therapy in hemopoietic stem cells feasible. 
Studies in mice have shown, that PHSCs are archetypal round cells, 
ultrastructurally distinct from lymphocytes41. The existence of a similar BM cell 
has been confirmed in rats, Rhesus monkeys, and humans42,43,44. The subsequent 
use of cell surface markers and light activated cell sorting has enabled the 
preparation of highly purified murine HSC suspensions. By using this 
technology, grafts of only 102 cells appeared to be sufficient to protect a lethally 
irradiated mouse from BM failure45.46. Among the cell surface markers avail-
able to isolate immature human hemopoietic cells, the CD34 antigen, identified 
by the MCAs My-1047, 12-848, BI-3C549, ICH350, and other MCAs, is of 
outstanding interest, since it is mainly expressed on immature hemopoietic cells 
of various differentiation lineages, including hemopoietic progenitor cells such 
as CFU-mix, CFU-GM, and BFU-E. Moreover, CD34 is present only on 1-4% 
of human BM cells and is not co-expressed with lymphatic markers (CD2, CD3, 
CD4, CDS, CD7, and CD8) and myeloid markers (CDll, CD14, CD15, CD16, 
16 
and CD18)51. 
The monoclonal antibody ICH3 is distinct from the other three in that it is a 
high avidity antibody of IgG 2a isotype that recognizes a peptide epitope and 
does not modulate or have any effector function such as complement (C') lysis. 
These properties make ICH3 preferentially suited for positive selection of HSCs 
for BM transplantation. My-10 and BI-3C5 do not cross react with Rhesus 
monkey BM cells at al152. In Chapter ill, the cross reactivity of the MCA ICH3 
will be described. This MCA has been used for positive selection of HSCs. In 
most of the studies in rodents, the enrichment of HSCs was monitored by a 
quantitative functional assay, that is, the spleen colony assay (SCA). In outbred 
species, such as Rhesus monkeys and humans, the most primitive detectable cell 
is measured as CPU-mix. However, the development of a complete hemopoietic 
system out of the progeny of a CFU-mix has never been demonstrated. Thus, the 
relationship between the CFU-mix and PHSCs is less well established than the 
relationship between the CFU-S and PHSCs. Studies on the nature of human 
PHSCs have been limited by the lack of a suitable assay, and by a restricted 
possibility for in vivo studies. Recently, an in vivo HSC assay in Rhesus monkeys 
has been developed in our laboratory53. This assay enables a quantitative com-
parison between enrichment of repopulating HSC as calculated from the in vivo 
regeneration rate and the enrichment of progenitor cells as calculated from in 
vitro assays. In Chapter ill, this assay will be used to monitor the positive selec-
tion of HSCs, based upon CD34 expression. 
1.2. Radiosensitivity of hemopoietic stem cells. 
Irradiation of the total body (TBI) with ionising radiation causes a dose 
dependent BM suppression. The severity and duration of the resulting pancyto-
penia depends on the number of repopulating HSCs that survive the irradiation. 
Following a BM ablative dose of TBI, hemopoiesis can only be restored by BM 
transplantation. Following lower doses of TBI, BM transplantation might reduce 
mortality and morbidity by shortening the duration of pancytopenic period54,55. 
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Therefore, a number of victims of accidental irradiation at nuclear power 
stations at Vinca (Yugoslavia) and Chemobyl (Soviet Union) have been treated 
with BM transplantation56,57,58. However, the conditions for a beneficial effect 
of BM transplantation in victims of radiation accidents are not accurately 
known59. The number of HSCs, that survive the irradiation and the damage to 
other organ systems are the major factors determining the benefit of BM 
transplantation. Observations in untransplanted victims of radiation accidents and 
nuclear warfare resulted in estimates of the LDso for TBI in humans varying 
from 2- 6 Gy60, but these values have no general significance, since survival of 
such victims is not only dependent on the number of HSCs that survived the ir-
radiation, but also on the degree of damage to other body systems, and on the 
efficacy of supportive care, including prevention and treatment of infections and 
transfusion of blood products. Furthermore, accidental irradiation is, in general, 
not distributed and absorbed homogeneously, resulting in a surviving HSC 
fraction which may be higher than after a comparable dose of homogeneous 
TBI. Unfortunately, there is no appropriate assay for human, and information 
about the radiosensitivity and frequency of human HSCs is scanty. Reliable infor-
mation on the radiosensitivity and frequency of the HSCs is essential for the de-
velopment of treatment regimens for victims of radiation accidents, and for im-
provement of treatment modalities for cancer patients requiring TBI. 
In rodents, survival of HSCs after irradiation has been determined using the 
spleen colony assay. In larger animals only data on the radiosensitivity of CFU-
Cs are available. The radiation sensitivity of HSCs and progenitor cells in differ-
ent species has been extensively reviewed by Hendry and Lord61. Representative 
data from this review are summarized in Table 1.1. Most of these studies 
concern measurements in the range between 0 and 5 Gy. The differences 
between the reported Do values of the CFU-S could be explained by differences 
in dosimetry, differences in genetics, age and sex of the mice. In the case of in 
vitro irradiations differences in oxygenation62 or pH63 may also have influenced 
the reported radiosensitivity. Recently, the Do value of day 7 CFU-S,· day 12 
CFU-S and MRA of mice have been compared, yielding a higher Do value for 
cells that are considered to be more primitive (for 300 kV X-rays 0.75, 0.94 and 
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1.18 Gy 64,65 respectively). This increase in radiosensitivity during maturation is 
unexpected, since more primitive cells are generally regarded to be -more 
radiosensitive. 
A dose of 10 Gy TBI, given at a dose rate of 0.02 Gy/min has been reported to 
result in a similar cell kill as a dose of 7.2 Gy TBI, given as a flash irradiation66. 
However, other authors could not demonstrate such an effect of the dose rate on 
the survival of CPU-S67,68. A small shoulder in the dose-survival curve was 
demonstrated by almost all authors. This shoulder is characterized by an extrapo-
lation number of about 2 for A (range 1.0-4.0) as well as X-rays (range 0.8-
5.2). Apparently, cells capable of protecting lethally irradiated mice have 
approximately the same radiosensitivity as CFU-S. 
In most studies, CPU-C appeared to be less radiosensitive than CPU-S. The 
canine CPU-C have a lower Do value than the human and the murine CPU-C. 
This might be due to a higher radiosensitivity of the canine CPU-C, but the 
influence of culture conditions on the Do value of CPU-C cannot be ruled out69. 
No data are available on the radiosensitivity of Rhesus monkey CPU-C. 
The only estimate of radiosensitivity of HSCs in larger animals was provided 
by Vriesendorp and van Bekkum70. Based on a comparison of LDso;30days for 
TBI to the autologous BM rescue dose in lethally irradiated animals, it was 
postulated, that the radiosensitivity of HSCs was similar for mice, rats, dogs, and 
Rhesus monkeys, but that the frequency of HSCs was negatively correlated with 
body weight. 
Intensive supportive care, including prevention of infections by prophylactic 
gastrointestinal decontamination, balanced fluid supply, and thrombocyte transfu-
sions, permit the study of endogenous regeneration patterns following doses of 
TBI, that were formerly assumed to be midlethal or lethaL By comparison of 
sue~ endogenous regeneration patterns to the regeneration following well 
defi:Qed autologous BM grafts, the radiation sensitivity of HSCs can be directly 
assessed. In Chapter IV, such an assessment is described for Rhesus monkeys, 
and the consequences for the clinical management of radiation casualties and for 
clinical BM transplantation will be pointed out. 
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TABLE 1.1 RADIOSENSITIVITY OF HEMOPOIETIC STEM CELLS AND 
PROGENITOR CELLS IN DIFFERENT SPECIES 
In vitrQ irradiation In vivo irradiation 
Species cell Radiation Do (Gy) Extra- Do (Gy) Extra- Reference 
type type mean± s.e. po1ation mean± s.e. po1ation 
number (R = Rontgen) number 
Mouse CFU-S r* 1.15 ± 0.08 2 7 
1.05 ± 0.13 2.5 0.95 ± 0.09 1.5 71 
' 0.93 ± 0.07 1.9 ± 0.8 0.98 ± 0.09 1.7 ± 0.6 72 
1.55 1.2 73 
0.86 ± 0.06 2.5 ± 0.7 74 
1.16 ± 0.10 1.2 ± 0.3 68 
X** 0.62 4.0 0.73 2.4 75 
1.04 ± 0.04 1.0 1.05 1.2 76 
0.67 ± 0.07 2.2 ± 1.2 0.70 ± 0.04 2.4 ± 0.5 72 
0.81 ± 0.05 0.9 77 
Repopu- X 1.05 ± 0.24 1 78 
1ating 0.84 (R/100) 2.5 79 
stem cell+ 
MRA X 1.18 65 
CFU-C 'Y 1.60 1 80 
1.60 ± 0.15 1.0 ± 0.2 81 
X 0.7 (R/100) 1 82 
1.57 ± 0.11 1.09 77 
BFU-E X 0.69 ± 0.09 0.89 77 
CFU-MIX X 1.44 ± 0.30 1.03 77 
Rat CFU-S 'Y 0.94 4.1 0.97 5.2 83 
Dog CFU-C 'Y 0.61 ± 0.02 84 
0.70 (R/100) 0.8 85 
BFU-E X 0.153 ± 0.018 1.05 ± 0.28 86 
Repopu- X 0.6 1 70 
lating 
stem cell 
* 60Co or 137 Cs y-rays 
•• 200 . 300 kV X-rays 
+ measured by 30 day survival of lethally irradiated animals. 
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Cont. Table 1.1 
Species cell Radiation Do (Gy) Extra- Do (Gy) Extra- Reference 
type type mean± s.e. po1ation mean± s.e. po1ation 
number (R = Rontgen) number 
Rhesus Repopu- X 0.6 1 70 
monkey 1ating 
stem cell 
Man CFU-C y 1.37 1.0 80 
1.60 1.0 69 
X 1.46 ± 0.12 1.0 87 
BFU-E X 1.27 ± 0.11 1.0 87 
1.3. Cytokines involved in the lympho-hemopoietic system. 
1.3 .1. Regulation of the production of blood cells. 
In humans, the process of hemopoiesis results in an average daily pro-
duction of about 1011 new blood cells88. In spite of this large daily 
production of at least 8 different blood cell types with markedly different life 
spans and therefore different production rates, the peripheral blood cell 
counts undergo only moderate fluctuations, even during states of increased 
demand, such as blood loss or infection. This is only possible, because hemo-
poiesis is tightly regulated. Furthermore, certain perturbations, such as 
resulting from infections, require, that specific blood cell types, such as 
lymphocytes, exert specific functional activities. 
Hormone-like peptide compounds, termed cytokines, influence cell 
proliferation and functional activity of the lymphohemopoietic system. Three 
different nomenclatures have been developed to designate these regulators: 
Interleukins (ILs), Interferons (IFNs) and Hemopoietic Growth Factors 
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TABLE 1.2 HUMAN CYTOKINES AFFECTING THE FUNCTION AND PRODUCTION 
OF BLOOD CELLS 
Factor Synonyms 
INTERFERONS 
IFN-a 
and 
IFN-B 
IFN-y 
INTERLEUKINS 
ILl Hemopoietin 1, 
Leukocytic endogenous 
mediator. 
Osteoclast activating factor, 
Lymphocyte activating 
factor. 
IL2 T cell growth factor 
IL3 Multi-CSF 
IL4 B cell stimulating factor 1 
B cell growth factor 
IL5 B cell growth factor 2 
IL6 B cell stimulating factor 2 
B cell differentiating factor 
IFN-B-2 
Hepatocyte stimulating 
factor 
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Biological effects 
Induces Class I expression. 
Stimulates NK activity. 
Antiproliferative effects. 
Induction of fever. 
Induces Oass I and II 
expression. 
Stimulates NK activity. 
Augments or inhibits 
effects of other cytokines 
Synergism with other HGFs. 
Induces synthesis of G-CSF 
GM-CSF, M-CSF. 
Osteoclast activation. 
Natriuresis. 
Acute phase response. 
Proliferation of 
activated T cells. 
Induces synthesis of 
other cytokines. 
See below 
Proliferation of 
activated B cells. 
Induces Class II expression 
onB cells. 
Proliferation ofT cells 
and mast cells. 
Induces synthesis of 
G- and M-CSF in fibroblasts. 
Stimulates growth 
and differentiation 
of B lymphocytes 
and eosinophils 
Synergism with 
GM-CSF and IL3 
in colony induction. 
Cellular 
Source 
activated 
T Lymphocytes 
activated 
Lymphocytes 
Macrophages 
Keratinocytes 
Glial cells. 
Endothelial cells 
Lymphocytes. 
Neutrophils 
T Lymphocytes 
activated 
T Lymphocytes 
T lymphocytes 
activated 
T Lymphocytes 
Fibroblasts 
Reference 
89 - 95 
96 - 99 
100- 134 
135- 143 
144- 146 
147- 148 
89 - 91 
149- 162 
Cont. Table 1.2 
Factor Synonyms Biological effects 
HEMOPOIETIC GROWTH FACTORS 
Erythro- Hemopoietine Stimulates CFU-E and 
poietin a subpopulation of 
(Ep) BFU-E. 
Multi- IL3, Stimulates stem cells 
CSF Stemcell Activating Factor and progenitor cells 
(SAF) of all lineages. 
GM-CSF CSF-a, Stimulates progenitor 
Pluripoietin, cells of several lineages. 
CSF-2 Induces M-CSF synthesis. 
Stimulates mature 
neutrophil functions. 
G-CSF CSF-B, Stimulates neutrophil 
progenitors and 
neutrophil function. 
M-CSF CSF-1 Stimulates monocyte/ 
urinary CSF macrophage progenitors. 
Induces synthesis 
ofiFN, TNF 
and G-CSF. 
Cellular 
Source 
Kidney 
cells 
T -lymphocytes 
T -lymphocytes 
Monocytes 
Fibroblasts 
Macrophages 
Fibroblasts 
Endothelial cells 
Macrophages 
Fibroblasts 
Endothelial cell 
Reference 
163- 177 
178-187 
188- 225 
226-239 
240-248 
(HGFs), the latter including the colony stimulating factors (CSFs) and some 
of the ILs and IFNs. Originally, these peptides have been named according to 
their biological effect. For instance, B-cell differentiating factor induces 
differentiation of activated B-cells, and T-cell growth factor stimulates T-
cells to proliferate. This descriptive nomenclature appeared to be 
unsatisfactory, since most of these cytokines exert multiple biological 
activities. Therefore, a nomenclature has been developed that employs the 
term IL followed by a number. 
IFNs were originally identified on the basis of the capacity to interfere with 
viral replication in infected cells. Three types of IFN are known: a-IFN, ~-
IFN, which is structurally related to a-IFN and y--lFN. 
CSFs stimulate HSCs and/or progenitor cells to proliferate and differentiate 
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in vitro, which under appropriate culture conditions results in colony 
formation. The nomenclature of the CSF resembles the nomenclature of the 
CFUs: a prefix indicates the major type of colony produced. G-CSF 
stimulates the formation of granulocyte colonies, M-CSF stimulates the 
formation of monocyte colonies, multi-CSF stimulates the formation of a 
variety of colonies. The present nomenclature of CSFs remains somewhat 
confusing. For example, GM-CSF was initially described as a factor 
stimulating the formation of granulocyte and/or macrophage colonies 188, 
whereas it is now clear, that it induces also colonies of other cell lineages 189. 
For some of the HGFs , such as M-CSF, the amino acid sequence homology 
of the protein is high between the human and the murine factor is high with 
functional cross reactivity, i.e. stimulation of murine cells by the human 
factor and/or inversely, has been demonstrated. Other factors, such as IL-3 
have much less homology and interspecies cross reactivity does not occur. 
The three different nomenclatures are imperfect and partially overlapping: 
IL-3 is a synonym of multi-CSF, and IL-6 (B cell growth factor and 
hepatocyte stimulator factor) which is identical to IFN-132 also acts 
synergistically with GM-CSF and IL-3 in the stimulation of colony 
formation154. 
Nowadays, a number of those cytokines have been isolated and the genes, 
coding for them have been cloned. This allows for the production and 
purification of these hormones on a large scale, enabling in vivo 
manipulation of the hemopoietic and immune system by the administration of 
pharmacological amounts of these substances. The most important factors and 
their major characteristics are listed in Table 1.2, and will be discussed 
below. 
a and 6 IFN induce Class I histocompatibility antigen expression, aug-
ment natural killer (NK) activity92, and have fever inducing and anti-
proliferative properties. y IFN induces the expression of Class I and Class IT 
histocompatibility antigens on a variety of cells. Furthermore, y-IFN 
augments NK activity, augments or inhibits the activity of other cytokines96. 
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The direct antiproliferative effects of interferons and the ability of these 
cytokines to activate NK cells have provided the rationale for clinical trials 
of IFN s in cancer patients92-95. 
IL2, a 17 to 22 kD glycoprotein, which has a central role in the immune 
responsel37, can be considered as the prototype of an interleukin. The gene 
encoding for human IL2 has been cloned143. IL2 initiates proliferation of 
activated T-cellsl38,139. Activation ofT cells by the specific antigen results in 
the appearance of high-affinity receptors for IL2. The binding of IL2 to 
these receptors result in T -cell proliferation. Elimination of the antigen 
results in the involution of these receptors and the cessation of prolifer-
ation135. IL2 further induces the secretion of other cytokines, such as IFNA, 
tumor necrosis factor (TNF) and IL4140. IL2 enhances the cytolytic activity 
of natural killer cells141. This property has led to clinical trials with IL2 in 
cancer patients. IL2 has been used alone and in combination with lymphokine-
activated killer cells. Although this immunotherapeutic approach has severe 
side effects, it may cause marked tumor regression in some patients 142. The 
value of this treatment remains to be established. 
IL4 was originally identified on the basis of its ability to induce prolifer-
ation of T lymphocytes and mast cells, to increase the production of im-
munoglobulins (Ig) as well as the expression of histocompatibility Class II 
antigens. Binding of antigens to the immunoglobulins on the cell surface of B 
cells results in proliferation of these cells144,145. More recently, IL4 was 
found to induce the synthesis of G- and M-CSF in fibroblasts146. 
ILS, which stimulates both proliferation and differentiation of B lym-
phocytes, also stimulates the growth of eosinophilic colonies147,148. 
Recently, the gene encoding human IL6, previously described as B cell 
differentiating factor orB cell stimulating factor 2, and nowadays termed has 
been cloned153. This factor was originally termed T cell replacing factor 
since it induced immunoglobulin synthesis in stimulated B cells in the absence 
ofT lymphocytes149. It appeared to be identical to interferon-8289,90, hepato-
cyte stimulating factor91, ·and 26 kDa protein 15 5. IL6 has a role in the 
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terminal differentiation of plasma cells from B lymphocytes149. Further-
more, IL6 induces the IL2 receptor157 as well as IL2 production158 in 
stimulated T -cells. In addition, IL6 can directly induce the growth of T-
cells159. Other biological functions of IL6 include a stimulation of the 
production of acute phase proteins in the liver91, induction of differentiation 
of neural cells160, and a stimulation of ACTH secretion by the pituary161. 
Finally, IL6 influences normal and malignant HPC: it supports colony forma-
tion by CFU-GM, acting synergistically with IL3 and GM-CSF150-154. 
Recently IL6 appeared identical to MGl-2, a factor that induces differenti-
ation in leukemic cells249. 
A human ILl eDNA has been cloned from messenger RNA of peripheral 
blood monocytes 102. Later two different human ILl proteins appeared to 
exist: ILl a and ILl B. The eDNA coding for ILl and the eDNA coding for 
ILl B were both isolated from a human macrophage eDNA library103. The 
two proteins are for 26% of their amino-acids homologous 104. Stimulation of 
monocytes with lipopolysacharide results in a 40-fold increase in ILl B 
production, whereas the increase in ILl a is only 2- to 3 fold, suggesting, 
that ILl B is the predominant form. In addition to the secreted ILl, a 
membrane- bound form of ILl has been described, which is predominantly 
ILl a105-107. Both ILl a and ILl B have a molecular weight of 17 kD.- ILl 
was first identified as a lymphocyte-activating factor (LAF), enhancing lym-
phocyte proliferation in response to mitogens108, but more recently many 
different effects on a variety of target cells have been described: ILl acts as a 
cofactor for Con A activation of T cells 109, as an inducer of IL2 and inter-
feron y productionllO, as a growth and differentiation factor forB cells111, 
and as a chemotactic factor for neutrophils, monocytes/macrophages and 
lymphocytesll2. Furthermore, it stimulates the proliferation of fibro-
blastsll3, and induces the production of collagen and interferon B by those 
cells114. ILl plays a crucial role in the acute phase response: it initiates fever 
by inducing an increase in hypothalamic prostaglandin Ez synthesis liS, it 
26 
triggers the synthesis of acute phase proteins in the liver 116, and amino acid 
release from muscles 117-118. Other biological effects of ILl include natriure-
sis119, osteoclast activation120, increase in procoagulant activity121, an in-
crease in release of platelet activating factor122 and plasminogen activator 
inhibitor123. Finally ILl plays an important role in the regulation of hemo-
poiesis. It induces the production of GM-CSF, G-CSF, and M-CSF by a va-
riety of cell types, such as endothelial cells, fibroblasts 124-126 mono-
cytes/macrophages126,127 and BM stromal cells128,129. In addition, ILl acts 
synergistically with G-CSF130, M-CSF131, GM-CSF132. 
ILl administration in mice stimulates granulocyte production133,134,196 and 
accelerates hemopoietic regeneration following TBI or chemother-
apy130,133,196,250. As ILl induces the production of a number of cytokines, it 
is difficult or impossible to discriminate between the biological effects of ILl 
itself and effects which are mediated by other cytokines. 
1.3.2. Hemopoietic Growth Factors (HGFs). 
Humoral factors have been recognized to play an important role in 
hemopoiesis. Evidence for a regulation by soluble factors, i.e. HGFs, dates 
back to 1906. The injection of serum from bled rabbits increased the number 
of blood cells in normal rabbits, indicating, that a soluble factor stimulates 
blood cell production163.Later, this factor appeared to be involved exclu-
sively in erythrocyte production and was termed erythropoietin164 (Ep). 
The isolation and identification of Ep as a glycoprotein was described in 
1960165. In contrast to other HGFs, detailed information on in vivo and in 
vitro characteristics of Ep has been obtained using purified material from 
urine, before its production with recombinant DNA technology was 
developed: Ep has been recognized as a physiological regulator of erythro-
poiesis. This is based on the observation, that artificially induced polycytemia 
shuts off erythropoiesis, which can be restored by Ep injections166. Further-
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more, hypoxia stimulates Ep production, resulting in an increased erythro-
poiesis167-169. Purification of Ep to apparent homogeneity170was performed 
in 1977. Recently the gene, coding for Ep has been cloned171, enabling the 
production of Ep on a scale, sufficient for clinical applications (see 1.3.3). 
Similar to the native peptide, recombinant Ep primarily stimulates the prolif-
eration and differentiation of CFU-E and a subset of BFU-E172. The numbers 
of CFU-E in BM rise in response to bleeding, hypoxia and injection of Ep, 
whereas the numbers of BFU-E are hardly influenced by such treatments173-
176. Thus, Ep mediates the regulation of the developmentally late events in 
erythropoiesis. Ep can be regarded as the prototype HGF: It increases the 
production of a well defined type of blood cells by stimulation of prolife-
ration and differentiation of the progenitors of these cells. Furthermore, the 
production of Ep is dependent on the demand for the blood cells in question. 
Recently, a human Multi-CSF eDNA clone has been isolated from a 
eDNA library prepared from stimulated human lymphocytes. The eDNA was 
identified on the basis of the sequence homology within the non-coding 
region of the murine multi-CSF178. Independently, others have isolated such 
a clone from a lymphoid cell line (MLA-144), using the gibbon IL3 eDNA as 
a hybridization probe180. This protein has a molecular weight of 14 to 30 
kilodalton (kD) (133 amino acids). Sequence homology between murine and 
human coding regions appeared to be only 45%, which is considerable less 
than the homology between other human and murine growth factors or 
lymphokines. Mouse Interleukin-3 (IL3) has been described as a proliferation 
stimulus for a variety of precursor cells: CFU-S, CFU-MIX, CFU-GM, CPU-
EO, mast cells and, in the presence of Ep, BFU-£181-185. In unfractionated 
human BM cell suspensions, human IL3 induces more colonies than in puri-
fied, CD34 positive cells. These results indicate that accessory, CD34 
negative cells, which do not form colonies by themselves, enhance colony 
formation. This enhancement can be explained by the production of other 
growth factors in response to IL3, or by direct cell-cell contact187. Finally, 
human IL3 stimulates the in vitro growth of leukemic cells from a majority 
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of the patients with acute myeloid leukemia (AML)179. 
Human GM-CSF will be described in more detail in section 1.4, and a 
number of in vivo experiments with recombinant human GM-CSF will be 
described in Chapter V, VI and VII. 
Human G-CSF has been purified from medium conditioned by a human 
bladder carcinoma cell line (5637)226 and from a human squamous 
carcinoma cell line (CHU-2)227. A synthetic oligonucleotide was used to 
isolate a G-CSF eDNA clone from a library of CHU-2 rnRNA. A similar 
approach resulted in the isolation of a G-CSF clone from a eDNA library of 
the bladder carcinoma cell line (5637)228. The mature protein has a mol-
ecular weight of 18-22 kD and consists of 174 amino acids. G-CSF 
predominantly stimulates granulocyte progenitors, although the induction of 
mixed colonies have been described228. However, the induction of mixed 
colonies could not be demonstrated in cultures of highly enriched progenitor 
cells, suggesting, that mixed colony-formation in G-CSF stimulated cultures 
is mediated by accessory cells. In addition to the influence of G-CSF on 
granulocyte progenitors, G-CSF also enhances functional activities of mature 
granulocytes, such as phagocytosis, superoxide release and chemotaxis230. In 
contrast to Multi-CSF, human and murine G-CSF are almost completely 
homologous and hence show biological and receptor binding cross reactivity 
to normal and leukemic murine and human cells231 . 
Human M-CSF has been purified from human urine240 Oligonucleotide 
probes were used to isolate several clones from a genomic library241. One of 
these clones was used to screen a 4-kb eDNA library made from rnRNA 
extracted from a stimulated human pancreatic tumor cell line (MIA Paca). 
This resulted in the isolation of a eDNA clone, which could be expressed in a 
monkey kidney cell line (COS) and in a Chinese Hamster Ovary cell line 
(CHO), resulting in production of a dimeric polypeptide, indistinguishable 
from urinary M-CSF242. The mature protein is a dimer consisting of two 
identical subunits with a molecular weight of 35-45 kD each. Human M-CSF 
induces colonies derived from both human and murine macrophage 
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progenitors245. M-CSF stimulates mature monocytes and macrophages to 
produce interferon (IFN), tumor necrosis factor (TNF), and various other 
CSFs- Factors regulating macrophage production can be isolated from the 
uteri of pregnant mice246. Since the receptor for M-CSF has been demon-
strated on a choriocarcinoma cell line, it has been suggested that M-CSF 
plays also a role in placenta growth247. 
The mechanisms which control the production of hemopoietic growth 
factors are largely unresolved. Possibly, ILl, which is produced in response 
to endotoxins251 and other bacterial products252,253, plays a crucial role in 
this regulationlOl. However, a feed-back mechanism, a most essential element 
for a regulatory function, has so far only been elucidated for Ep and not for 
ILl or any of the other growth factors. To resolve the physiological 
regulatory function, a feed-back mechanism between production and demand 
should be demonstrated. HSCs in the BM may occupy niches in which the 
local production and action of compartmentalized growth factors modulate 
proliferation and differentiation. Such niches may provide local control. The 
stromal aminoglycans may be involved in such a local control by selective 
retention of HGFs254. Furthermore, stromal cell lines produce soluble 
factors, which support the growth of multi-lineage colony formation, but can 
be distinguished from multi-CSF and GM-CSF. These factors still support the 
growth of multi-lineage colony formation, indicating the existence of other 
stimulating mechanisms than provided by the hitherto identified HGFs255,256. 
A direct contact between stromal cells and HSCs is postulated to influence 
I 
self-replication and proliferation257,258. The mechanisms by which overall 
coordination is exerted in all those processes, remain to be elucidated. 
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1.3 .3. Clinical applications of hemopoietic growth factors. 
Several hemopoietic growth factors have become available by recombinant 
DNA technology on a scale that allows for their clinical use. Potential applica-
tions are summarized in Table 1.3. Some of these applications are currently 
the subject of clinical trials. 
TABLE 1.3 POTENTIAL APPLICATIONS OF HEMOPOIETIC GROWTH FACTORS 
Substitution of deficient factors. 
Mitigation of pancytopenia induced by radio- and chemotherapy. 
Mitigation of pancytopenia in relation to bone marrow disease. 
Treatment and classification of leukemia. 
In vitro and in vivo stem cell assays. 
In vitro and in vivo stem cell multiplication. 
Genetic modification of stem cells. 
Therapeutic use of hemopoietic growth factors includes substitution of 
deficient factors as well as pharmacological manipulation of hemopoiesis. 
The most commonly known growth factor deficiency is anemia in end-stage 
renal disease. In recent clinical trials, Ep substitution has been successfully 
used to correct anemia resulting from renal failure259,260. In patients with 
congenital agranulocytosis (Kostmann's Disease), which is considered as a 
possible G-CSF deficiency, treatment with recombinant G-CSF has been 
reported to result in an increase in the numbers of neutrophils261. 
Pharmacological manipulation of hemopoiesis could be beneficial in con-
ditions characterized by a lack of peripheral blood cells. Since most of these 
conditions are not caused by a deficiency of one or more of those factors, 
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supraphysiological serum- and tissue concentrations are required to achieve a 
therapeutic effect. Furthermore, systemic administration will probably result 
in an abnormal tissue distribution compared to local production under 
physiological conditions. This might result in unpredictable side effects. 
BM suppression is one of the most important dose limiting factors in 
chemotherapy and in treatment modalities involving TBL Irradiation- or 
chemotherapy induced pancytopenia is characterized by a partial eradication 
of normal BM. As a consequence, the residual HSCs will be stimulated to 
renew themselves and to differentiate in order to restore homeostasis. The 
time required for such a regeneration is dependent on the number of 
surviving HSCs and progenitor cells, the proliferation rate, and the fraction 
of cells in cycle. Pharmacological manipulation of hemopoiesis could reduce 
this pancytopenia by stimulation of HSCs and progenitor cells. The same 
principle, visualised in Figure 1.2, could mitigate the pancytopenia occurring 
in the first weeks following BM transplantation (mechanism 1). G-CSF has 
been used successfully to reduce chemotherapy induced neutropenia in 
clinical trials with patients suffering from transitional-cell carcinoma of the 
urothelium232 and in patients suffering from a variety of other malignant dis-
eases233-235. 
Preclinical studies with G-CSF in healthy, hamsters have shown a tenfold 
rise in peripheral blood granulocyte counts, and a dose dependent throm-
bopenia. This thrombopenia appeared to be reversible in spite of continuation 
of the treatment. After a single dose of G-CSF the granulocytosis was noticed 
as early as two hours after administration, indicating mobilisation of 
granulocytes from the BM into the peripheral blood236. Similar results have 
been obtained in cynomolgus monkeys. Furthermore a shortening of 
cyclophosphamide induced granulocytopenia has been reported226_ G-CSF 
also stimulates granulocyte production after BM transplantation238. 
GM-CSF has also been used successfully to reduce shortage of peripheral 
blood cells under several circumstances. This will be discussed in section 1.4. 
The influence of other hemopoietic growth factors on chemo- and radio-
therapy induced pancytopenia is subject of ongoing studies. Since synergism 
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between different growth factors has been demonstrated in vitro262,263,264, as 
well as in mice265 ,266, maximal reduction of pancytopenia can be expected 
from a combination of synergistically acting hemopoietic growth factors. 
However, in patients with hematological malignancies, such treatments should 
be. considered with great caution, as hemopoietic growth factors have been 
shown to induce proliferation of leukemic cells in vitrol79,221-224. 
Treatment with hemopoietic growth factors is expected to be beneficial in 
BM insufficiency caused by a wide variety of diseases such as aplastic 
anemia, myelodysplasia, BM infiltration by malignant cells, acquired 
immunodeficiency syndrome (AIDS) and other infections. fu such conditions, 
the regulation of hemopoiesis is disturbed and growth factor responses might 
be different from normal regenerating BM. 
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nism 1). For explanation, see text. 
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The induction of leukemic cell proliferation by hemopoietic growth factors 
may provide a means to make those cells more sensitive for S-phase specific 
cytostatic agents, such as cytosine arabinoside (Ara-C). Recently, 
enhancement of in vitro Ara-C cytotoxicity on AML clonogenic cells by 
multi-CSF pretreatment has been demonstrated267. This application could 
also result in an increased toxicity for normal BM cells, recruited into cycle 
as well. Consequently a longer duration of the pancytopenia can be expected, 
unless BM toxicity is not the dose limiting factor, such as in conditioning 
regimens for BM transplantation. The patterns of responsiveness of dono-
genic leukemic cells to growth factors show a striking variability179. Correla-
tion of those patterns with morphological, clinical, and immunological 
datamight result in a better understanding of malignant growth, and to new 
classification criteria for leukemia. 
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Figure 1.3 Putative effects of hemopoietic growth factors (HGFs) before 
high dose radio-/chemotherapy: radioprotection by increases in 
peripheral blood cells (mechanism 2) and in stem cells (mechanism 3). For 
explanation, see text 
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Hemopoietic growth factors which stimulate the proliferation of HSCs are, 
in principle, useful for the development of HSC assays in vitro. In patients 
with pancytopenia, induced by irradiation and or chemotherapy, regeneration 
of peripheral blood cells without BM transplantation will be dependent on the 
number of residual repopulating HSCs. A response of peripheral blood cell 
counts upon in vivo administration of appropriately selected HGFs could 
possibly be used in such patients to estimate the number of repopulating HSCs 
in vivo, which enables the prediction of endogenous regeneration. This will 
be discussed for GM-CSF in Chapter VII. 
Graft failure is one of the principle problems of BM transplantation. In 
human patients receiving autologous BM transplantation, the number of trans-
planted HSCs is probably lower than in allogeneic BM transplantation due to 
previous exposure to anticancer agents and due to storage. In allogeneic BM 
transplantation, GvHD can be prevented by T -cell depletion, but this 
procedure results in an increased risk of graft rejection (reciprocal 
interference268), especially in MHC mismatched donor recipient combina-
tions. The probability of graft failure following BM transplantation can be 
reduced by increasing the graft size269, but the number of HSC that can be 
harvested is limited. This problem could be circumvented by selective multi-
plication of HSCs in vitro. In serum free, liquid cultures of mouse BM, 
containing murine IL3 and ILl, an actual increase of CFU-S has been 
demonstrated. However, the increase of day 8 CFU-S was higher than that of 
day 12 CFU-S, indicating the induction of differentiation rather than that of 
self-replication. Under those culture conditions repopulating HSCs were 
maintained, whereas the number ofT-lymphocytes was largely reduced. This 
has been demonstrated by semiallogeneic BM transplantation with a limited 
number of cultured BM and spleen cells resulting in sustained chimerism in 
the absence of GvHD270. Control mice, which received the same cell 
suspensions before culturing invariably died from GvHD. Pilot experiments 
in Rhesus monkeys have demonstrated the maintenance of repopulating HSCs 
as wel1270. However, the actual application of such a method for BM 
transplantation in humans still requires considerable developmental research 
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in preclinical models such as the Rhesus monkey. 
In addition to stimulation of hemopoiesis· following chemotherapy or ir-
radiation (mechanism 1, Figure 1.2), treatment with hemopoietic growth fac-
tors before chemotherapy or TBI could expand the number of peripheral 
blood cells, resulting in a later onset of the pancytopenia (mechanism 2, 
Figure 1.3). However, since most blood cells have a very short lifespan, this 
mechanism may only be relevant for some cell types such as lymphocytes and 
thrombocytes. Pretreatment with HGFs could also expand the HSC and pro-
genitor cell compartment, resulting in a reduction of pancytopenia 
(mechanism 3, Figure 1.3). However, such a pretreatment with HGFs 
stimulates HSC into cycle, making them more sensitive for cycle specific cyto-
toxic agents271,272. Again, considerable research will be required to select the 
appropriate (combination of) growth factor(s) and administration schedules, 
and to avoid possible undesired effects. 
The development of retrovirus mediated gene transfer into the hemopoietic 
system requires DNA replication and, hence, in vitro self-replication of 
HSCs. Therefore, definition of the culture conditions for selective mul-
tiplication of HSCs will be required for this type of genetic modification of 
hemopoietic cells. 
1 A. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). 
1.4.1. Biochemistry and molecular biology of human GM-CSF. 
The complementary DNA (eDNA) of human GM-CSF has been cloned 
from a eDNA library which was constructed from messenger RNA (mRNA) 
of the Mo cell line (a HTLV transformed T-cell line) in p91203(B) ex-
pression vectors. These constructs were transfected into COS-1 monkey cells 
and screened for GM-CSF expression by testing the ability of the COS-1 
supernatant to stimulate colony formation by the KG-1 human myeloid 
leukemia cell line and by normal human BM. The GM-CSF eDNA contains a 
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single long open reading frame of 432 nucleotides, encoding 144 amino 
acids. Comparison of this sequence with that of natural GM-CSF, purified 
from Mo cell-conditioned medium suggested, that GM-CSF is synthesized as 
a precursor from which 17 amino acids are cleaved to yield the 127 amino 
acids mature protein. After purification, the mature protein is heterogenous 
when analyzed by sodium dodecyl sulfate-plyacrylamide gel electrophoresis 
(SDS-PAGE), migrating with an apparent molecular weight of 18 to 24 kD. 
This is probably due to variable glycosylation; the protein contains two poten-
tial NH2-glycosylation sites. The nucleotide sequence of the isolated eDNA 
consists of 754 nucleotides including 8 nucleotides of 5' and 314 nucleotides 
of 3' non coding regions. Sequence homology between murine and human 
GM-CSF is 70% for nucleotides and 60% for amino acidsl91 Independently, 
almost identical eDNA have been isolated by other groupsl92-194. The minor 
differences between those cDNAs may represent allelic variation. 
By in situ hybridisation, the gene has been localized to chromosome 5q21-
32195. The gene encoding for IL3273 has been localized in the same region. 
The genes encoding for GM-CSF and IL3 have been demonstrated to be 
separated by only 9 kilobases of DNA186. Also the genes encoding for M-
CSF274, endothelial cell growth factor275, IL5276, the receptor of platelet 
derived growth factor277, and for the c-fms proto-oncogene, (the receptor 
for M-CSF278,279,280), are localized to this region of chromosome 5. Thus all 
of these genes are deleted in the 5q- syndrome. It is temptating to speculate 
on a possible relationship between deletions of genes encoding HGFs and/or 
receptors in the 5q- syndrome and the pathogenesis of myelodysplastic 
syndromes. 
Sequences coding for the human GM-CSF protein were expressed in Es-
cherichia Coli, resulting in a high yield synthesis of nonglycosylated human 
GM-CSF. This preparation contains an extra methionine residue at position 1 
and has the same biologic activity as purified natural GM-CSF133,196. 
37 
1.4.2. Influence of human GM-CSF on bone marrow cells in culture. 
GM-CSF was initially described as a factor stimulating the formation of 
granulocyte and/or macrophage colonies188. It is now clear, that GM-CSF 
also induces colonies of other cell lineages 189. In contrast to semipurified 
natural G-CSF, recombinant GM-CSF induces colony formation at day 14 
rather than at day 7, just like semipurified natural GM-CSF197-198. The day 
14 colonies are derived from CFU-GM, CFU-M, CFU-G, and CFU-EO. GM-
CSF alone does not stimulate erythroid or mixed colonies. However, addition 
of GM-CSF to cultures containing Ep results in the formation of two- to 
threefold higher numbers of erythroid colonies (BFU-E) than in cultures 
containing only Ep, and in the formation of small numbers of CFU-MIX189. 
After elimination of adherent cells, GM-CSF does not enhance erythroid 
colony formation199. Furthermore, if clones, initiated in GM-CSF containing 
cultures, are subsequently transferred to cultures stimulated with GM-CSF 
and Ep erythroid colony formation does not occur197. Those data indicate, 
that the influence of GM-CSF on erythroid colony formation requires the 
presence of accessory cells, which may produce (an) additional HGF(s). GM-
CSF has also been found to stimulate megakaryocytopoiesis in vitro200. In 
cultures of CD34 positive, monocyte depleted human BM cells, GM-CSF 
predominantly stimulates CFU-Eo, but no CFU-GM, CFU-M or CFU-G281. 
GM-CSF stimulates in vitro colony formation and a limited differentiation 
of AML cells from most patients179,221-224. GM-CSF also stimulates the 
growth of several human leukemic cell lines such as HL-60 and KG-1. In the 
former, but not in the latter, GM-CSF induces differentiation199. 
In addition to its effects on progenitor cells, GM-CSF also induces func-
tional changes in mature cells. These effects on neutrophils include 
enhancement of phagocytosis201, chemotaxis202,203, lysozyme secretion, and 
superoxide production in response to bacterially derived f-Met-Leu-
Phe204,205. In monocytes, GM-CSF enhances cytotoxicity in vitro206, super-
oxide production, phagocytosis, and class II MHC expression207. Some of 
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these functional changes are probably related to GM-CSF induced expression 
of CD11b208 a surface glycoprotein that is essential for adhesion dependent 
granulocyte functions such as phagocytosis, aggregation and chemotaxis209. 
1.4.3. Clinical applications of GM-CSF. 
GM-CSF has been used in clinical trials to examine its benefits following 
chemotherapy, electively supported by autologous BM transplantation211-214. 
In patients treated with 8-32 p.g/kg GM-CSF, the average duration of 
leukopenia was two days shorter than in historical controls. Conflicting 
results were obtained on the effect of GM-CSF on thrombocyte counts. Doses 
up to 16 p.g!kg were tolerated well, but those 4 patients who received a dose 
of 32 p.g!kg/day developed edema. Also other phase I trials, which are not 
effectivity studies, point to a reduction of chemotherapy related pancyto-
penia. 
In patients with pancytopenia due to myelodysplasia, lower doses (30-250 
p.g/m2/day, approximately 0.8-7 p.g/kg) resulted in a rise in leukocytes, 
whereas higher doses (120-500 p.g/m2, approximately 3-15 p.g/kg) induced a 
rise in hematocrit values thrombocyte counts and a reduction in transfusion 
dependency215. 
In leukopenic patients with AIDS, administration of GM-CSF resulted in an 
increase of granulocytes, eosinophils and monocytes. Following high doses 
also a rise of lymphocyte numbers was described, but significant changes in 
reticulocyte- and thrombocyte counts were not noted216. 
Victims of a recent irradiation accident have been treated with GM-CSF217, 
but the efficacy of this treatment is difficult to interpret, since adequate 
control groups are lacking, and the irradiation dose on the BM is difficult to 
assess following accidental irradiation which is in general inhomogeneous. 
Preclinical data in primate models included an increase in peripheral blood 
cell counts in healthy, not pretreated animals218,219 and a reduction of the 
pancytopenic period following TBI and autologous BM transplantation220,225. 
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1.5. The Rhesus monkey as a preclinical model for studies on hemopoiesis. 
For nearly 30 years the Rhesus monkey (Macaca mulatta) has been used for 
investigations on BM transplantation. Since the early 1960s it was felt, that 
the gap between mouse models and clinical BM transplantation had to be 
bridged by a species that was more similar to man. 
Human and Rhesus monkey BM have many similar properties: human and 
Rhesus monkey BM contain approximately the same numbers of CPU -C282. 
After albumin density centrifugation of human and Rhesus monkey BM, 
HSCs and progenitor cells can be found in the same fractions283. In addition, 
in contrast to mouse BM, a high content of T cells is present in human as 
well as subhuman primate BM284, capable to induce severe Graft versus Host 
Disease (GvHD), even in MHC identical donor recipient combinations285. Fur-
thermore, the Major Histocompatibility Complex (MHC) of the Rhesus 
monkey, termed RhLA, closely resembles the human HLA system286. A 
number of monoclonal antibodies (MCA) directed against human cell surface 
antigens cross react with antigens on the same cells of Rhesus mon-
keys287 ,288,289. 
The similar properties of monkey and human BM have been used to test 
many techniques involved in BM transplantation before their introduction 
into clinical practice: methods for cryopreservation of HSCs290, conditioning 
regimens291, and mitigation of GvHD, by methotrexate292, by antilym-
phocyte globulin293,294, by MHC matching295, by decontamination of the 
digestive tract and by T cell depletion296,297. 
The frequency of HSCs in mammalian BM is supposed to be inversely 
correlated with body weight, implying a lower HSC frequency in man than in 
Rhesus monkeys298. This idea is based on extrapolation of differences in the 
LDso of TBI in different species and on the minimal number of transplanted 
BM cells per kg required for survival after high dose TBI. It is not clear 
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whether these differences can be directly related to stem cell numbers. Until 
now, other differences in Rhesus monkey and human hemopoiesis have not 
been demonstrated. 
Clinical treatment of patients, including full supportive care, can be 
imitated under standard conditions in Rhesus monkeys. 
The disadvantages of the monkey model are mostly technical, and the high 
costs of experiments with Rhesus monkeys prevent the use of large numbers 
of animals. 
For the reasons mentioned above, the majority of data obtained in Rhesus 
monkeys, can be extrapolated to the clinical situation with more confidence 
than data obtained in more generally used laboratory animals, making the 
Rhesus monkey the most reliable animal for preclinical studies on 
hemopoiesis and BM transplantation. 
1.6. Rationale of the study. 
The hemopoietic system is highly sensitive to cytotoxic damage, such as 
chemotherapy and ionising irradiation. Therefore survival following high 
dose chemotherapy and/or TBI, electively in combination with BM 
transplantation is only possible because the system has a great regenerative 
capacity. Hemopoietic regeneration following therapeutic or accidental 
cytotoxic damage, cannot always be predicted since quantitative information 
on the process of regeneration is insufficient. Self replication and 
differentiation of HSCs and progenitor cells are essential in this process. 
Therefore a sufficient number of HSCs is required for regeneration. Un-
fortunately, a suitable assay for human HSCs is not available. Cell surface 
markers expressed on HSCs could possibly be used for the development of 
such an assay. Furthermore characterization of HSC surface markers can be 
used for the preparation of BM grafts as discussed in section 1.1. In the ex-
perimental work described in chapter ill, a recently developed in vivo HSC 
assay is used to investigate the expression of the CD34 antigen on 
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repopulating HSCs. 
Another approach to estimate the number of HSCs and to predict 
endogenous regeneration following cytotoxic damage, is a calculation based 
on the sensitivity of HSCs for chemotherapy or irradiation. Radiosensitivity 
can be characterized quantitatively by the relationship between the irradiation 
dose and the fraction of surviving HSCs. In Chapter IV this relationship will 
be described for 6 MV and for 300 kV X-rays. Such quantitative information 
on HSC numbers is essential for the assessment of the role of BM transplanta-
tion in the treatment of victims of radiation accidents. 
Even if the radiosensitivity and the original number of HSCs is precisely 
known, inadequate dosimetric information and inhomogeneous irradiation 
might hamper a precise estimate of the number of surviving HSCs and a 
reliable prediction of endogenous regeneration in victims of radiation 
accidents. A response of peripheral blood cell counts upon in vivo 
administration of appropriately selected HGFs could possibly be used in such 
patients to estimate the number of residual HSCs in vivo, which enables the 
prediction of endogenous regeneration. This application of HGFs, and 
especially GM-CSF, will be discussed in Chapter VII. 
If the number of surviving and/or transplanted HSCs is sufficient for 
regeneration, this process is a matter of self replication and differentiation. 
HGFs might accelerate this process by stimulating the proliferation of HSCs 
and progenitor cells. Furthermore HGFs can stimulate the functional activity 
of peripheral blood cells. In Chapter V, the effect of GM-CSF on peripheral 
blood cells in normal monkeys will be described. In Chapter VI and VII, the 
possible beneficial influence of GM-CSF on hemopoietic regeneration 
following TBI with or without BM transplantation will be described in 
relation to the number of surviving HSCs. 
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CHAPTER II 
MATERIALS AND METHODS 
2.1. Experimental animals. 
Rhesus monkeys (Macaca mulatta) were bred at the Primate Center TNO, 
Rijswijk, The Netherlands!. Both male and female animals were used for the 
experiments. The monkeys weighed 2.5-4 kg and were 2-4 years old at the time 
of the experiment. They were all typed for RhLA-A, -B and -DR antigens, as 
described2. Furthermore, all animals used in this study were seronegative for 
Simian Immunodeficiency Virus (SlY) , as tested at the Virus Reference Labor-
atory, Southwest Foundation for Biomedical Research, San Antonio, TX, U.S.A. 
Leukocyte counts, differential counts, red blood cell counts, hemoglobin levels, 
hematocrit values, thrombocyte counts and reticulocyte counts were determined 
as described in section 2.10. 
Only monkeys with normal values for those parameters were used for the 
experiments described in this thesis. 
2.2. Bone marrow procurement and preparation of cell suspensions. 
For autologous bone marrow (BM) graft harvesting, the monkeys were 
anaesthetized with 10 mg ketamine (Ketamin R, Tesink B.V., Oudewater, The 
Netherlands) and 1 mg acepromazine (Vetranquil R, Sanofi sante animale, Paris, 
France). BM aspirates of 1-3 ml were collected by puncturing the femoral shafts. 
For allogeneic BM graft harvesting, the donor monkey was sacrificed and the 
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bones were pressed as described3. The BM was suspended in PBS or HBSS, con-
taining 500 U Heparin (ThromboliquinR, Organon Technika, Boxtel, The Nether-
lands) and 0.1 mg/ml Deoxyribonuclease I (Calbiogem, San Diego, CA, U.S.A.). 
T -cell depleted stem cell concentrates were produced as illustrated in Figure 
2.1. Mononuclear cell suspensions were prepared by neutral density cen-
trifugation, using lymphocyte separation medium (LSM, Organon Technika 
Corporation, Durham, NC, U.S.A., density: 1.077 g/cm3; l8°C, 500 g, 20 mi-
nutes). The erythrocytes were resuspended into 25-50 ml pyrogen free NaCl 
0.9% and reinfused into the animal as soon as possible. Further enrichment of 
stem cells and progenitor cells was achieved by a discontinuous albumin density 
gradient. T -cell depleted stem cell concentrates were produced by albumin 
density gradient centrifugation. This procedure generally resulted in a 10-30 
fold concentration of precursor cells and in an elimination of about 80-90% of 
the T -lymphocytes and 90-95 % of all nucleated cells4. This procedure was 
followed by T cell depletion, either by sedimentation of cells which bind sheep 
red blood cells, hereafter referred to as E-rosette centrifugations, or by comple-
ment (C') mediated lysis of CAMP ATH I positive cells6. Both procedures 
resulted in an additionall-2 log T-cell depletion. All cell suspensions were cul-
tured for CFU-C, as described below. 
For most experiments, these T-cell depleted stem cell concentrates were 
cryopreserved, since the conditioning regimen that was used for autologous BM 
transplantation required two days. The BM cells were thawed immediately 
before use by stepwise dilution. By using this method, significant losses of CFU-
C did not occur7. Therefore, it was assumed, that significant losses of PHSC due 
to the cryopreservation procedure could also be avoided. 
These stem cell concentrates were used as autologous BM grafts or for further 
purification of stem cells on the basis of the expression of cell surface markers. 
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2.3. Monoclonal antibodies. 
ICH3, a murine monoclonal antibody (MCA), which recognizes an epitope of 
the CD34 antigen, also termed Human progenitor cell Antigen 1 (HPCA 1) was a 
gift of Dr R. Levinski (Institute of Child Health, London, U.K.). This antigen is 
expressed on 1-4% of human bone marrow cells, including hemopoietic progeni-
tor cells such as CPU-blast, CPU-mix, CFU-GM, and BFU-E. ICH3 was 
-
produced as described earlier8: Cells were labelled by adding 2 J.!l ICH3 (1 
mg/ml IgG2a) to 5 x 106 pelleted cells and the mixture was incubated for 30 
minutes at 4°C. After washing with Hanks Balanced Salt Solution (HBSS), whith 
1% fetal calf serum (FCS), 5 X 106 cells were stained with 50 J.!l anti-IgG2a, 
conjugated to fluorescein isothiocyanate (FITC) (Nordic, Tilburg, The 
Netherlands), and diluted 1:30 in HBSS/FCS, for 30 minutes at 4°C. 
CAMP ATH I, a rat MCA directed against human and Rhesus monkey9 B- and 
T lymphocytes, was a gift of Dr H. Waldman (Department of Pathology, 
University of Cambridge, U.K.). Cells were labelled by adding 0.1 ml 
CAMPATH I (0.1 mg/ml, Ig M) to 106 pelleted cells and incubated for 30 
minutes at 4°C, followed by C' mediated lysis, using autologous serum as a 
' 
source of complement6, or by staining of the positive cells with goat anti rat 
(GARA), conjugated to FITC. 
DR positive cells were labelled with anti-HLA-DR conjugated to phy-
coerythrin (PE) (Becton & Dickinson, Immunocytometry Systems, Mountain 
View, CA, U.S.A.) (10 J.!l, 25 J..Lg/ml, IgG2ato 5 x 106 cells.) 
CD4 and CDS positive cells were labelled with PE conjugated Leu 3A (2 J.!l, 
10 J..Lg/ml, IgG1 to 106 cells) and Leu 2A (Becton & Dickinson) (2 12.5 J..Lg/ml 
IgG2a to 106 cells), respectively. 
CDllb positive cells were labelled with Mol/FITC (Coulter Immur10logy, 
Hialeah, FL, U.S.A.) (10 J.!l, 1 J..Lg/ml to 5 x 106 cells) for fluorescence analysis 
or with Mol/biotin (Coulter). Cells labelled with Mol/biotin were wq.shed and 
stained with Streptavidin/PE (Becton & Dickinson) (1 J.!l, 250 J.!g/ml to 106 
cells). For immunomagnetic cell separation Mol (Coulter) (2J..Llfl06 cells) was 
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used. 
2.4. Immunofluorescence analysis and cell sorting. 
A modified fluorescence activated cell sorter (F ACS II, Becton & Dickinson) 
with the laser at 488 nm (0.5 W) was used for analysis and sortinglO. In some 
experiments, four parameters were analyzed. For these experiments, an eight 
parameter cell sorter, termed Rijswijk Experimental Light Activated Cell Sorter 
II (RELACS II) was used. The sheet fluid consisted of PBS. Forward light 
scatter (FLS) intensity, which is related to cell size, was measured with the laser 
beam blocking bar in its narrowest orientation, and linearly amplified. 
Perpendicular light scatter (PLS) intensity, which is related to cell structure, was 
measured by an S-11 type photomultiplier (Thorn EMI, Middlesex, U.K.) and 
linearly amplified. Based on FLS and PLS, several subpopulations of BM cells 
can be distinguishedll, as indicated in Figure 2.2. FLS signals were used for 
triggering the measurements. Erythrocytes were electronically excluded from 
analysis. FITC was measured through a combination of broad band multicavity 
interference (520-550 nm: Pompfret Research Optics Inc, Stanford, CT) and a 
530 nm cut-off filter (Ditric Optics, Hudson, MA) by an S-20 type 
photomultiplier. PE was measured through a 550 nm cut-off filter (Schott, 
Mainz, Germany) by photomultiplier R1477 (Hamamatsu, Japan). Logarithmic 
amplifiers were used to process the signals of fluorescence. A comparison 
network was used to eliminate the orange emission of FITC from the orange 
PEchannal12. NoPE emission could be detected in the green channal.Cells were 
sorted into 15 ml glass tubes. The wall sides where the sorted cells were 
deposited were rinsed before sorting with PBS containing 10% fetal calf serum 
(FCS). The data were collected as a 4-parameter (FLS, PLS, FITC, and PE) list 
mode on a HP 220 computer for later analysis13. 
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2.5. Isolation of CD 34 positive cells by using immunomagnetic beads. 
One monkey was transplanted with BM from which the CD34+ cells were 
removed by binding to immunomagnetic beads. Magnetic microspheres, 
Dynabeads1M (Dynal, A.S., Oslo, Norway), coated with goat anti-mouse IgG, 
and a magnetic particle concentrator, Dynal MPCTM were used14. 1.25 x 109 
beads were incubated with 1.25 ml ICH3 for 20 hours at 4 oc on a rotating wheel 
to keep particles in suspension. After washing, the ICH3-carrying beads were in-
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cubated with 2.5 x 108 LSM isolated mononuclear BM cells in 12 ml PBS, for 20 
minutes at 4°C on a rotating wheel. Following this procedure, each CD34 
positive cells was bound to a number of immunomagnetic beads. Such a complex 
was termed a rosette. Rosette forming cells were removed by using the magnetic 
particle concentrator as illustrated in Figure 2.3. Since pilot experiments had 
demonstrated the presence of residual CD34 positive cells after this separation, a 
second separation step was introduced: to remove these cells, the depleted 
fraction was incubated with ICH3 as described in section 2.2, washed, and 
incubated with beads (20 minutes, 4°C), coated with goat anti-mouse. Residual 
rosetting cells were removed, again by use of the magnetic particle concentrator. 
For positive selection of ICH3+ cells, a modification of this separation method 
was developed, since it appeared difficult to remove the beads from the cells if 
the method described above was used. Briefly, uncoated beads were activated and 
incubated with protein A, washed four times and incubated with ICH3. By this 
procedure the immunomagnetic beads were coated with ICH3 and could be used 
for the isolation of CD34 positive cells by incubation of stem cell concentrates 
(section 2.2) followed by isolation of rosette forming cells using the magnetic 
particle concentrator. The beads were removed from the cells by adding an 
excess bovine IgG, provided by bovine plasma, followed by isolation of the cells 
by using the magnetic particle separator again (Figure 2.3). 
2.6. Culture of in vitro colony forming cells (CPU-C). 
2.6.1. Agar cultures. 
BM cells were cultured using the double-layer agar technique with a feeder 
layer of human peripheral blood leukocytes, according to Pike and Robinson IS. 
Briefly, human leukocytes were suspended in supplemented Dulbecco's modified 
eagle medium (Gibco Ltd. Paisley, U.K.), containing 20% FCS (Biochrom, 
Berlin, Germany), and 0.5% agar (Bacto agar, Difco Laboratories, Detroit, MI, 
U.S.A .. 106 cells were plated into 35 mm Petri dishes 
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Figure 2.3 
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Magnetic cell separator (DynaiR). A tube, containing a cell suspension is 
placed against the magnet. Positive cells, linked to immunomagnetic beads, are at-
tracted by the magnet and can be separated from the negative cells by removing 
the suspension from the tube. 
(Falcon, 1008). 1 to 7 days later, appropriate numbers of rhesus monkey BM 
cells, suspended in a similar medium, were plated on top of these feeder layers. 
The cultures were incubated for 7 days at 37°C in a saturated humidified atmo-
sphere of 7.5% C02 in air. Colonies larger than 50 cells were scored on day 7 
using an inverted microscope (Zeiss) at a 30-fold magnification. 
2.6.2. Methylcellulose cultures. 
BM cells were cultured without feeder layers in methylcellulose. This method 
is a modification of a previously described serum-free culture method for 
murine BM cells16. Briefly, appropriate numbers of BM cells were suspended in 
supplemented Dulbecco's modified eagle medium (Gibco) containing 0.8% 
methylcellulose (Methocel A4M Premium grade, Dow chemical), 10% FCS 
(Biochrom), bovine serum albumin (Sigma, St Louis, MO, U.S.A), iron 
saturated human transferrin (Behringwerke), Na2Se03 (Merck, Darmstadt, 
Germany), B-mercapto-ethanol (Merck), nucleosides (Sigma), linoleic acid, 
(Merck), and cholesterol (Sigma). Recombinant human GM-CSF was used at 
supraoptimal concentrations to stimulate the cells as indicated in the results. 
These cell suspensions were plated into 35 mm Petri dishes (Falcon, 1008). The 
cultures were incubated for 10 days at 37°C in a saturated humidified atmo-
sphere of 7.5% C02 in air. Colonies larger than 50 cells were scored on day 10 
using an inverted microscope (Zeiss) at a 30-fold magnification. 
2. 7. Total Body Irradiation (TBI) and bone marrow transplantation. 
The monkeys selected for BM transplantation were anaesthetized as described 
in section 2.3 and conditioned for BM transplantation with 12 Gy bilateral TBI, 
given in two equal fractions separated by 24 hours. Physical parameters: 6 MV 
X-rays, average dose rate 0.15 Gy/min., source-to-surface distance 3.60 meters. 
To avoid radiation pneumonitis, the lungs were shielded by 10 mm lead resulting 
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in a total lung dose of 8.5 Gy. 
For the experiments described in Chapter N and VII, monkeys were irra-
diated without BM transplantation. For these experiments, graded, single doses 
of TBI without lung shielding were given under similar conditions. 
Other monkeys were exposed to a single fraction TBI, delivered by 2 
opposing X-ray generators. Physical parameters: 300 kV X-rays, average dose 
rate 0.20 Gy/min., source-to-surface distance 0.8 meter, as described 
elsewhere17. 
BM, prepared as described in section 2.3 and 2.4, was injected into a 
peripheral vein 24 hours after TBI. The day of transplantation was designated 
day 0. In irradiated, untransplanted monkeys the day of TBI was designated day 
0. 
2.8. Recombinant human GM-CSF. 
Recombinant human GM-CSF was kindly provided by Biogen Inc., and later 
by Glaxo Inc. (Geneve, Switzerland), and stored at -20° C until dilution of the 
daily dose into 1 ml pyrogen free 0.9% NaCl immediately prior to use. A 
similar culture system whithout the human GM-CSF gene was used for the 
production of a placebo. The purification procedures of GM-CSF and placebo 
were similar. Placebo or GM-CSF was injected subcutaneously once daily or 
continuously iv in different doses and under different conditions as will be 
described. 
2.9. Supportive care. 
The animal care after transplantation was a modification of that described 
before9,18. Briefly, acidified (pH3) drinking water and reverse barrier nursing 
were used for all animals. Selective decontamination of the digestive tract was a-
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chieved by oral administration of antimicrobial agents starting at day 0 in trans-
planted monkeys or at day 1 in irradiated, not transplanted monkeys. The agents 
were polymixine B, norfloxacin (NoroxinR, Chibret, Haarlem, The Netherlands) 
and nystatin (Nystatin LabazR Sanofi B.V., Maassluis, The Netherlands) for the 
transplanted monkeys. The experiments with untransplanted monkeys were part 
of a preclinical study on the treatment of victims of irradiation accidents. For 
these monkeys cotrimoxazole (BactrimelR, Hoffmann-La Roche, Mijdrecht, The 
Netherlands) was used instead of polymixine B and norfloxacin because it is 
easier available in times of emergency. If resistant gram negative bacteria 
persisted in the faeces, the prophylactic antibiotic treatment was adapted to the 
antibiogram of these bacteria. Selective decontamination and reverse barrier 
nursing was continued until leukocyte counts exceeded 1 x 109/l. In case of fever 
(body temperature> 39.5°C), a blood sample was taken for culture and systemic 
antibiotic treatment (cephamandol in combination with ticarcilin) was started im-
mediately. This treatment was adapted as soon as the antibiogram of a positive 
blood culture demonstrated the presence of resistant bacteria. 
Irradiated platelet transfusions were given whenever thrombocyte counts 
reached values lower than 40 x 109/1. Irradiated packed cells were given if the 
hematocrit was lower than 20%. 
Dehydration and electrolyte disturbances, caused by the gastro-intestinal 
syndrome, were treated by appropriate parenteral fluid and electrolyte 
administration. 
2.10. Observations following TBI. 
The animals were subjected to a thorough inspection twice daily: general 
condition, appetite, body weight, axillary body temperature, hydration, and 
production of faeces and urine were recorded. Peripheral blood cell counts were 
determined daily. Leukocyte counts, red blood cell counts, hemoglobin levels 
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and hematocrit values were determined with a 7000TM Cell Counter (Baker 
Instruments, Amersfoort, The Netherlands). Reticulocyte counts were 
determined by staining with brilliant cresy 1 blue. Differential counts were done 
morphologically after May-Grtinwald-Giemsa staining. The leukocyte counts 
were corrected for normoblasts. Thrombocyte counts were determined with an 
8101M Platelet Analyzer (Baker Instruments). 
Twice weekly, serum protein, sodium, potassium, chloride, C02, SGOT, 
SGPT, LDH, alkaline phosphatase and albumin were determined on a routine 
base at the laboratory of the cooperating Delft hospitals, Stichting 
Samenwerkende Delftse Ziekenhuizen, (SSDZ). 
Complete autopsy was performed as soon as possible following spontaneous 
death or immediately following euthanasia of moribund animals. The other 
monkeys were kept alive for separate studies concerning long term effects of 
BMT, TBI and treatment with hemopoietic growth factors. 
2.11. Statistics. 
Mean, standard deviation, and correlation coefficient, and linear regression 
equations were calculated according to the standard formulasl9. The student's T 
test was used to calculate the 95 % confidence limits. The relationship between 
irradiation dose and mortality in Chapter IV was calculated by probit/logit 
analysis. 
Blood cell counts are subject to random day to day fluctuations, that hamper a 
proper evaluation. To avoid the influence of those variations and to evaluate the 
total response of treatment with GM-CSF, a parameter, independent of those 
fluctuations and covering the whole observation period was used to quantify the 
influence of this treatment on the production of a specific blood cell type. This 
parameter, termed cumulated cell count, is the sum of the daily assessed cell 
counts during a certain observation period. 
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CHAPTER III 
CD34 EXPRESSION ON RHESUS MONKEY HEMOPOIETIC 
STEM CELLS AND PROGENITOR CELLS. 
3.1. Introduction. 
Cell surface markers and light activated cell sorting have been used for 
characterization and purification of murine stem cellsl,2. By using these techniques, 
grafts of only 102 purified PHSC appeared to be sufficient to protect a lethally 
irradiated mouse from bone marrow failure. Among the cell surface markers avail-
able to isolate immature human hemopoietic cells, the CD34 antigen, identified by 
the MCAs My-103, 12-84, BI-3C55, ICH36, and others is of outstanding interest, 
since it is mainly expressed on immature hemopoietic cells along various differen-
tiation lineages, including hemopoietic progenitor cells such as CPU-blast, CPU-
mix, CFU-GM, and BPU-E. Moreover, it is present only on 1-4 % of human bone 
marrow cells. The characteristics of the CD34 antigen, also termed the Human 
Progenitor Cell Antigen 1 (HPCA-1) are summarized in Table 3.1. The monoclonal 
antibody ICH3 is distinct from the other three in that it is a high avidity antibody of 
IgG 2a isotype that recognizes a peptide epitope and does not modulate or has any 
effector function such as complement lysis. 
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Table 3.1 CELL NIEMBRANE GLYCOPROTEIN CD34 (HPCA-1) ASSOCIATED 
WITII HUMAN HEMOPOIETIC PROGENITOR CELLS 
115 leD glycoprotein 
available monoconal antibodies: 
selectivity: 
My-10 
12.8 
BI-3C5 
ICH3 
1 - 4 % of all bone marrow cells 
basement membranes 
capillary endothelia 
Civin et al., 1984.3 
Andrews eta., 19864 
Tindle et al., 19855 
Watt et al., 19876 
These properties make ICH3 preferentially suited for positive selection of 
stem cells for bone marrow transplantation. My-10 and BI-3C5 do not cross react 
with rhesus monkey bone marrow cells7. For My-10 and BI-3C5 a carbohydrate 
structure of the epitope is involved in antigen recognition, which is not the case for 
ICH3. Since peptide structures are probably better conserved during evolution than 
carbohydrate structures, the cross reactivity of ICH3 with rhesus monkey 
hemopoietic progenitor cells and stem cells was investigated. 
In most of the studies in rodents, the enrichment of stem cells was monitored 
by the quantitative and functional spleen colony assay (SCA). In outbred species, 
such as rhesus monkeys and humans, the most early detectable cell is the CFU-mix8. 
However, the development of a complete hemopoietic system out of the progeny of 
a CPU-mix has never been demonstrated. Accordingly, the relationship between 
CPU-mix and stem cells is less well established than the relationship between CFU-S 
and stem cells. Studies on the nature of human stem cells have been limited by the 
lack of a suitable assay and by a restricted possibility for in vivo studies. Recently, a 
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semiquantitative in vivo stem cell assay in rhesus monkeys has been developed in 
our laboratory. This autologous regeneration assay is based on the observation that 
the peripheral reticulocyte and leukocyte regeneration times after ABMT are 
directly related to graft size (Figure 3.1). This assay has been used to demonstrate 
that the regeneration time is independent on the presence ofT-lymphocytes in the 
graft9. It also enables a quantitative comparison between enrichment of repopulating 
cells as calculated from the in vivo regeneration time and the enrichment of 
progenitor cells as calculated from in vitro assays. 
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Dependence of the regeneration time of reticulocytes on the number of 
autologous BM cells grafted. This is used as the basis for a regenerating stem 
cell assay in vivo9. An example is given: if the reticulocyte counts persistingly exceed 
a value of 1 %, starting from day 19, the graft size is equivalent to 9 x 106 to 2 x 107 
unfractionated BM cells/kg (95% confidence limits). 
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MHC Class II antigens have been demonstrated on HPC of human and subhuman 
primates10,11,12 and on PHSC which are capable of restoring hemopoiesis in vivo in 
mice and dogs 13,14,15, 16. Previously, the autologous regeneration assay was used to 
demonstrate the expression of MHC Class II (RhLA-DR) antigens on PHSC17. The 
DR antigen is not exclusively expressed on HPC and PHSC. Therefore, higher HPC 
concentration factors can be obtained by multiparameter cell sorting, based on the 
expression of DR and other antigens. Purification of PHSC on the basis of 
simultaneous expression of the CD34 and the DR antigen has been suggested. 
3.2. CD34 expression on Rhesus monkey hemopoietic progenitor cells. 
To test the expression of the CD34 antigen on hemopoietic progenitor cells, stem 
cell concentrates were incubated with ICH3 and stained with anti IgG 2a 
conjugated to FITC, as described in section 2.3. The fluorescence of the cells was 
analyzed and cells were sorted on the basis of the fluorescence signal as described in 
section 2.4. The sorted cells were cultured as described in section 2.6. Figure 3.2 
shows the histogram of Rhesus monkey stem cell concentrates labelled with ICH3. 
About 20% of the cells reacted with ICH3. 
Sorting of ICH3 positive cells resulted in a 45-100 fold enrichment of CFU-C, while 
sorting of ICH3 negative cells resulted in a CFU-C depletion. Sorting of the 3% 
most bright cells resulted in a higher enrichment, but also in a significant loss of 
CFU -C, as shown in Table 3 .2. 
To test the reliability of the sorting procedure, sorted ICH3 positive cells were 
reanalysed for FITC fluorescence. The histogram of this analysis, shown in Figure 
3.3, demonstrates, that more than 95 % of the sorted cells are CD34 positive. 
The CD34 expression on a small population of Rhesus monkey bone marrow 
cells, confined to immature hemopoietic cells, including hemopoietic progenitor 
cells, is similar to that observed in human bone marrowl8, 19. 
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Figure 3.2 Distribution of Rhesus monkey T-lymphocyte depleted stem cell 
concentrates according to fluorescence intensity after labeling with ICH3 
(anti CD34) and anti IgG 2a/FITC. The frequency of CFU-C and the CFU-C 
concentration factor (in parenthesis) is indicated for all cells, all positive cells and the 
most brightly fluorescent 3% of the distribution. 
Table 3.2 CD34 EXPRESSION ON RHESUS MONKEY CFU-C 
(mean of 3 experiments) 
EM fraction CFU -C/1 05cells cone. factor* 
(mean± s.d.) (mean± s.d) 
mononuclear cells 59± 13 2± 0.2 
stem cell concentrates** 736 ± 275 25± 4 
sorter control*** 759 ± 59 26± 4 
CD34- 178 ± 157 6± 5 
CD34+ 2519 ± 1171 80±30 
CD34++ **** 4788 ± 1019 155 ± 13 
* relative to unfractionated punctured BM, which was set at a value of 1 
** prepared as described in section 2.2 
*** all <:ells of stem cell concentrates sorted with label 
**** 3% most bright fluorescent cells 
recovery 
(mean± s.d.) 
100 ± 19 
68±39 
72±32 
10± 10 
37±30 
8± 5 
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Figure 3.3 Effect of flowcytometric cell sorting. Distribution of Rhesus monkey T-
lymphocyte depleted stem cell concentrates according to fluorescence intensity after 
labeling with ICH3 (anti CD34) and anti IgG 2a/FITC before (upper panel) and after 
(lower panel) sorting of ICH3 positive cells. 
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3.2.1.Enrichment of Rhesus monkey CFU~C by two colour cell sorting. 
In the previous section, the enrichment of Rhesus monkey CFU-C on the basis of 
the expression of the CD34 antigen was demonstrated. HPC and PHSC can also be 
enriched on the basis of the expression of MHC class II antigens (DR). To obtain a 
higher CFU-C enrichment, it was attempted to combine staining with anti-DR and 
ICH3. Rhesus monkey BM cells were enriched by albumin density centrifugation as 
described in section 2.2, incubated with ICH3, washed, and stained with anti-
IgG 2a, conjugated to FITC, Subsequently, the cells were washed twice and 
incubated with anti HLA-DR conjugated toPE, as described in section 2.4. The cells 
were analyzed and sorted on the basis of red and green fluorescence, and cultured 
for CPU-C. The results are shown in Figure 3.4, in which three 
populations can be discerned: CD34-, CD34+/DR bright, and CD34+ /DR dull. The 
percentage of the nucleated cells, the CFU-C concentration factor and the CFU-C 
recovery are indicated in this Figure. Selection of CD34+/DR+ cells did not improve 
the enrichment of CFU-C as compared to selection of CD34+ cells alol)e. This was 
due to the heterogeneity of DR-expression among CFU-C, which caused a 
separation of the CD34+ fraction into a brightly and a dull anti-DR si~ined fraction. 
3.3. Repopulating capacity of CD34 positive cells 
The expression of the CD34 antigen on hemopoietic progenitor cells has been 
described in section . To test whether CD34+ BM cells were capable of restoring 
hemopoiesis in vivo, Rhesus monkeys were transplanted with isolated, CD34+ BM 
cells. For a quantification of the enrichment of PHSC by positive selection on the 
basis of CD34 expression we used the autologous regeneration 
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Figure 3.4 Dot plot of Rhesus monkey T -lymphocyte depleted stem cell concentrates 
according to red and green fluorescence intensity after labeling with ICH3 
(anti CD34), anti IgG 2a/FITC and anti HLA-DR/PE. The frequency of CFU-C 
and the CFU-C concentration factor (in parenthesis) is indicated for all cells, for the 
CD34+/DR+ and for the CD34+JDR- populations. 
assay as described in section 3.1. To assess the capacity of CD34+ cells for 
sustaining chimerism, Rhesus monkeys were transplanted with CD34+ BM cells 
from RhLA identical, sex mismatched siblings. 
3.3.1. Enrichment of repopulating cells by positive selection of CD34+ 
To quantify the enrichment of repopulating cells by positive selection of CD34 
positive BM cells,Rhesus monkeys, irradiated with 2 x 6 Gy TBI, (described in 
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section 2.7), were transplanted with small standardized numbers of autologous 
CD34+ cells, selected by sorting ICH3-labelled BM. Two monkeys received a graft 
of 2 x 105 sorted ICH3+ cells/kg body weight. The regeneration time of 
reticulocytes in one monkey was similar to the regeneration time after 
transplantation of 8.5-17.2 x 106 (95% confidence limits) unfractionated BM 
cells/kg, while the other regenerated as if it had received 13.5-28.3 x 106 un-
fractionated BM cells/kg body weight (Figure 3.1 and 3.5, Table 3.3). In order to 
demonstrate, that the regeneration time, expressed as the day at which reticulocyte 
counts exceed 1% is a representative parameter for the regeneration, in Figure 3.6 
the leukocyte regeneration of these monkeys is compared with the regeneration of 
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Figure 3.5 Regeneration of reticulocytes following transplantation of autologous 
CD34 positive BM cells. Conditioning with 2 x 6 Gy (6 MV X-rays) TBI. 
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control monkeys, which received graded numbers of unfractionated bone marrow 
cells. The enrichment of repopulating cells was not reflected by an early leukocyte 
regeneration in one of the two monkeys. In this monkey the early phase after 
transplantation was complicated by sepsis with fever (>40° C) from day 10 - 18, a 
severe ulcerating gingivitis from day 7 - 20, and blood cultures revealing 
Streptococcus mitis on days 7, 9, 10, and 14. In the other monkey, which had no 
infectious complications, the regeneration time of leukocytes indicated a similar 
stem cell concentration as that of reticulocytes (Figure 3 .6). 
These results indicate a 40- to 140-fold enrichment of repopulating cells (Table 
3.3), which is in the same order of magnitude as the enrichment of CFU-C (Table 
3.2). 
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Figure 3.6 Regeneration of leukocytes following transplantation of autologous CD34 
positive BM cells. Conditioning with 2 x 6 Gy (6 MV X-rays) TBI. 
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Table 3.3 CD34 EXPRESSION ON RHESUS MONKEY STEM CELLS AS. 
DEMONSTRATED FROM THE REGENERATION RETICULOCYTES 
AFTERBMT 
UMN* GRAFT RETICULOCYTE REGENERATION BMequiv.** STEM 
size popu- TIME (da;):} _x 106Jkg CELL 
x106 la- expected on observed (calculated) cone. 
!kg tion graft size factor** 
stem 
1LG 3 cell 25 18 11-22 4- 7 
cone.*** 
M5 0.2 CD34+ >30 19 9-17 42-86 
D35 0.2 CD34+ >30 17 14-28 67- 142 
1TP 20 CD34- 14 22 4- 9 0.2- 0.4 
* Unique Monkey Number 
** 95% confidence limits 
*** prepared as described in section 2.2 
As a negative control, one monkey was grafted with 2 x 107 LSM separated 
cells/kg body weight from which the ICH3 positive cells had been removed by using 
immunomagnetic beads, as described in section 2.5. This procedure resulted in 90 
% CFU-C depletion (table 3.2). 
The regeneration time of the reticulocytes in this monkey was similar to a regene-
ration time following transplantation of 4.1 - 8.5 x 106 unfractionated bone marrow 
cells/kg (95% confidence limits) (Table 3.3). This observation demonstrated a 60 -
80% depletion of repopulating cells, which is in the same order of magnitude as the 
CFU-C depletion (Table 3.2). In this monkey, which had no infectious complica-
tions, the regeneration time of leukocytes was similar to that following transplan-
tation of 4 x 105 - 1 x 107 unfractionated cells/kg, indicating a similar depletion of 
repopulating cells. 
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3.3.2. Chimerism studies following BM transplantation with CD34+ cells 
To study the capacity of CD34+ cells to establish sustained chimerism, two female 
Rhesus monkeys were transplanted with small numbers of allogeneic CD34+ BM 
cells/kg, obtained from a RhLA identical male sibling. Allogeneic BM 
transplantation requires more cells than autologous transplantation. As isolation of 
sufficient numbers of CD34+ cells for allogeneic BM transplantation by 
flowcytometric cell sorting requires approximately 30 hours of sorting, the CD34+ 
cells were isolated by means of immunomagnetic beads, as described in section 2.5. 
The number of residual T lymphocytes in the CD34+ cell suspensions was deter-
mined by flow cytometric analysis after staining with Leu 2a/PE and Leu 3a/PE, 
(see section 2.3 and 2.4.) 
The characteristics of the grafts are summarized in Table 3.4. The monkeys were 
conditioned by TBI with 9.5 Gy TBI (6 MV X-rays) on day -1, and received 
supportive care, starting at day 1, as described in section 2.9. 
Positive selection of CD34+ cells by immunomagnetic beads following PHSC 
enrichment by albumin density centrifugation results in a four- to twelve fold 
further CFU-C enrichment (Table 3.4). Both monkeys were transplanted with 3.5 x 
106 CD34+ cells/kg, which is the CFU-C equivalent of 2 x 108 unfractionated BM 
cells/kg. (range 1.4- 2.5 x 108). 
The regeneration time and chimerism status of these monkeys were compared 
with a control monkey, which was transplanted with E-rosette depleted, albumin 
gradient concentrated PHSC, containing the CFU-C equivalent of 2.5 x 108 BM 
cells/kg. This graft was also prepared from the BM of a RhLA identical sibling. 
The regeneration patterns following transplantation of CD34+ cells in RhLA 
identical siblings are shown in Figure 3.7 and 3.8. The regeneration time, expressed 
as the day at which reticulocyte counts exceed a value of 1 % was similar to the 
regeneration time of the control animal. Following the dose of TBI used in these 
monkeys, endogenous regeneration of reticulocytes can be calculated to occur not 
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Regeneration of reticulocytes following transplantation of CD34 
positive, allogeneic, RhLA identical sibling BM cells. Conditioning with 
9.5 Gy (6 MV X-rays) TBL The control monkey was transplanted with the CFU-C 
equivalent of 4 x 108 unfractionated BM cells/kg. 
earlier than at day 21 (p < 0.05). indicating, that allogeneic CD34+ cells have the 
capacity to repopulate an irradiated recipient. 
To investigate the capacity of CD34+ cells to sustain chimerism, the Y 
chromosome was used as a marker. Other markers for discrimination between 
recipient cells and RhLA identical donor cells were not available. BM cells were 
cultured as described in section 2.10., and chromosome preparations were made. 
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Table 3.4 CHARACTERISTICS OF ALLOGENEIC CD34+ BM GRAFTS 
ficoll albumin ICH3+ ICH3-
density (graft) gradient 
punctured BM for 
unique animal no. 8647 
CFU-C/105 293 871 10595 101 
concentration factor 2.0 6.0 72.4 0.6 
number of 
nucleated cells 1626 150 9.8 53 
(x 106) (= 3.5/kg) 
%of total 
nucleated cells 100 9.2 0.6 3.2 
% CFU -C recovery 100 49.7 39.0 2.0 
% T lymphocytes 6.1 14.2 2.7 20.9 
absolute number of 
T lymphocytes 992 211 2.7 107 
(x 105) (= 1/kg) 
pressed BM for 
unique animal no. 1 ZN 
CFU-C/105 104 585 2040 123 
concentration factor 2 11.2 39.2 2.4 
number of 
nucleated cells 2170 150 9.4 91.3 
(x 106) (= 3.6/kg) 
%of total 
nucleated cells 100 6.9 0.4 4.2 
% CFU-C recovery 100 46.3 5.8 9.4 
% T lymphocytes 9.7 5.6 1.2 7.3 
absolute number of 
T lymphocytes 210 8.4 1.0 66.6 
(x 105) (= 1/kg) 
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Cont. Table 3.4 
buffy coat albumin Following AET depletion -
pressed BM for 
unique animal no. 1 VL 
CFU-C/105 7.3 65 46 
concentration factor 8.9 6.3 
number of 
nucleated cells 2192 228 160 
(x 106) (= 40/k:g) 
%of total 
nucleated cells 100 10.4 7.3 
% CFU -C recovery 100 93.5 46.1 
% T lymphocytes n.d. n.d. 1.0 
absolute number of 
T lymphocytes n.d. n.d. 16 
(x 105) (= 4/k:g) 
Both recipients were female and both donors were male, so that the presence of a Y 
chromosome in a cell indicates the donor origin of that cell, and the absence of a Y 
chromosome indicates recipient origin (Figure 3.9). The results are summarized in 
Table 3.5. 
The regeneration of these monkeys is much earlier than is expected without 
allogeneic BM transplantation, indicating the donor origin of the repopulating cells 
(the repopulating capacity of the allogeneic CD34+ cells). However, complete 
chimerism was not achieved in these monkeys. Nevertheless, the persistence of 
donor derived progenitor cells up to 160 days following BM transplantation indicate 
the stem cell properties of a subpopulation of the CD34+ cells. 
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Regeneration of leukocytes following transplantation of CD34 
positive, allogeneic, RhLA identical sibling BM cells. Conditioning with 
9.5 Gy (6 MV X-rays) TBI. The control monkey was transplanted with the CFU-C 
equivalent of 4 x 108 unfractionated BM cells/kg. 
On the basis of the data which will be described in Chapter IV, the number of resid-
ual recipient PHSC following the conditioning TBI was estimated to be the equival-
ent of approximately 5 x 106 unfractionated BM cells/kg body weight. The number 
of transplanted cells was the equivalent of 1.4 x 108 and 2.5 x 108 unfractionated 
BM cells/kg respectively. The ratio between the number of calculated, resid-
ual recipient PHSC and the number of transplanted PHSC was different from the 
ratio between recipient and donor derived progenitor cells after regeneration. A 
similar, but less pronounced phenomenon was observed in the control monkey. For 
a definite proof of the capacity of CD34+ cells to sustain long term complete 
chimerism, additional experiments are required. In such experiments, a more 
intensive conditioning regimen should be used to reduce endogenous regeneration. 
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Table 3.5 CHIMERISM FOLLOWING TRANSPLANTATION OF HSC 
Time Unique Number Number Total 
(day) animal of donor of recipient number 
cells cells 
20 8647 2 8 10 
27 0 25 25 
33 1 24 25 
104 1 8 9 
131 4 36 40 
19 1ZN 42 8 50 
32 5 20 25 
74 5 15 20 
103 1 49 50 
160 13 12 25 
13 1 VL 42 8 50 
45 40 10 50 
73 30 20 50 
101 18 7 25 
129 16 9 25 
171 25 15 40 
200 36 14 50 
3.4. Discussion. 
Identification and positive selection of early repopulating cells for ABMT was 
successfully performed in Rhesus monkeys by use of the anti-CD34 antibody, ICH3. 
The CFU-C assay appeared to be predictive for the enrichment of repopulating 
cells. This confirms the notion, that ICH3 does not inactivate the labelled cells in 
vivo, which has been described for many other MCA20,21. 
Endogenous regeneration can never be completely ruled out following autologous 
BM transplantation, but the high regeneration time that was observed following 
transplantation of ICH3 positive cells excludes an endogenous origin of the early 
repopulating cells. 
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Figure 3.9 Karyotyping of Rhesus monkey BM cells after transplantation of RhLA-
identical male BM in a female recipient. In this case, the presence of a Y 
chromosome (arrow) in a cell indicates the donor origin of that cell, and the absence of a 
Y chromosome in a complete karyogram indicates its recipient origin. 
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Although the cells measured by the regeneration assay have the capacity for early 
repopulation, it is by no means certain that these cells also have sufficient self-
renewal capacity to sustain blood cell production over a long period of time. This 
capacity of CD34+ cells was tested in an additional experiment with RhLA identical 
siblings. In allogeneic bone marrow transplantation, the relationship between graft 
size and regeneration time has not yet been studied in detail. Therefore the 
enrichment of repopulating cells cannot be calculated. In addition to the early 
regeneration after transplantation of CD34+ cells, sustained chimerism was 
obtained. However, only a minority of the progenitor cells were from donor origin. 
These results may indicate, that the self-renewal capacity of ICH3+ cells is limited, 
which means, that the PHSC are not sufficiently enriched by isolation of ICH3+ 
cells. Alternatively, immunological factors might result in the disappearance of the 
donor derived cells. The immunological mechanisms involved in mixed chimerism 
are poorly understood. The probability of graft rejection decreases with the number 
of transplanted T lymphocytes, and with the immunosuppressive effect of the condi-
tioning regimen (reciprocal interference between graft versus host and host versus 
graft)22. Thus the number of transplanted T-lymphocytes could be too low to allow 
complete chimerism following a conditioning TBI dose of 9.5 Gy, 6 MV X-rays 
(equivalent to 8.3 Gy, 300 kV orthovolt) (see Chapter IV). In that case, an 
immunological reaction rather than insufficient self- replication capacity of the 
CD34+ cells is the most likely explanation for the low frequency of donor derived 
progenitor cells following transplantation of allogeneic CD34+ cells. Further experi-
ments, including a more immunosuppressive conditioning regimen, are required to 
prove this hypothesis. 
The data from the present autologous transplantations further indicate, that T 
lymphocytes in BM grafts are not required as accessory cells for the early regene-
ration. This is consistent with the observation in mice, that very small numbers of 
highly purified stem cells can repopulate a lethally irradiated animaL and with 
observations in Rhesus monkeys, which demonstrate that T lymphocyte depletion 
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does not jeopardize the regeneration after autologous BM transplantation-
Primate PHSC can also be enriched on the basis of the expression of MHC class ll 
antigens (DR). However, selection of CD34+ cells has obvious advantages over 
selection of DR+ cells. Firstly, class ll MHC antigens are expressed on a wide 
variety of cell types, including B-lymphocytes, activated T-lymphocytes, and 
monocytes/macrophages, and on a number of malignant cell types. Therefore, 
removal of undesirable DR+ cells would still be required to achieve optimal results. 
This complication does not occur when stem cells are selected on the basis of CD34 
expression. Thus, positive selection of CD34+ cells results in a higher degree of 
CFU-C enrichment than selection of DR+ cells. However, in a number of acute 
myeloid leukemia patients, the malignant cells express the CD34 antigen. Obviously, 
in such patients, the CD34 antigen can not be used to separate PHSC from malignant 
cells. Furthermore, expression of DR- antigens on HSC and HPC appeared to be 
heterogenous: approximately equal fractions of those cell types were found among 
the dull and bright DR+ cells- Isolation of cells on the basis of simultaneous CD34 
and DR expression did not result in higher degree of CFU-C enrichment than 
selection of CD34+ cells alone. This is due to the heterogeneous expression of DR 
among CFU-C. Since a similar heterogeneity of DR expression was earlier observed 
for repopulating HSC as detected by the autologous regeneration assay, it was not at-
tempted to use two-colour cell sorting for BM transplantation. In contrast to DR 
expression, the expression of CD34 appeared to be more homogenous, although 
sorting of the most bright CD34+ cells resulted in a higher CFU -C enrichment than 
sorting of all CD34+ cells. However, this is possibly not due to heterogeneity of 
CD34-expression, but to a more complete elimination of CD34- cells from the 
bright fraction. 
Other investigators have studied the repopulating capacity of CD34 positive cells 
in baboons23. However, in this study, the enrichment of PHSC was not quantified, 
and a 10 fold greater number of CD34+ cells was required to achieve a similar 
regeneration time as was presented in section 3.3.1. These authors therefore did not 
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exclude the possibility of inactivation of CD34+ cells by the MCA used. In our study 
such an inactivation is unlikely, since calculated recoveries and concentration factors 
for in vivo repopulating HSC and for in vivo detected HPC appeared to be very 
similar. Therefore, special precautions to prevent such inactivation in vivo are not 
required if the anti-CD34 MCA ICH3 is used. This considerably simplifies the 
development of methods applicable to clinical BM transplantation as compared to 
the other available anti-CD34 MCA. 
The frequency of repopulating cells in primate BM is unknown, but positive 
selection of CD34+ cells does not result in a purification of HSC to homogeneity. 
Further enrichment might be possible with additional markers such as lectins, 
rhodamine 12324,25, or other MCAs directed against surface antigens26,27. Although 
such a further enrichment is interesting, it is not essential for a number of 
applications of purified stem cells: CD34+ cells can be used to study the direct 
effects of hemopoietic growth factors on in vitro proliferation and differentiation of 
hemopoietic stem cells and progenitor cells, in the absence of CD34- accessory 
cells28, for studies at the molecular analysis of early hemopoietic cell differentia-
tion, including genetic modification of stem cells for possible therapeutic purposes. 
The current flow cytometric cell sorting techniques are very useful for analytical 
purposes. However, for the purification of PHSC for clinical BMT a more rapid 
and aseptic technique is required, which can be performed on a large scale. The 
immunoabsorption technique with immunomagnetic beads, used for the 
experiments, described in section 3.3 is safe and easier to perform at a large scale. 
This development brings positive selection of stem cells as a general applicable 
method to eliminate T-lymphocytes and/or tumour cells from BM grafts, within the 
reach of clinical application. 
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CHAPTER IV 
RADIATION SENSITIVITY OF HEMOPOIETIC STEM CELLS 
4.1. Introduction. 
The hemopoietic system is highly sensitive to Total Body Irradiation (TBI) 
and other cytotoxic- agents. TBI or chemotherapy eliminates hemopoietic stem 
cells (HSCs) and progenitor cells, resulting in a reduction in blood cell produc-
tion and consequently a lack of peripheral blood cells, (pancytopenia). Self-
replication and differentiation of the surviving HSCs result in regeneration of the 
damaged bone marrow (BM) and resumption of normal blood cell production. 
The regeneration time is dependent on the number of residual HSC. Following a 
dose of total body irradiation (TBI) that eliminates more than a certain fraction 
of HSCs, hemopoiesis can only be restored by BM transplantation. Following 
doses of TBI, that leave a higher number of HSCs, BM transplantation might 
reduce mortality and morbidity by shortening the duration of the pancytopenic 
period I ,2. Therefore, a number of victims of accidental radiation at nuclear 
power stations at Vinca (Yugoslavia) and Chemo~yl (Soviet Union) have been 
treated by allogeneic BM transplantation3,4. However, the conditions for a 
beneficial effect of BM transplantation in such emergencies, i.e the conditions 
under which the advantages of a shorter duration of pancytopenia outweigh the 
risks of allogeneic BM transplantation, are poorly defined. 
The duration of radiation induced pancytopenia depends on the number of 
HSCs that survive irradiations. The number of surviving HSCs is dependent on 
the initial number of HSC and their radiosensitivity, the radiation dose and the 
relative biological effectiveness (RBE) of the radiation type. Therefore reliable 
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information on the radiosensitivity and the frequency of HSCs is essential for the 
development of a treatment strategy for victims of radiation accidents. 
In rodents, survival of HSCs following TBI or irradiation of BM in vitro has 
been determined using the spleen colony assay. The radiation sensitivity has been 
characterized by a Do value between 0.7 and 1.1 Gy and an extrapolation number 
between 1 and 3 for 200-300 kV X-rays (see section 1.2). For outbred species, 
such as dogs, Rhesus monkeys and humans, the information on the radio-
sensitivity and frequency of HSCs is limited. The only available information is an 
indirect estimate by Vriesendorp and van Bekkum6. They investigated the 
LDso/30days for TBI in several species as well as the BM graft size required for 
50 % survival after supralethal TBI (rescue doseso) (Table 4.1). They concluded 
from those data, that the number of Rhesus monkey HSC, surviving 5.25 Gy 300 
kV X-rays was the equivalent of a BM graft of 7.5 x 106 cells, transplanted after 
supralethal TBI. On the basis of radioiron incorporation, the total number of 
bone marrow cells in normal monkeys was estimated at 24 x 109Jkg7,8. On this 
basis, the Do value of Rhesus monkey HSCs was estimated to be 0.6 Gy for 300 
kV X-rays; They further observed, that smaller animals have a higher LDso130 
days for TBI than larger species, and that smaller animals require less bone 
marrow cells per kg body weight than larger species to survive lethal irradia 
Table4.1 
Species 
Mouse 
Rat 
Rhesus 
Monkey 
Dog 
TOXICITY OF TBI (300 kV X-RAYS) AND BONE MARROW 
CELL DOSE REQUIRED FOR RESCUE 
Body weight 
(kg) 
0.025 
0.20 
2.60 
12.0 
LDso/30days 
(Gy) 
7.00 
6.75 
5.25 
3.70 
Autologous or syngeneic 
rescue doseso 
(BM cells x 106/kg) 
2.0 
3.8 
7.5 
17.5 
Data from Vriesendorp and van Bekkum 1980. 
Adapted with permission from Reference 6. 
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tion. Since these differences could not readily be explained from differences in 
the radiation sensitivity of HSC or cell kinetic parameters determining the rate of 
blood cell production, an inverse relationship between HSC frequency and body 
weight was postulated. 
Modem intensive supportive care enables the study of endogenous regene-
ration of blood cell production following TBI doses that were hitherto assumed 
to be lethal. By comparing endogenous regeneration patterns to the regeneration 
patterns after high dose TBI followed by autologous BM rescue, the frequency 
and radiosensitivity of HSCs was investigated. The irradiations were performed 
with 300 kV and with 6 MV X-rays. The RBE for the BM syndrome for 6 MV 
X-rays was assessed to enable a comparison of the data obtained for both types of 
radiation. Since large numbers of animals are required for such an assessment, 
this study was performed with mice. There is no reason to assume that the RBE 
for Rhesus monkey HSCs would differ significantly from that for murine HSC. 
The assessment of the RBE of 6 MV X-rays for HSCs will be described in 
section 4.2.1. 
Gerritsen et al. have demonstrated, that the regeneration time of peripheral 
blood cells following autologous BM transplantation is directly related to the 
number of transplanted cells9. This relationship can be characterized by the 
formula 
Y=a-blnT (1) 
in which Y represents the day at which peripheral blood cell numbers exceed a 
certain value (regeneration time), and T the number of transplanted autologous 
BM cells. 
If we assume, that endogenous hemopoietic regeneration following TBI is the 
same process as regeneration following autologous BM transplantation, a similar 
relationship between the number of surviving HSC and the regeneration time can 
be expected. However, following the injection of a BM graft in a lethally 
irradiated recipient, only a certain fraction of the injected HSCs reaches an 
appropriate site for hemopoiesis. This "homing fraction", estimated to be 0.3 in 
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miceiO, has not been determined in Rhesus monkeys, while the frequency of 
HSCs in the femoral bone marrow is unknown. It is also unknown, whether the 
frequency of HSCs in femoral BM is equal to the frequency at other BM sites. 
Another uncertainty is caused by admixture of the punctured BM with peripheral 
blood, in the autologous BM transplantation experiments. For all these reasons 
equation (1) can not be used to calculate the absolute number of HSC that survive 
a certain dose of TBI. However, the relative number of surviving HSC can be 
calculated if we assume that: 
1. Endogenous regeneration from HSCs that survived TBI is the same process as 
regeneration from transplanted autologous HSCs. 
2. The number of surviving HSCs rather than radiation damage to the BM 
microenvironment determines the time of endogenous regeneration following 
TBI. 
3. The homing fraction of transplanted BM cells is not dependent on the number 
of transplanted cells, in the range between 106 to 108 cells/kg body weight. 
On the basis of these assumptions, the number of BM cells (N), that survives a 
sublethal dose of TBI and results in an endogenous regeneration time Y can be 
regarded as proportional to the number of BM cells transplanted (T) following 
a marrow ablative dose of TBI that results in a similar regeneration time 
T=cN (2) 
in which N is the number of surviving HSC, and c is regarded as a constant 
factor, dependent on the homing fraction, the frequency of HSC among 
punctured BM cells and among BM cells in vivo. Substitution ofT in equation 
(1) by eN (equation 2) results in a relationship between the number of surviving 
HSC and the regeneration time. 
Y=a-blnN-blnc (3) 
106 
c: 
0 
... 
0 
10 
... 
.... 
Cl 
c: 
> 
> 
... 
:J 
Ill 
Figure 4.1 
10° 
10-1 
10-2 
10-3 
10-4 
10° 
10-1 
10-2 
10-3 
10-4 
0 
SINGLE HIT 
MODEL 
5 10 0 
••••• n=S 
---- n=4 
-- n=2 
-·-n=1 
MULTITARGET 
MODEL 
LINEAR 
QUADRATIC 
MODEL 
5 
dose ( Gy) 
10 
Mathematical descriptions of cell survival following ionising 
irradiation. 
107 
The relationship between radiation dose and cell survival can be characterized 
by various mathematical descriptions, based upon the Poisson distribution of the 
probability of lethal lesions. The most simple mathematical description is the 
single hit model 
S =NINo = e -DIDo (4) 
in which N is the number of surviving cells, No the total number of irradiated 
cells, D the radiation dose and Do the dose resulting in an average of one lethal 
lesion per cell. Since the probability of lethal lesions follows a Poisson 
distribution, a radiation dose of Do Gy results in a surviving fraction e- 1, i.e. the 
fraction of cells with 0 lethal lesions. In most cell types, the dose survival curve 
shows a shoulder in the lower dose range. This shoulder is not described by 
equation (4). Other mathematical models, summarized in Figure 4.1 include the 
description of this shoulder. 
The available data on the radiosensitivity of HSCs in a variety of species (see 
section 1.2) indicate only a small shoulder in the survival curve. In the dose 
range between 5 and 10 Gy, the survival of HSCs can therefore be approximated 
by equation (4). This equation can be rewritten as 
ln N -ln No= -DIDo (5) 
Elimination of N from equation (3) and (5) results in a relationship between the 
radiation dose and the endogenous regeneration time: 
b 
Y={a-b(lnNo+lnc)}+-- D 
Do 
(6) 
This relationship will be fitted to the experimental data in section 4.2.2, and in 
section 4.2.3 the radiosensitivity of HSC will be calculated under a variety of 
indicated assumptions. 
The slope of the curve described by equation ( 6) is independent of the uncertain 
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relationship between T and N (c in equation 2). For an estimate of absolute 
numbers of surviving cells, we have to assume a certain homing fraction, and 
HSC distribution over the body. However, the result of a Do calculation 
according to equation (6) is not influenced by such assumptions. 
4.2. Results. 
4.2.1. The Relative Biological Effectiveness (RBE) of 6 MV X-rays for 
hemopoietic stem cells determined in mice. 
The relative biological effectiveness (RBE) of 6 MV X-rays for hemopoietic 
HSCs was determined in female (Cs7BVRij x CBA/Rij)F1 (BCBA) mice at the 
age of 12- 15 weeks. These mice were irradiated with graded doses of 6 MV X-
rays or 300 kV X-rays. The relationship between the dose of TBI and 30-day 
mortality for both types of radiation was established by probit analysis as shown 
in Figure 4.2. Data of two pooled experiments were used, and the numbers of 
animals used for each dose are indicated. The RBE for 6 MV X-rays was 
calculated by dividing the LDso/30 days for 300 kV X-rays by the LDso/30 days for 
6 MV X-rays, resulting in a value of 0.87. The RBE for 60Co y radiation was 
determined in the same experiment, as shown in Figure 4.3. The calculated RBE 
for 60Co y radiation was 0.88, which closely approximates the value of 0.85 Gy 
that was reported earlierll. 
4.2.2. Relationship between dose of TBI and regeneration time of peripheral 
blood cells in Rhesus monkeys. 
The regeneration time of peripheral blood cells following TBI, without 
transplantation of hemopoietic cells, was thought to be directly related to the 
number of repopulating hemopoietic cells that survived the irradiation, which is 
dependent on the absorbed dose of irradiation. To assess this relationship, 
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Figure 4.2 Survival curves used for the calculation of the relative biological effect 
(RBE) of 6 MV X-rays. Female CBA x Cs7bl Fl (BCBA) mice, 12 weeks of age 
were used. The RBE was calculated by 
LDso, 30 days, 300 kV 
------- = 0.87 
LDso. 30 days, 6 MY 
The numbers in parentheses indicate the number of animals that died before day 
30/the number of animals used. 
monkeys were treated with graded doses of TBI over a range of 4,0 to 10 Gy 6 
MV X-rays. Other monkeys were irradiated with 300 kV X-rays, over a dose 
range of 5.0 to 9.8 Gy. The physical parameters and dosimetry of both types of 
irradiation are described in section 2.7. For comparison of both radiation types, 
it was assumed, that the RBE of 6 MV X-rays for Rhesus monkey HSCs is 
similar to·the RBE for murine HSCs, i.e. 0.87 (see section 4.2.1). 
All monkeys received full supportive care as described in section 2.9. 
In Figure 4.4, the influence of supportive care on mortality rate after TBI is 
demonstrated. Almost all animals which were submitted to supportive care, sur-
vived for more than 30 days, and showed endogenous regeneration, which is not 
the case for the animals without supportive care. The mortality following TBI 
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without supportive care have been described earlier12. Under full supportive 
care, only 2 monkeys died before day 30: Monkey 8650 (10 Gy, 6 MV) died 
from sepsis on day 14. Monkey 1 ZU (10 Gy, 300 kV) suffered from severe 
diarrhoea starting at day 5. Repeatedly, no pathogenic micro-organisms could be 
demonstrated in its faeces. fu spite of parenteral fluid and electrolyte administra-
tion, the monkey lost 40 % of its body weight and died at day 24, after almost 3 
weeks of severe diarrhoea. During the observation period, bleeding or infectious 
problems did not occur. Autopsy revealed a complete villous atrophy of the 
colon, jejunum and ileum. Four monkeys (2 BU, 1 YK, 1 JB and 1HK) died after 
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Figure 4.3 Survival curves used for the calculation of the relative biological effect 
(RBE) of 137Cs y-rays. Female CBA x Cs7b!Fl (BCBA) mice, 12 weeks of age 
were used. The RBE was calculated by 
LDso, 30 days 300 kV 
------- = 0.88 
LDso, 30days Y 
The numbers in parentheses indicate the number of animals that died before day 
30/the number of animals used. 
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Figure 4.4 Influence of supportive care on survival30 days of Rhesus monkeys 
following TBI with 300 kV X-rays. (thrombocyte transfusions, erythrocyte 
transfusions, selective decontamination, parenteral fluid and systemic antibiotics). 
Data without supportive care derived from reference 11. 
full hemopoietic regeneration had occurred. Two of these monkeys (1 HK and 1 
JB) died from sepsis, and two monkeys (2 BU and 1 YK) died from diarrhoea 
caused by flagellate infections. All other animals are alive and well after a 
median observation time of 335 days (range 165-508 days). The endogenous 
regeneration of the peripheral blood cells following TBI is shown in Figure 4.5 
for 6 MV X-rays and in Figure 4.6 for 300 kV X-rays. The most essential data 
of the individual monkeys are summarized in Table 4.2a for 6 MV X-rays and in 
Table 4.2b for 300 kV X-rays. The regeneration time of peripheral blood cells 
was defined as the day at which reticulocyte counts exceeded a value of 1%, 
leukocyte counts a value of 109/l, or thrombocyte counts persistently reached 
values of 40 x 109/1 or more without transfusions. The three monkeys, which 
were irradiated with 5 Gy 6 MV X-rays, showed a regeneration time similar to 
that following transplantation of 108 BM cells/kg. This indicates, that the number 
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Table 4.2a SURVIVAL OF RHESUS MONKEYS AND REGENERATION OF 
BLOOD CELLS FOLLOWING TBI WITII 6 MV X-RAYS 
Unique dose Reti- Leukocxtes Thrombocytes Alive* Cause 
animal (Gy) >1% > 109 /l penia >40 X 109/l and well of 
number (day) (day) (days) (day) (days) death 
8654 4.0 10 22 5 NA** >296 
BB 31 5.0 10 20 12 15 >365 
BB40 11 21 11 NA > 365 
1 UP 9 18 9 NA > 365 
8667 6.0 13 17 6 NA > 171 
1XT 13 21 16 NA > 365 
C28 8.0 20 18 12 19 >365 
1 ZF 20 24 19 23 > 193 
1 YK 10.0 18 21 16 17 103 diarrhoea*** 
2BU 24 25 20 24 71 diarrhoea*** 
8650 > 14 > 14 >9 > 14 sepsis**** 
* Survival time October, 1989. 
** NA =Not Available, since cell counts remained above threshold value. 
***Flagellate enteritis. 
****Gram positive rod. 
Table 4.2b SURVIVAL OF RHESUS MONKEYS AND REGENERATION OF 
BLOOD CELLS FOLLOWING TBI WITII 300 kV X-RAYS 
Unique dose 6MV Reti- Leukocytes Thrombocytes Alive* Cause 
animal (Gy) dose >1% > 109 /l penia >40x109fl and well of 
number equivalent (day) (day) (days) (day) (days) death 
BB48 5.0 5.7 NA** 17 10 14 >365 
1 xs 10 19 14 15 >212 
1 ZG 13 19 12 14 >216 
8622 9.0 10.3 29 31 23 50 > 165 
1JB 9.6 11.0 28 23 18 24 45 sepsis*** 
1 HK 9.8 11.3 31 26 22 37 42 sepsis**** 
gastro-
lZU 10.0 11.5 >24 >24 >18 >24 24 intestinal 
syndrome 
* Survival rime on October, 1989 
** NA =Not Available, since cell counts remained above threshold value. 
***Proteus mirabilis 
****Mulriresistent Gram positive coccus. 
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of HSCs that survives this dose of TBI was the equivalent of 108 transplanted BM 
cells/kg. The relationship between the number of transplanted cells and the 
regeneration time was previously assessed in the range between 106 and 108 
cells/kg. This means, that the monkey irradiated with 4 Gy 6 MV X-rays, should 
not be included in the calculation of the Do value, since its number of residual 
HSCs exceeded the maximum numbers of BM cells transplanted in the ex-
periments that were used as a basis for calibration. 
Since most animals were irradiated with 6 MV X-rays, the relationship 
between the regeneration time and the dose of TBI was calculated fOr this 
radiation type. The dose of the monkeys irradiated with 300 kV X-rays was 
converted to an equivalent of a dose of 6 MV X-rays. For this conversion the 
dose of 300 kV was divided by 0.87, which is the RBE for 6 MV X-rays. The 
regeneration time of the peripheral blood cells appeared to be directly related to 
the dose of TBI. In the dose rage between 5 and 11 Gy (6 MV X-rays), this 
relationship, shown in Figure 4.7, can be characterized by the following re-
gression equations: 
For reticulocytes: 
Y = 3.0 D- 5.2 (7) 
in which Y is the day at which reticulocyte counts exceeded a value of 1% and D 
is the dose of TBI (6 MV X-rays) in Gy (r=0.95, p < 0.001). 
For leukocytes: 
Y = 1.1 D + 12.7 (8) 
in which Y is the day at which leukocyte counts exceeded a value of 1 x 109/1. (r 
= 0.72, p < 0.01). The regeneration time of granulocytes and lymphocytes were 
not significantly different from each other and from the regeneration time of all 
leukocytes. 
For thrombocytes: 
Y = 3.3 D- 4.0 (9) 
in which Y is the day at which thrombocyte counts persistently exceeded a value 
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of 40 x 109/1 without transfusions. (r = 0.69, p < 0.02). 
Essentially, the relationship between the dose of TBI and the day at which 
regeneration of peripheral blood cells occurs is not linear over a wide range of 
doses, since low doses of TBI do not result in a measurable pancytopenia (day of 
regeneration= 0), and "marrow ablative" doses are not followed by regeneration 
at all (day of regeneration = oo ). However, in the dose range between 5 and 11 
Gy (6 MV X-rays), the regeneration time was in the same range as was described 
for monkeys transplanted with graded numbers of autologous BM cells between 
106 and 108/kg. In these transplanted monkeys a log-linear relationship between 
the number of transplanted cells and the regeneration time was demonstrated9. 
Furthermore, in the dose range tested, a log-linear relationship between the 
fraction of surviving cells and the dose of irradiation can be expected. 
Therefore, within the dose range tested, the relationship between the dose of TBI 
and the regeneration time was expected to be linear. 
The correlation coefficient for the relationship between the dose of 
irradiation and the regeneration time was higher for reticulocytes than for 
leukocytes and thrombocytes. This can be explained by the influence of external 
factors on the regeneration of peripheral blood cells. The most important 
external factor is probably the occurrence of infections, which influences 
leukocyte and thrombocyte counts, but is not expected to affect the reticulocyte 
counts as long as extensive hemorrhages do not occur. 
4.2.3. Radiation sensitivity of hemopoietic stem cells. 
In the previous section, a linear relationship between the dose of TBI and the 
regeneration time of peripheral blood cells was described. Following autologous 
BM transplantation, the relationship between the number of cells transplanted 
and the regeneration time of peripheral blood cells was described earlier9. 
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Figure 4.6a 
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times of leukocytes, thrombocytes and reticulocytes were def"med as the day at which 
a level of more than 109, 40 x 109 and 1 %, respectively was exceeded. Data points 
indicate the average of 2 to 4 monkeys. Shaded areas represent 95 % confidence 
limits. 
120 
The latter relationship, based on experiments performed by Gerritsen et al.9 can 
be rewritten as 
Y = 83.2 - 4.0 ln T (10) 
in which Y is the day at which the reticulocyte count exceeds a value of 1 % and 
Tis the number of transplanted cells/kg body weight (r=0.98, p=O.OOOl). 
Comparison of the endogenous regeneration times, characterized in section 
4.2.1., to the regeneration times following autologous BM transplantation results 
in a relationship between the dose of TBI and the number of surviving HSCs, as 
explained in section 4.1. Under the assumptions, discussed in the same section, 
this relationship enables a calculation of the Do value for HSCs, irradiated in 
vivo. As explained in section 4.2.3, the monkey irradiated with 4 Gy 6 MV X-
rays, was not included in the calculation of the Do value, since its number of 
residual HSCs was expected to exceed the maximum numbers of BM cells trans-
planted in the experiments that were used as a basis for calibration. 
Since the leukocyte and thrombocyte counts appeared to be more sensitive to 
external factors than the reticulocyte counts, calculation of the Do value on the 
basis of the regeneration of leukocytes and thrombocytes results in extremely 
wide 95 % confidence limits (1.2 - 4.8 Gy for leukocytes and 1.0 -7.3 Gy for 
thrombocytes). Therefore, the regeneration time of reticulocytes was used only. 
From equation (6) and (7) the relationship between b and Do can be 
calculated: 
b=3 Do (11) 
In equation (10) the value of b was found, so that the Do value for 6 MV X-rays 
could be calculated and appeared to be 1.33 Gy (95 % confidence limits 1.16 -
1.61 Gy). The dose/survival curve is shown in Figure 4.8. Multiplication of the 
Do value for 6 MV X-rays by the -RBE (0.87) results in a Do value of 1.16 Gy 
(95 % confidence limits 1.0,-1.40 Gy) for 300 kV X-rays. In order to confirm 
that the RBE value used (0.87), (based on experiments with mice) (section 
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4.2.1), also applies for Rhesus monkeys, the Do value for 300 kV X-rays was 
calculated separately. In spite of the small number of monkeys irradiated with 
300 kV X-rays, the calculated Do value appeared to be 1.04 Gy, which is within 
the 95 % confidence limits of the Do value calculated above. 
Extrapolation of our data cannot be used for a calculation of the total number 
of BM cells for two reasons. Firstly, the relationship between N and T in 
equation (2), which is required for such a calculation, is not known. Secondly, 
the 95 % confidence limits of the Do value are wide, and small variations in Do 
value will result in large variations in the extrapolated numbers. Other investiga-
tors have estimated the total number of Rhesus monkey BM cells as 24 x 
109fkg7,8. Inclusion of this total number of bone marrow cells in the calculation 
requires an assumption on the relationship between N and Tin equation (2). The 
most important factors in this respect are the homing fraction and the 
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Figure 4.8 Calculated survival of hemopoietic stem cells after TBI with 6 MV X-
rays, using the single hit model. The data points shown were derived from the 
regeneration time of reticulocytes and indicate the average of 2 to 4 monkeys. 
122 
extrapolation number, (n). If we assume, that the homing fraction of Rhesus 
monkey HSC is equal to that of murine CFU-S, the numbers of transplanted BM 
cells should be multiplied by this factor (0.3) to get the number of endogenous 
HSC according to equation (2). When No is set at 24 x 109/kg7.8 the surviving 
fraction of cells can be calculated for each dose of TBI, and the best fitting Do 
value can be found. This calculation resulted in a Do value of 1.09 Gy for 6 MV 
X-rays. Assumptions on the extrapolation number, n, in this calculation result in 
a further change in the Do value (Table 4.3), but not in significant changes in the 
survival curve of HSC (Figure 4.9). For n = 2, which is the median value de-
scribed in all studies (Table 1.1), the Do value is 1.05 Gy (0.88-1.30) for 6 MV 
X-rays, and 0.91 Gy (0.76-1.13) for 300 kV X-rays. 
Table 4.3 INFLUENCE OF Tiffi EXTRAPOLATION NUMBER n ON THE 
CALCULATED Do VALUE OF RHESUS MONKEY HSC 
total 
number 
of 
BMcells 
not included 
24 X 109 /kg *) 
extrapolation 
number 
(n) 
1 
12 
1 
2 
4 
12 
*) A homing fraction of 0.3 was assumed. 
Do value Do value 
(Gy) (Gy) 
for 6 MV for 300 kV 
X-rays X-rays 
(95% conf. lim.) 
1.33 1.16 
(1.14-1.61) (0.99-1.40) 
1.29 1.12 
(n.a.) (n.a.) 
1.09 0.95 
(0.93-1.33) (0.81-1.16) 
1.05 0.91 
(0.88-1.30) (0.76-1.13) 
1.01 0.88 
(0.83-1.27) (0.73-1.11) 
0.95 0.83 
(0.77-1.24) (0.67 -1.08) 
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Figure 4.9 Calculated survival of hemopoietic stem cells after TBI with 6 MV X-
rays, using the multi target model, and various assumptions were 
made for the extrapolation number, n. (n was set at 1, 4 and 12 
respectively). The data points shown are derived from the regeneration time of reticu-
locytes. In the calculation, the total number of BM cells was assumed to be 24 x 
109/kg and the homing fraction was assumed to be 0.3. 
4.3. Discussion. 
Comparison of the endogenous regeneration time after TBI to the re-
generation time observed following autologous BM transplantation yields a 
relationship between radiation dose D and the number of surviving HSCs (N). N 
can be regarded as the HSC equivalent of a number of unfractionated, trans-
planted, punctured autologous femoral BM cells. The relationship between N and 
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the actual number of surviving HSCs is dependent on the frequency of HSCs 
among femoral BM cells, the frequency of HSCs among other BM cells, the 
fraction of peripheral blood in punctured BM, and on the homing fraction of 
intravenously injected HSCs. However, as long as these factors are constant, they 
do not influence the calculated Do value as explained in section 4.1. 
In the transplanted monkeys, on which equation (10) was based, the number 
of endogenous HSCs that survives the conditioning 9.6 Gy TBI, was assumed to 
be negligible in comparison to the number of transplanted cells. Previous ob-
servations indicate, that this cell number iS approximately the equivalent of 106 
transplanted autologous BM cells/kg body weight9. Similar Do calculations wit-
hout neglecting this cell number do not result in significant changes. 
The Do value calculated here is greater than the value of 0.6 Gy, which was 
calculated earlier6. This earlier analysis was also based on a comparison of 
endogenous regeneration with regeneration after autologous BM transplantation. 
However, the number of autologous BM cells required to rescue 50 % of the 
animals after supralethal TBI, was an extrapolation. Furthermore, survival was 
used as an endpoint. In contrast to the monkeys in which endogenous regenera-
tion was studied, the transplanted monkeys were subjected to supportive care, 
which was almost identical to the present supportive care and the influence of 
this treatment on survival was neglected. The influence of supportive care on 
survival after TBI is demonstrated in Figure 4.4. Although the number of 
monkeys is small, the dose survival curve for TBI followed by intensive and 
prophylactic supportive care indicates, that supportive care results in an increase 
of the LDso;3o days by at least 3 Gy (Figure 4.4). If this effect is taken into 
account, also the data used for the earlier calculation are compatible with a Do 
value of about 1 Gy for 300 kV X-rays. 
Also for other reasons a Do value of 0.6 Gy can be excluded: The 
endogenous regeneration time following a dose of 9.7 Gy (300 kV X-rays) TBI 
is not significantly different from regeneration following transplantation of 106 
BM cells/kg body weight, indicating, that the number of residual HSC following 
9.7 Gy TBI is the equivalent of 106 BM cells. On the basis of this observation No 
in equation (5) can be calculated under the assumption of a Do value of 0.6 Gy 
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and an extrapolation number6 of n = 1 
ln (106) -ln No= -9.7/0.6 (12) 
Equation (12) results in a value of 1013 for No, which would indicate, that the 
total number of HSC in Rhesus monkeys is the equivalent of 1013 BM cells/kg 
body weight, which is physically impossible, since 1012 BM cells weigh 
approximately 1 kg. 
' The earlier analysis was dependent on a number of assumptions on the rela-
tionship between the actual number of surviving HSCs following TBI and the 
HSC equivalent of a number of unfractionated, transplanted, punctured 
autologous femoral BM cells (c in equation 2). In addition, an assumption was 
made for the total number of BM cells in non-irradiated Rhesus monkeys. In the 
present experimental design, these assumptions could be avoided and, therefore, 
do not influence the calculated Do value, as explained in section 4.1. 
The data presented in this chapter can not be used to calculate the frequency 
of HSC among BM cells. Vriesendorp and van Bekkum have reported, that 
smaller animals have a higher LDso/30 days for TBI than larger species, and that 
smaller animals require less bone marrow cells per kg body weight (BM rescue 
dose) than larger species to survive lethal irradiation (Table 4.1). On the basis of 
these differences, an inverse relationship between HSC frequency and body 
weight among species was postulated. This postulate was based on the 
assumption, that survival following TBI is dependent only on the number of 
residual or transplanted HSC. Although the duration of pancytopenia is 
dependent the number of HSC, survival of an organism following TBI is also 
determined by external influences, such as the bacteriological status and 
supportive care (Figure 4.4 ). Therefore, the lower LDso130 days and the lower 
BM rescue dose for small species in comparison to larger species can also be ex-
plained by other factors than HSC frequency, such as the bacteriological status, 
or the bacteriological barrier function of the mucous membranes against 
infectious agents. Therefore differences in HSC frequency among species can 
only be investigated by a comparison of regeneration times, which should be 
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corrected for possible cytokinetic differences. 
As discussed earlier, extrapolation of the data described in this chapter 
cannot be used for a reliable calculation of the total number of BM cells, but 
other investigators have estimated the total number of Rhesus monkey BM cells 
to be 24 x 109 Jkg7,8. If we suppose the homing fraction to be 1, which is 
probably an overestimation, the fraction of peripheral blood admixture in 
punctured BM to be 0, which is certainly an underestimation, if we further 
suppose the extrapolation number, n, to be 1.0, the total number of BM cells is 
between 1.4 x 109 and 1010/kg body weight (95 % confidence limits). Even 
under these extreme assumptions, the extrapolated No is significantly lower than 
the reported estimate of the total number of BM cells (24 x 109Jkg7,8). A similar 
problem was observed in earlier Do calculations of murine HSC. In these 
calculations, endogenous regeneration from a shielded femur was compared to 
regeneration following syngeneic BM transplantation, and spleen weights and 
BM cellularity were used as end points13. The difference between the No value, 
extrapolated from the present data and the reported total number of BM cells 
might be explained by systemic errors in the radioiron method that was used and 
resulted in an overestimation of the total number of BM cells 14,15. Alternatively, 
a difference in the frequency of HSCs between femoral BM and other BM locali-
sations might cause that our calculation is an underestimation of the total number 
of BM cells. Local anoxia in the BM could result in a radioprotective effect on a 
subpopulation of the HSCI6. Such an effect could result in a Do, which is rela-
tively high in the high dose range in which the present data were obtained. 
However, the data reported by Vriesendorp and van Bekkum were obtained in a 
lower dose range (0- 5 Gy) and, as discussed above, also these data indicate a Do 
value of approximately 1 Gy for 300 kV X-rays. Thus, the most likely explana-
tion of the difference between the extrapolated No and the reported total number 
of BM cells is the unreliability of extended extrapolations as would be necessary 
here. 
As explained above, our method can not be used in the lower dose range. 
Therefore the extrapolation number, n, can not be calculated on the basis of the 
obtained data. These data do not predict linearity in the low dose range, but all 
127 
available data, reviewed in section 1.2 and more extensively by Hendry17, indi-
cate a low extrapolation number (1 < n < 5), i.e. only a small shoulder in the 
dose survival curve of HSCs for all species investigated. Figure 4.1 demonstrates 
that, in the higher dose ranges, the dose survival curves of highly radiosensitive 
cells, described by different radiobiological models, approach to the curves de-
scribed by the single hit model. Assumptions on the extrapolation number, n, do 
not significantly influence the Do value: For n = 12, the Do value was calculated 
to be only 0.04 Gy lower than for n = 1. Roughly, a higher extrapolation 
number results in an parallel upward shift of the dose survival curve, and in a 
lower No value. 
Under the assumptions mentioned earlier, inclusion of the total number of 
bone marrow cells in the calculations results in lower Do values, which are more 
influenced by the extrapolation number. However, in the dose range tested, even 
an unrealistically high extrapolation number (n = 12) does not result in a 
significant change in the fitted dose survival curve (Figure 4.9). 
Although the anaesthesia that was used in the monkeys which were irradiated 
with 6 MV X-rays, does not alter the arterial oxygenation18, the influence of 
anaesthesia on the radiosensitivity of HSC in vivo cannot be excluded completely. 
However, the monkeys which were irradiated with 300 kV X-rays and were not 
anaesthetized, yield a Do value of HSC of 1.04 Gy, which is fully compatible 
with that obtained for 6 MV X-rays. Therefore significant influences of this type 
of anaesthesia on the radiosensitivity of HSC can be excluded, unless the RBE of 
6 MV X-rays, which was based on mouse data, would be significantly higher for 
Rhesus monkey HSC. 
Our measurements of the radiation sensitivity of HSCs have implications for 
the conditioning for clinical BM transplantation and for the treatment of victims 
of radiation accidents. Following allogeneic BM transplantation, mixed 
chimerism frequently occurs 19,20,21. Apparently, the addition of chemotherapy 
to the clinically used conditioning doses of TBI does not kill a sufficient number 
of HSC to prevent endogenous regeneration completely. The Do value of leu-
kemic HSCs has been calculated to be 1.0 Gy22, indicating, that the current condi-
tioning regimens for BM transplantation are insufficient to eradicate 1010 
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leukemic cells, which is approximately the detection level of human leukemia23. 
BM transplantation following accidental doses of TBI larger than 10 Gy is 
not effective, since such high doses frequently result in death due to irreversible 
gastrointestinal damage12. Endogenous regeneration following 9.8 Gy TBI has 
been observed on day 30, which is not significantly different from the re-
generation time observed following transplantation of 106 autologous BM 
cells/kg. If we assume, that the total number of Rhesus monkey BM cells is the 
equivalent of 1010 transplanted cells/kg, we can calculate, that the HSC equivalent 
that survives 9.8 Gy TBI ranges from 5 x 104 to 1 x 107 cells/kg (95% conf. 
lim.), resulting in a complete hemopoietic reconstitution within 6 weeks. This 
implies that if optimal supportive care can be provided, the hemopoietic 
syndrome is not the dose limiting factor for TBI. This is especially true for acci-
dental irradiation which is always inhomogeneous. Endogenous regeneration 
from a small number of surviving HSCs will take more time than regeneration 
from a much larger number of transplanted HSCs. The probability to survive the 
irradiation induced pancytopenia is dependent on the quality of the supportive 
care and on the duration of this phase. Consequently the aim of BM trans-
plantation in the treatment of victims of irradiation accidents can only be 
shortening of the pancytopenic phase rather than replacement of destroyed BM. 
The emerging availability of recombinant hemopoietic growth factors (HGFs) 
has stimulated trials to shorten the pancytopenic phase after TBI and/or BM trans-
plantation by in vivo administration of HGFs. A number of victims of a recent 
radiation accident has been treated with GM-CSF, which demonstrated the 
validity of this approach24. 
In spite of full hemopoietic regeneration, a number of monkeys died from 
infections between day 42 and day 100, suggesting impaired immunological resis-
tance. This was not further investigated. Since these monkeys had normal values 
for granulocytes, lymphocytes and monocytes, it is highly unlikely, that such 
events can be prevented by allogeneic BM transplantation. 
Our data cannot precisely predict the regeneration time in human victims of 
radiation accidents, since differences in hemopoietic cell kinetics between 
humans and Rhesus monkeys have been described25. However, it is a time 
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proven model for most other comparative parameters26. Without supportive 
care, the LDso/30 days is 5.0 Gy for Rhesus monkeys12 and estimated to be 4.5 Gy 
for humans27, although higher (> 5 Gy28) and lower (3 Gy29 and 3.15 Gy30) 
values have been reported. Therefore, the Rhesus monkey is the best available 
model for preclinical studies on radiation sensitivity of hemopoietic HSCs. The 
principles discussed in this chapter are most likely valid for the human situation. 
In summary, our data indicate, that primate HSCs are less sensitive for X-
rays than was assumed previously. The radiation sensitivity can be characterized 
by a Do value of at least 0.9 Gy instead of 0.6 Gy for 300 kV X-rays. This is 
based on only two assumptions: 
Firstly, repopulating cells can be regarded as a homogeneous cell population. 
Secondly, endogenous regeneration is the same process as regeneration following 
autologous BM transplantation, which means, that differences in transplanted cell 
numbers in the range between 106 and 108 BM cells/kg do not influence c in 
equation (2). Consequently, endogenous regeneration would still be expected 
following doses of TBI which result in 100% gastrointestinal mortality. Shorten-
ing of irradiation induced pancytopenia can be achieved by BM transplantation, 
and, in principle, also by administration of hemopoietic growth factors. The 
application of these growth factors for the treatment of victims of irradiation 
accidents is currently under study. The influence of GMCSF on the duration of 
the pancytopenic phase following different doses of TBI will be discussed in 
Chapter VII. 
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CHAPTER V 
THE EFFECT OF HUMAN RECOMBINANT GRANULOCYTE 
MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) 
IN NORMAL MONKEYS 
5 .1. Introduction. 
In the previous chapter, the radiosensitivity of Rhesus monkey hemopoietic 
stem cells (HSC) was discussed. Of most significance was the finding of a high 
probability of endogenous regeneration following doses of (accidental) total 
body irradiation (TBI) which were hitherto assumed to be lethal. Therefore, 
under conditions of optimal supportive care, bone marrow (BM) trans-
plantation may be not an absolute requirement for hemopoietic regeneration 
after accidental high doses of TBI. Consequently the role of BM trans-
plantation as a treatment modality for high doses of accidental irradiation is 
reduced to a shortening of the duration of radiation induced pancytopenia, an 
intention, which has to be outweighed against the risks of allogeneic BM 
transplantation. In principle, such a reduction of the pancytopenic period may 
also be obtained by stimulation of hemopoiesis in vivo with hemopoietic 
growth factors (HGFs). 
Granulocyte:Macrophage Colony Stimulating Factor (GM-CSF), has been 
used in clinical trials for its benefit following chemotherapy, electively sup-
ported by autologous BM transplantation1,2,3A. As discussed in section 1.4, 
the efficacy of this treatment is difficult to evaluate. The patients, used for 
these studies, form a heterogeneous group and were not treated under 
standard conditions. Furthermore, adequate controls were lacking. 
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Victims of a recent radiation accident have been treated with GM-CSF5, but 
again, the efficacy of this treatment is difficult to interpret, as discussed in 
section 1.4.3. 
GM-CSF has a broad range of action on hemopoietic progenitor cells, 
including multipotent cells. GM-CSF stimulates the formation of colonies 
derived from progenitors of granulocytes, macrophages6, and other 
lineages7,8. GM-CSF also stimulates in vitro colony formation of several 
human leukemic cell lines, in some of which GM-CSF also induces differ-
entiation9. 
In addition to the effects of GM-CSF on HPC, GM-CSF induces functional 
changes in peripheral blood granulocytes and monocytes, a feature which 
might be important for prevention of infections in immunosuppressed pa-
tientsiO, 11,12, 13, 14,15, 16, 17, 18. 
In the present chapter, pilot experiments concerning the dose of GM-CSF 
and the route of administration will be described. On the basis of these data 
the route of administration of GM-CSF for experiments on mitigation of pan-
cytopenia has been selected. Continuous intravenous (iv) administration of GM-
CSF resulted in an increase in peripheral blood cell counts in healthy, 
Cynomolgus monkeys (Macaca fasicularis)19. Similar effects have been demon-
strated in Rhesus monkeys following daily iv administration over 6 hours or 
subcutaneous (sc) administration three times daily20. However, the activity of 
GM-CSF in a practical schedule of one sc administration daily, has never been 
compared to other administration schedules. Therefore, we compared the 
effects of continuous iv administration of GM-CSF to those of sc administra-
tion once daily, in normal Rhesus monkeys. 
5.2. Development of a continuous intravenous administration system in Rhesus 
monkeys. 
Continuous intravenous (iv) administration of drugs requires an intravenous 
access, which can be connected to a pump. Such a system was not only 
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developed for the experiments with GM-CSF, but also for separate studies on 
other cytokines such as IL3 and IL2. Rhesus monkeys will spontaneously 
remove systems for iv administration, unless special precautions are taken. 
Therefore a jacket was used in combination with a Porth-a-CathR system and 
an electric insulin pump (Dahedi Instruments), which can be carried in the 
inside pocket of the jacket. A Porth-a-CathR system consists of a chamber 
which is connected to an iv catheter (Figure 5.1). The chamber can be 
implanted sc and punctured many times with a special fine needle. 
Figure 5.1 Port-A-CathR (Pharmacia) implantable infusion system, used for 
intravenous GM-CSF administration. The chamber is implanted 
subcutaneously and the catheter is introduced into the internal jugular vein. A 
special needle can be introduced percutaneously into the chamber. 
In the electric insulin pump, a 2 ml syringe can be placed and the pump 
expels on each pulse 12.5 ).11 from the syringe into a tubing which is connected 
to a needle (Figure 5.2). This needle is pierced into the chamber of the Port-a-
CathR system. The pulse frequency can be adjusted in the range from 1.3 to 12 
pulses per hour. 
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5 .2.1. Design of a Rhesus monkey jacket. 
A jacket was developed to prevent the destruction or removal of the iv 
administration system and to carry the pump. A perfectly fitting, light cotton 
jacket was produced for one Rhesus monkey, which was supposed to wear it 
for several weeks. Unfortunately the jacket was easily destroyed. Another 
jacket, prepared from canvas resulted in redness and irritation of the skin 
. / 
under the seam of the sleeve, but it took a week for the monkey to destroy this 
jacket. To prevent irritation of the skin a raglan sleeve and a flannel lining 
was chosen for the next devise. Furthermore the outside of the jacket was 
strengthened by a leather stitched covering. This jacket, which was provided 
with an inner pocket to carry the insulin pump, could be worn for several 
months (See Figure 5.2). 
5 .2.2. Introduction of a Porth-a-CathR systems into Rhesus monkeys. 
Rhesus monkeys were anaesthetized as described in section 2.2. The skin of 
the neck was incised and the jugular vein was released between the sterno-
cleidomastoid and the omohyoid muscle. The internal jugular vein was ligated 
and incised caudally from the ligature (Figure 5.3a). The catheter was intro-
duced into the internal jugular vein, fixed (Figure 5.3b), and tunnelled median 
from the sternocleidomastoid muscle to the back (Figure 5.3c and d). The 
sternocleidomastoid and the omohyoid muscle were attached to each other 
with catgut sutures, and the skin was closed with nylon sutures. Just below 
the scapula a second skin incision was made and the chamber was fixed 
subcutaneously and connected to the catheter. Unfortunately, a few hours after 
the operation the monkey removed the sutures in the neck as well as the 
catheter. To prevent this problem, in the subsequent monkeys, a horizontal 
skin incision was made two em above the right mammilla. This incision was 
shoved up to the neck to enable the release of the internal jugular vein. The 
further procedure was not changed. The result of this modification was that 
138 
Figure 5.2 Canvas Rhesus monkey jacket and insulin pump. 
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the two skin wounds were fully covered by the jacket, so that it was 
impossible for the monkey to remove the system. However, during the weeks 
after the operation, these monkeys scrubbed their back against the wall of the 
cage continuously. In spite of the protection by the jacket a small skin 
laceration developed, which resulted in a local infection in 3 out of 3 
monkeys. Systemic antibiotic treatment in combination with local measures 
could not prevent the spread of this infection. Therefore removal of the 
system was inevitable. 
To prevent this problem, in all other monkeys (n = 7), the chamber of the 
Porth-a-CathR system was tunneled to the lateral side of the thoracic wall 
(Figure 5.3e, f and g). In 6 out of 7 monkeys this procedure resulted in 
uncomplicated wound healing. The final surgical procedure is illustrated in 
Figure 5.3. An X-ray photograph of the Porth-a-CathR system, introduced 
into a Rhesus monkey is shown in Figure 5.4. The system was flushed every 
four weeks with 500 U heparin in NaCl 0.9%. The system was not used until 
the wounds were completely healed. 
5.2.3 Procedure for continuous administration of GM-CSF to Rhesus-
monkeys. 
For the intravenous administration of GM-CSF the daily dose was dissolved 
in 1.8 ml NaCl 0.9% in a 2 ml syringe, which was introduced in the pump. 
The pump was fixed in the inside pocket of a Rhesus monkey jacket, and 
the syringe was connected with a needle, which was percutaneously introduced 
into the Port-a-CathR chamber. Each day a new syringe filled with GM-CSF 
was put into the pump and the needle was replaced twice weekly. 
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Figure 5.3 Surgical procedure for the implantation of a Port-a-Cath in a 
Rhesus monkey. For explanation see text. 
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Figure 5.4 
5.3. Results 
X-ray photograph of a Port-A-Cath inplanted in a Rhesus 
monkey. 
A dose of 10 )lg/k:g/day was administered iv for 14 days and the effects 
were compared to those of subcutaneous administration of 10 or 30 )lg/k:g GM-
CSF/day. One monkey received 3 J..Lg/k:g GM-CSF/day for 7 days. On day 2 of 
the intravenous administration, a tube came untied from the syringe in the 
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pump, resulting in the loss of an unknown quantity of GM-CSF. 
The influence of GM-CSF on the production of white blood cells is shown 
in Figure 5.5. Continuous iv administration of 10 )lg GM-CSF resulted in a 
tenfold increase in white blood cell counts, while sc administration once daily 
resulted only in four- to fivefold rise, even when a higher dose (30 )lg/kg/day) 
was used. The effect of 3 )lg!kg/day sc for 7 days is only marginal. The 
leukocytosis is mainly due to a rise in neutrophils and eosinophils. 
Continuous iv treatment with GM-CSF resulted in a marked 
thrombocytosis. During sc administration of 30 )lg/kg/day, a temporary rise 
in thrombocyte counts was observed. Lower sc doses did not result in changes 
in thrombocyte counts (Figure 5.6). Also in the placebo treated monkey, the 
reticulocyte and thrombocyte counts increased, probably induced by the daily 
procedure of taking blood samples and giving sc injections. The effects of GM-
CSF administration on reticulocyte counts were not significantly different 
from the placebo treated control. (Figure 5.7). 
At pharmacological doses, GM-CSF does not only stimulate the production 
of granulocytes and eosinophils, but also affects other cell lineages. To 
quantify the differential effects of the treatment with GM-CSF we used the 
cumulated cell counts (see section 2.11). In Figure 5.8 these effects of GM-
CSF are shown. Treatment with GM-CSF predominantly influences the counts 
of granulocytes and eosinophils. The normoblastosis during treatment with 30 
)lg!kg and to a lesser extent with 10 )lg/kg s.c. was not reproduced in the other 
monkeys. The absence of a significant effect of GM-CSF on monocyte counts 
was riot expected. 
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5.4. Discussion 
Continuous iv administration of 10 J.Lg/kg GM-CSF/day results in a tenfold 
increase in leukocytes, and a two- to threefold rise in thrombocyte counts. The 
absence of an effect during the first days of administration can partially be 
explained by the disconnection of a tube, which resulted in the loss of an 
unknown quantity of GM-CSF at day 2. 
As expected from the in vitro characteristics of GM-CSF, treatment with 
GM-CSF predominantly influences the counts of granulocytes and eosino-
phils7,8,9,21,22,23,. This in vivo effect was also found by other investi-
gatorsl9,20. The normoblastosis, which was observed in two monkeys was not 
reported earlier. This effect will be further discussed in Chapter VI. A rise in 
monocyte counts, which was observed by others, was only observed in one 
monkey. A possible explanation for this discrepancy could be the inaccurate 
quantification of monocytes, which is caused by the low frequency of 
monocytes among peripheral blood leukocytes. Only the dose schedules that 
resulted in the largest numbers of granulocytes (10 J.Lg/kg/day iv and 30 
J.Lg/kg/day s.c) resulted in an increase in thrombocyte counts. GM-CSF has 
also been found to stimulate thrombopoiesis in vitro-. The effects of GM-CSF 
on thrombocytes in vivo will be discussed in more detail in Chapter VI and 
VII. 
Administration of GM-CSF once daily sc resulted also in a marked 
leukocytosis, but this effect was less pronounced than that of continuous iv 
treatment. Other investigators who compared iv and sc administration have 
reported, that sc was more effective than iv20. However they compared a dose 
schedule of 3 dd sc to iv infusion that lasted only 6 hours a day. After a single 
sc adminstration, serum GM-CSF levels peak at 4 to 6 hours and persist for 14 
to 24 hours24. Mter a single iv bolus injection, GM-CSF is cleared from the 
circulation with a half life of seven minutes during the initial a phase and 85 
minutes during the subsequent 13 phasel9. Consequently, cessation of the iv 
147 
infusion after six hours results in rapidly decreasing and very low GM-CSF 
levels for a large part of the day, which is not the case for sc administration 
thrice daily. 
Although continuous IV administration of GM-CSF resulted in higher 
leukocyte counts than sc administration once daily, the latter schedule also 
effectively induced a leukocytosis, and its efficacy could be augmented by 
elevation of the dose. For clinical applications, especially in out-patients, sc 
administration once daily is more practical than, continuous iv administration 
or sc administration thrice daily. Therefore, sc administration once daily was 
used for the experiments on mitigation of pancytopenia, which will be de-
scribed in Chapter VI and VII. 
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CHAPTER VI 
MITIGATION OF BONE MARROW TRANSPLANTATION 
RELATED PANCYTOPENIA BY 
TREATMENT WITH GM-CSF 
6.1. Introduction. 
As discussed in Chapter IV, high dose chemotherapy and/or total body 
irradiation (TBI), electively followed by BM transplantation results in a 
(temporary) lack of peripheral blood cells termed pancytopenia. 
Thrombopenia may result in haemorrhagic complications, and leukopenia 
increases the risk for serious infectious complications, particularly when 
neutrophil counts fall below 0.5 x 109/11. Therefore, if treatment with HGFs 
results in a mitigation of the neutropenia, serious infectious complications 
might be prevented. 
Other investigators have described, that treatment with GM-CSF result in 
a reduction of leukopenia following autologous BM transplantation in Rhesus 
monkeys2,3. In those studies, large numbers (0.5 to 5 x 108/kg) of low 
density autologous bone marrow cells were transplanted. Since a reduction of 
pancytopenia is especially of clinical relevance under conditions associated 
with a long duration of pancytopenia, (if the number of HSC is limited), the 
influence of GM-CSF on hemopoietic regeneration after transplantation of a 
small number of autologous B M cells was investigated. T -cell depleted stem 
cell concentrates were used to exclude any production of HGFs by grafted 
lymphocytes. This approach provides a highly critical experimental setting to 
evaluate the influence of GM-CSF on BM transplantation related 
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pancytopenia. 
The dose-effect relationship of GM-CSF so far has not been studied 
systematically under such critical conditions. Therefore, we undertook the 
study of graded doses of GM-CSF, ranging from 3 to 100 J.lg/kg/day, on 
hemopoietic regeneration after transplantation of limited numbers of 
autologous, T -cell depleted, concentrated HSC. 
6.2. Effects of different doses of GM-CSF on peripheral blood cells 
following transplantation of autologous T -cell depleted stem cell 
concentrates. 
Rhesus monkeys were conditioned by two equal fractions of 6 Gy TBI as 
described in section 2.7 on day -1 and day -2. On day 0, an autologous T-cell 
depleted stem cell concentrate, prepared as described in section 2.2, was 
injected into a peripheral vein. This graft was prepared two weeks before 
irradiation, stored in liquid nitrogen, and thawed by stepwise dilution. In all 
monkeys, the graft size was the CFU-C equivalent of 107 unfractionated BM 
cells/kg body weight. Peripheral blood cell counts were determined daily 
after autologous BM transplantation. All monkeys received supportive care 
as described in section 2.9. Recombinant human GM-CSF was administered 
sc once daily from day 1 to day 30. Graded doses, ranging from 3 to 100 
J.lg/kg body weight were used. For each dose level of GM-CSF, one monkey 
was used, except for the dose of 10 J.lg/kg which was studied in three 
monkeys. Table 6.1 gives specific details of the transplanted monkeys. 
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Table 6.1 SURVIVAL OF RHESUS MONKEYS FOLLOWING GM-CSF 
TREATMENT AFIER TRANSPLANTATION OF AUTOLOGOUS 
T-CELL DEPLETED STEM CELL CONCENTRATES 
Unique GM-CSFdose Alive and Cause of 
animal (!lg/kg/day) well (days) death 
number 
M19 3 126 diarrhoea* 
11Z 10 >365 
1 YN 33 sepsis 
K25 >365 
(hyper-
transfusion) 
1 WE 30 >365 
1 ZB 100 31 CMV 
1 YA 24 sepsis 
D29 placebo 56 sepsis 
(equivalent 
of 30 !lg/kg) 
BB 33 placebo 129 diarrhoea* 
(equivalent 
of 100 !lg/kg) 
BB34 noHGF >365 
* Flagellate enteritis 
Figure 6.1 shows the maximum effects of GM-CSF on the regeneration 
patterns of leukocytes, reticulocytes, and thrombocytes. These maximal 
effects were observed at different doses. As expected, the effect on 
leukocytes was more pronounced than the effect on thrombocytes and 
reticulocytes. A considerable leukocytosis was observed during the third and 
fourth week of GM-CSF administration, demonstrating the effectiveness of 
the treatment. However, an actual shortening of the leukopenic phase, 
(defined as the day at which the leukocyte counts exceeded a value of 109!1) 
was restricted to 2-7 days as compared to placebo treated or untreated 
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Peripheral blood cell counts during administration of GM-CSF 
after TBI and transplantation of autologous stem cell con-
centrates. For each cell type the monkey in which the highest cell counts 
were observed was selected. GM-CSF was administered once daily s.c. for 
30 days after TBI (2 x 6 Gy 6 MV X-rays) and transplantation of autologous 
T-lymphocyte depleted concentrated stem cells, equivalent to 107 un-
fractionated cells/kg. 
control monkeys. This is illustrated in Table 6.2, in which the peak value of 
the leukocytosis and the duration of the leukopenia are shown for all doses of 
GM-CSF in comparison to untreated and placebo treated control monkeys. 
To avoid the influence of random day to day fluctuations and to evaluate the 
Table 6.2 INFLUENCE OF GM-CSF ON DURATION OF LEUKOPENIA AND 1HE 
REBOUND LEUKOCYTOSIS AFTER TRANSPLANTATION OF AUTO-
LOGOUS T-CELL DEPLE1ED S1EM CELL CONCENTRA1ES 
Unique GM-CSFdose Number Leukocytes Maximum observed value 
animal (!lg/kg/day) of > 109!1 of leukoc)1es 
. number septic (day) cell number reached 
episodes* (x 109!1) at day 
D29 placebo 0 20 5.9 29 
(equivalent 
of 30 !lg/kg) 
BB 33 placebo 1 21 2.7 25 
(equivalent 
of 100 !lg/kg) 
BB34 noHGF 3 18 5.3 30 
mean 20 4.6 28 
M19 3 0 14 9.0 30 
11Z 10 2 15 19.2 29 
1 YN 2 16 23.4 26 
K25 0 14 15.5 30 
(hyper-
transfusion) 
mean 15 19.3 28 
1WE 30 0 14 42.6 30 
1 ZB 100 1 14 22.3 25 
1 YA 1 11 26.4 21 
mean 13 24.3 23 
* Axillary temperature > 40° C and positive blood culture. 
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total response of the treatment with GM -CSF, cumulated cell counts were 
used to quantify the effects of GM-CSF on the production of different blood 
cell types. Figure 6.2 depicts the relationship between cumulated cell counts 
and GM-CSF dose administered for leukocytes, neutrophils, eosinophils, 
basophils, monocytes, lymphocytes, normoblasts, reticulocytes and thrombo-
cytes, thus giving a fair account of the total GM-CSF stimulated output of 
blood cells and the differential dose-effect relationships for each of these cell 
types. Table 6.2 and Figure 6.2 demonstrat~s that the effect of the GM-CSF 
treatment is clearly apparent in the whole dose range. The dose effect rela-
tionship for the leukocytes, as deduced from the maximum cell counts (Table 
6.2), was confirmed by analysis of the cumulated cell counts (Figure 6.2). 
Increasing the dose up to 30 J.Lg/kg/day resulted in an increased effect of GM-
CSF on the counts of all types of leukocytes. Increasing the dose to 100 
)lg/kg/day did not exert a greater effect, but tended to lower leukocyte values 
of all types. This effect was not apparent for normoblasts and reticulocytes 
which exhibited the highest values upon stimulation with the highest dose 
(100 )lg/kg/day) of GM-CSF administered. In contrast, thrombocyte peak 
values were highest at the 10 )lg/kg/day dose in one of the monkeys and did 
not significantly exceed the control values at the dose of 30 and 100 
)lg/kg/day. In Figure 6.2 it is shown, that the effect of GM-CSF on the 
production of blood cells is predominantly an effect on granulocytes, eosino-
phils, normoblasts and monocytes. The effects on other cell types are 
significant, but much less pronounced. The effect of GM-CSF on peripheral 
blood normoblasts and reticulocytes was largely or completely abolished 
when the transfusion of thrombocyte concentrates was replaced by whole 
blood transfusions, as shown in Figure 6.3. 
Compared to the large effects of GM-CSF on maximum cell counts (for 
instance about 7-fold more granulocytes and monocytes, and about 150-fold 
more normoblasts, at the maximum counts achieved), the effect on the 
duration of the pancytopenic phase (Table 6.2) was limited: an average 
leukopenic phase of 19.7 ± 1.2 (s.d.) days was reduced to 14.0 ± 1.4 days. 
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GM-CSF. The number of animals might be not sufficiently large to detect a 
reduction of the occurrence of sepsis. This subject will be discussed in more 
detail in section 7.4 
6.3. Infectious complications during treatment with GM-CSF. 
Leukopenia is associated with an increased risk of serious infectious 
complications. Therefore, prevention of these complications is one of the 
major objectives of treatment with GM-CSF. In the present experimental 
setting, sepsis caused by multiresistent streptococci is the most common 
infectious complication. The frequency of sepsis during leukopenia and 
regeneration is indicated in table 6.2. In spite of a shortening of the pancy-
topenia, the frequency of sepsis was not reduced in the monkeys treated with 
GM-CSF. The number of animals might be not sufficiently large to detect a 
reduction of the occurrence of sepsis. This subject will be discussed in more 
detail in section 7 .4. 
6.4. Adverse effects of GM-CSF. 
GM-CSF was well tolerated in the dose range_ tested. As shown in Figure 
6.4, body weight, serum protein, liver enzymes, renal function and axillary 
body temperature in the animals treated with GM-CSF were not different 
from control animals. Four animals died from unrelated causes. One animal 
died on day 31 after autologous BM transplantation from a cytomegalovirus 
infection. Another monkey died on day 60 from Lamblia enteritis, which is 
endemic in the Rhesus monkey colony. Two animals died on day 24 
respectively on day 29 from sepsis, caused by multiresistent streptococci, an 
endemic problem in the Rhesus monkey colony·. The other animals are alive 
and well after an observation period of more than a year. 
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Discussion. 
GM-CSF administration after autologous BM transplantation resulted in a 
dose dependent rise in peripheral blood cell counts. This was most 
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pronounced during the fourth week of administration. 
Adverse effects of GM-CSF were not observed. The most commonly 
described adverse effects of GM-CSF include fluid retention, rash, myalgia, 
arthralgia, bone pain and fever4,5,6,7 Some of these effects, such as myalgia 
can not be appropriately evaluated in monkeys. Furthermore, the 
experiments were designed as an efficacy study rather than a toxicity study. 
The toxicity of the conditioning TBI and the subsequent pancytopenia, might 
have masked the relatively mild toxic effects of GM-CSF. 
As expected on the basis of the in vitro stimulating properties of G M-
CSF8,9,10, treatment with GM-CSF mainly influenced the numbers of granulo-
cytes, eosinophils and monocytes, rather than thrombocytes and reticulocytes. 
To observe a stimulating effect of GM-CSF on the production of all types of 
leukocytes, 30 ).lg/kg/day appeared to be the optimal dose. Increasing the dose 
to 100 ).lg/kg/day did not result in a further increase in leukocyte production. 
However, the maximal effect on the numbers of normoblasts and reticulocyt-
es was observed during treatment with the highest dose of GM-CSF (100 
).lg/kg/day). This may indicate, that stimulation of the red cell series requires 
higher doses of GM-CSF than stimulation of the white cell series and 
thrombocytes. The effect of GM-.CSF on peripheral blood normoblasts and 
reticulocytes was largely, or completely abolished when the transfusion of 
thrombocyte concentrates was replaced by whole blood transfusions. The 
latter type of transfusions resulted in a more pronounced prevention of trans-
plantation related anaemia. This demonstrates that the GM-CSF stimulated 
normoblastosis was co-dependent on erythropoietin, indicating increased 
erythropoiesis. GM-CSF stimulated erythropoiesis appeared to be largely 
ineffective, in that the huge rise of normoblasts was disproportionate to the 
quite moderate increase in reticulocyte numbers. The GM-CSF induced 
normoblastosis has not been described in clinical studies. This can be 
explained by the higher frequency of red cell transfusions in the patients, 
compared to the Rhesus monkeys described in this chapter. 
Compared to the pronounced effects of GM-CSF on maximum cell counts 
and on the cumulated cell counts, the effect on the duration of the leukopenic 
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phase was restricted to a shortening by 5.7 ± 1.5 days, while the duration of 
the leukopenic period was 19.6 ± 1.2 days in monkeys not treated with GM-
CSF. Such a shortening could also be obtained by transplanting 5 to 10 times 
more HSCll, indicating, that during the first 2 weeks after transplantation 
the treatment with GM-CSF resulted in a production increase equivalent to an 
average of 3 additional cell divisions along the granulocyte pathways. 
Apparently, the lowest dose of GM-CSF (3 Jlg/kg/day sc)is already saturating 
for this effect. Other authors have described a more promising shortening of 
the pancytopenic phase2,3. This may be explained by a 20-fold larger number 
of transplanted cells than in the present study. Furthermore, as discussed in 
paragraph 6.1, the experiments described in this chapter were purposely 
designed with low numbers of concentrated stem cells, which were T -cell de-
pleted. The present observations indicate that, under these conditions, the 
effect of GM-CSF is limited, and suggests that GM-CSF, without the addition 
of other HGFs, does not exert much effect on the early phase of exponential 
growth after BM transplantation. Therefore it was postulated, that early after 
transplantation the number of GM-CSF sensitive cells is the limiting factor. 
Later after transplantation, when more GM-CSF sensitive cells are present, 
the response is much more dramatic, and increase with the dose of GM-CSF, 
with a maximum at 30 jlg/kg. To test this hypothesis prospectively, we made 
use of the known relationship between dose of TBI and residual stem cell 
numbers (Chapter IV), and studied the effect of GM-CSF on endogenous 
regeneration following graded doses of TBI as is described in the next 
chapter. 
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CHAPTER VII 
MITIGATION OF RADIATION INDUCED PANCYTOPENIA 
BY TREATMENT WITH GM-CSF 
7 .1. Introduction 
From the results, described in Chapter VI it was concluded that white blood 
cell production following autologous bone marrow transplantation could be 
accellerated by treatment with GM-CSF. The effect became apparent near the 
end of the leukopenic period and lead to a marked leukocytosis which peaked 
between day 25 and day 30. Increasing the dose of GM-CSF resulted in increased 
responses up to 30 J..lg/kg/day, which appeared to be the optimal and· saturating 
dose. In spite of the clear cut effects of GM-CSF, in this experimental setting the 
duration of the leukopenia was reduced by only 4 to 8 days. In the dose range be-
tween 3 and 100 J..lg/kg, the duration of the leukopenia was not related to the dose 
of GM-CSF given. This indicates an increased leukocyte production rate, which 
is equivalent to 3 additional cell divisions during the first 2 weeks of hemopoietic 
regeneration. Other investigators who have transplanted larger numbers of BM 
cells have reported a more pronounced reduction of the leukopenia. I ,2. We 
postulated that early after transplantation the number of GM-CSF sensitive cells 
(dependent on the number of transplanted stem cells) was the limiting factor. 
The postulated relationship between the GM-CSF effect and stem cell numbers 
was studied by measuring the endogenous of peripheral blood cells following 
graded doses of Total Body Irradiation (TBI). This approach is based on the 
established relationship betwe~n the number of residual stem cells and the dose 
of TBI (Chapter IV). In addition, this approach would yield direct data on the 
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maximum irradiation dose, for which GM-CSF would still be effective as a 
treatment of pancytopenia. 
Accidental irradiation is often not a homogeneous exposure, resulting in 
damage to the hemopoietic system, which is difficult to predict. In case of a 
relationship between the number of HSC and the response to HGFs, the latter 
could be used to estimate the fraction of surviving HSC following 
inhomogeneous TBI and/or in situations of uncertainty on the irradiation dose. 
Pancytopenia following TBI can be regarded as a general model for cytotoxic 
insult to the hemopoietic system. Toxicity to the hemopoietic system is dose 
limiting for many chemotherapy schedules in cancer patients. Individual vari-
ations in pharmacokinetic parameters of cytotoxic drugs influence the effects of 
chemotherapy and thereby hamper an adequate evaluation of the influence of 
treatment with GM-CSF or other HGFs on chemotherapy induced pancytopenia. 
Such factors do not play a role in sensitivity to TBI. Therefore, TBI can be 
employed to study the conditions under which treatment with GM-CSF reduces 
pancytopenia following cytoreductive treatment. 
7 .2. Dose scheduling of GM -CSF following TBI 
To determine the most effective dose schedule, monkeys were irradiated with 
5 Gy TBI (6 MV or 300 kV X-rays), and treated with 30 M-glkg GM-CSF/day 
(see section 6.3). The day of TBI was designated day 0; full supportive care was 
provided from day 1 until leukocyte counts exceeded 109/1. Blood cell counts 
were determined daily. Four different dose schedules were used, as summarized 
in Table 7.1. The peripheral blood cell counts are shown in Figure 7.1 and 7.2. 
Daily treatment with 30 M-g GM-CSF/kg, initiated on the first day post TBI, 
almost completely prevented leukopenia. A later onset of the treatment with GM-
CSF was less effective and resulted only in a moderate reduction of leukopenia. 
Although the delayed treatment with GM-CSF resulted in a significant increase 
in white blood cell counts (Table 7 .2), this increase occurred too late to mitigate 
the leukopenia (Figure 7.2). 
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Table 7.1 INFLUENCE OF VARIOUS SCHEDULES OF GM-CSF TREATMENT* 
ON LEUKOPENIA, INDUCED BY 5 GY TBI 
unique irradiation HGF duration of 
animal source treatment leukopenia 
number (days) 
1 UP 6MVX-rays PLACEBO 9 
BB40 11 
BB 31 12 
BB47 6MVX-rays GM-CSF 2 
day 1 to 14 
1XK 0 
8607 6MVX-rays GM-CSF 
day 1 to 7 
BB52 0 
1ZM 6MVX-rays GM-CSF 7 
day 7 to 21 
BB50 300 kV X-rays PLACEBO 10 
1 xs noHGF 14 
1ZG noHGF 12 
BB48 300 kV X-rays GM-CSF 15 
day-14to-1 
* 30 IJ.g/kg/day sc. 
Pretreatment with GM-CSF did not result in a later onset or an earlier ending 
of the leukopenic period. In the pretreated monkey, there was even a slightly 
earlier onset of the leukopenia and a slightly delayed regeneration. Although 
only one monkey was studied, the absence of any beneficial effect contrasts 
strongly to the post irradiation treatment schedules and an unfavourable effect of 
pretreatment with GM-CSF can not be excluded. 
Treatment with GM-CSF during days 1-14 after TBI resulted in higher WBC 
than treatment from day 1-7. Figure 7.2 suggests, that this difference was 
already present during the first week of observation. Comparison of the 
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Table 7.2 
TilE EFFECTIVENESS OF DIFFERENT TREATMENT SCHEDULES OF GM-CSF* 
CUMULATED LEUKOCYTE COUNTS FOLLOWING TBI WITH 5 GY 
CUMULATED LEUKOCYTE COUNTS 
HGF treatment day 2-8 day 2-25 
placebo (a) 11.9 34.3 
GM-CSF (b) 20.9 63.1 
day 1-7 
GM-CSF (c) 42.6 146.6 
day 1-14 
GM-CSF (d) 15.6 159.7 
day 7-21 
p value b-a < 0.05 < 0.01 
(Student T) 
c-a < 0.05 < 0.005 
d-a N.S. < 0.01 
b-e N.S. <0.02 
d-b N.S. N.S. 
* 30 !lg/kg/day sc 
cumulated cell counts of these two treatment groups demonstrates, that this 
difference is not significant during the first week (day 2 to 8), (p > 0.1). 
However, the GM-CSF treated groups showed significantly higher cumulated 
cell counts (day 2 to 8) than the control group. For the whole observation period 
(cell counts cumulated from day 2 to 25) a significantly different effect between 
treatment for 7 days and treatment for 14 days was found (Table 7.2). 
At pharmacological doses, GM-CSF does not only stimulate the production 
of granulocytes, but it also activates other celllineages3. The cumulated cell 
counts were used for a quantification of effects of GM-CSF on the production of 
a number of different blood cell types. In Figure 7.3 these effects are shown 
separately for neutrophils, eosinophils, basophils, monocytes, lymphocytes, reti-
culocytes and thrombocytes, thus giving an overall impression of the total GM-
172 
CSF stimulated output of blood cells for each of these cell types. As was 
expected on the basis of the in vitro characteristics of GM-CSF, treatment with 
GM-CSF predominantly influences the counts of granulocytes, eosinophils and 
monocytes. The effect on basophil counts is probably due to the representation as 
a percentage of the average control value, since basophils were found only 
rarely in the control monkeys. Treatment with GM-CSF resulted also in an 
increased output of lymphocytes. However, these cells were only characterized 
on the basis of morphology, which is not always reliable during early 
regeneration. Also slight effects of treatment with GM-CSF on reticulocytes and 
thrombocytes were found. Thrombocyte transfusions were only rarely required, 
and thus hardly influenced the thrombocyte counts. 
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Figure 7.3 Cumulated differential counts of peripheral blood cells under GM-CSF 
administration after 5 Gy TBI with 6 MV X-rays. GM-CSF administration 
was as given in the legend of Figure 7 .2. Cell counts cumulated from day 2 to 25: 
The data described above (Table 7.2 and Figures 7.1 and 7.2) demonstrated 
that treatment with GM-CSF from day 1 - 14 was more effective than the other 
schedules. Therefore, this schedule was used for the subsequent experiments on 
the effects of treatment with GM-CSF following graded doses of TBI. 
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7.3. Relationship between GM-CSF effects and the number of residual stem 
cells and progenitor cells. 
To determine the relationship between the GM-CSF effect and the number of 
residual stem cells (HSC), Rhesus monkeys were irradiated with graded doses of 
TBI covering the range from 4 to 8 Gy 6 MV X-rays. For each dose of TBI, 
two monkeys were used, except for the doses of 4 and 7 Gy for which one 
monkey was used. The day of TBI was designated day 0, and full supportive care 
was provided from day 1 until leukocyte counts exceeded 109/1. Blood cell 
counts were determined daily. A daily dose of 30 !lg!kg GM-CSF was adminis-
tered from day 1 to day 14, which appeared to be the most effective dose 
schedule (see paragraph ). The regeneration curves of these monkeys are shown 
in Figure 7.4. 
As pointed out in Chapter IV, the relationship between the residual fraction of 
HSC and the dose of TBI can be calculated: 
1n S = -D/1 (1) 
in which S is the surviving fraction, D the dose of TBI in Gy, and 1 the Do value 
for 6 MV X-rays as calculated in Chapter 1V. 
To express the GM-CSF effects in relation to the irradiation dose, the 
cumulated cell counts were used. This relationship is shown in Figure 7.5. for 
leukocytes. The difference between the GM-CSF regression line and the placebo 
regression line is considered to be the GM-CSF effect. It will be clear from 
Figure 7.5, that the GM-CSF effect decreases with increasing doses of TBI, 
which means with decreasing numbers of residual HSC. Following a dose of 
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rays followed by treatment with GM-CSF. Once daily, 30 microgram GM-
CSF was administered s.c. from day 1 to 14. 
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Figure 7.5 Cumulated leukocyte counts, related to the dose of TBI (6 MV X-
rays ). Effect of GM-CSF administration as given in the legend of Figure 7 .4. Cell 
counts cumulated from day 6 to 25. 
8 Gy TBI the effect is statistically not significant and extrapolation of the GM-
CSF regression line shows, that following a dose of 10 Gy an effect of GM-CSF 
can not be expected any more. In Figure 7 .6, a similar effect is demonstrated for 
the cumulated thrombocyte counts. As expected, the effect of GM-CSF on throm-
bocyte production is moderate as compared to the leukocyte response, but the 
same principle is valid: a low dose of TBI results in a relatively high GM-CSF ef-
fect. The effect of GM-CSF on reticulocytes is marginal and only statistically 
significant for doses of TBI < 6 Gy, as shown in Figure 7.7. 
The effectiveness of GM-CSF is dependent on the dose of TBI and can be 
characterized by subtracting the regression equation for placebo treated animals 
from that for GM-CSF treated animals. By use of equation (1 ), this can be linked 
to the fraction of surviving HSC. This is shown in Table 7 .3. The data, presented 
in this chapter did not demonstrate a significant effect of GM-CSF on leukocytes 
following TBI at a dose of 8 Gy or more, i.e. following more than 3 log stem 
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Figure 7.6 Cumulated thrombocyte counts, related to the dose of TBI (6 MV X-
rays ). Effect of GM-CSF administration as given in the legend of Figure 7 .4. Cell 
counts cumulated from day 6 to 25. 
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Figure 7.7 Cumulated reticulocyte counts, related to the dose of TBI (6 MV X-
rays). Effect of GM-CSF administration as given in the legend of Figure 7 .4. Cell 
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cell kill. The data further indicate, that GM-CSF has no effect at all on leuko-
cytes following 10 Gy, on thrombocytes following 9.5 Gy and on reticulocytes 
following 7 Gy, i.e. at a residual HSC fraction of 5 x 10-5 for leukocytes and 
higher for the other cell types. 
Table 7.3 GM-CSF EFFECTIVENESS RELATED TO THE IRRADIATION DOSE 
cell type significant effect observed no effect expected at all 
dose of corresponding fraction dose of corresponding fraction 
TBI of surviving stem cells TBI of surviving stem cells 
leukocytes* <8 Gy > 3 X 10-4 10 Gy 5 X 10·5 
thrombocytes .. <7Gy > 10·3 9.5 Gy 7 X 10-5 
reticulocytes <6Gy > 3 X 10-3 7 Gy 10-3 
*representing neutrophils, eosinophils, monocytes and lymphocytes 
7 .4. GM-CSF response as an in vivo assay for repopulating cells. 
In victims of radiation accidents, the rate of hematological regeneration is 
dependent on the number of residual HSC. Dosimetric problems4 ,5,6 and 
inhomogeneity of the irradiation hamper a reliable estimate of the residual HSC 
number in such individuals?. In the previous section, the relationship between the 
dose of TBI and the effects of treatment with GM-CSF has beeh demonstrated 
and quantified in relation to the number. of residual HSC. In principle, this 
relationship can be used as an in vivo HSC assay for victims of radiation acci-
dents (biological dosimetry) and for cancer patients receiving chemotherapy 
(estimate of BM reserve). Measurement of the cumulated WBC (day 6 - 25) fol-
lowing an unknown dose of TBI and treatment with GM-CSF (day 1 - 14) 
enables an estimate of the dose of TBI (i.e. the number of residual HSC). We 
further analyzed the time point after TBI at which the GM-CSF response can be 
used to assess the radiation damage. For that purpose, the effects of GM-CSF on 
the cumulated WBC were also analyzed for shorter observation periods (Figure 
7.8). During the first five days following TBI, the WBC decrease, and the 
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cumulated WBC were not related to the radiation dose. Although treatment with 
GM-CSF resulted in an increase of the cumulated WBC during this episode, this 
effect was not related to the dose of TBI. Hence the cumulated WBC during the 
first five days following TBI can not be used for biological dosimetry. In GM-
CSF treated monkeys, the cumulated leukocytes in the period between day 6 and 
day 8 were correlated weakly to the dose of TBI. This was not the case in the 
control group. Therefore, the cumulated leukocytes in the period between day 
six and day eight, allow for only a very rough estimate of the dose of TBI 
(Table 7.4). Longer observation periods (day 6 - 15 or day 6 - 22) result in a 
slight increase of the accuracy of the dose estimate. Without GM-CSF, the 
cumulated cell counts can only be used for biological dosimetry following 3 
weeks of observation, and the estimate of the irradiation dose is even less 
accurate. 
Table 7.4 BIOLOGICAL DOSIMETRY BASED UPON THE EFFECT OF GM-CSF 
ON CUMULATED WBC FOLLOWING TBI 
GM-CSF PLACEBO 
observation dose cumulated wbc dose range cumulated wbc dose range 
period (Gy) (calculated) (95 % conf lim) (calculated) (95 % conf lim) 
(days) 
6-22 4 112 <5.0 21 < 5.6 
6 68 4.6- 7.1 16 <7.2 
8 28 >6.9 11 >6.4 
6- 15 4 61 < 5.1 10 
6 30 4.9-7.0 8 
8 0 >7.0 5 
6-8 4 21 < 5.1 3 
6 10 4.8- 7.0 3 
8 0 >6.8 2 
7.5. Prevention of leukopenia related sepsis. 
In section 7.3 a profound effect of treatment with GM-CSF on radiation 
induced leukopenia was reported. Reduction of the leukopenia is especially 
important since it is associated with an increased risk of infectious complications, 
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especially sepsis. Sepsis with gram negative bacteria can be prevented by 
selective decontamination of the digestive tract, as described in section 2.9. 
However, the digestive tract of the majority of our Rhesus monkeys is colonized 
with low numbers of streptococci, which are resistant to the commonly used 
antibiotics. Selective decontamination of the digestive tract therefore results in a 
selective growth of these streptococci. Consequently, during leukopenia, the 
frequency of sepsis caused by these streptococci is high. Therefore, our Rhesus 
monkeys provide an extremely sensitive model to test the efficacy of prevention 
of bacterial infections by treatment with HGFs. 
The frequency of sepsis in the GM-CSF treated animals and in the placebo 
treated control animals is summarized in Table 7.5. Sepsis was defined as an 
axillary temperature > 40° C and a positive blood culture. In spite of a reduction 
of leukopenia in GM-CSF treated monkeys, the number of septicemic episodes 
was not reduced. In fact a tendency towards a negative effect was observed. 
Despite reduction of leukopenia by treatment with GM-CSF, 11 septic episodes 
were observed in 9 GM-CSF treated monkeys versus 4 septic episodes in 10 
control monkeys. If the transplanted monkeys, described in Chapter VI are 
included, 16 episodes of sepsis were observed in 15 GM-CSF treated animals, 
versus 8 episodes in 13 control monkeys. 
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Table 7.5 INFLUENCE OF GM-CSF ON THE FREQUENCY OF SEPSIS* 
AFTER TBI IN RHESUS MONKEYS 
Dose GM-CSF PLACEBO OR NO HGFs 
(Gy) 
unique number unique number 
' animal of septic animal of septic 
number episodes number episodes 
TBI 
4 (6MV) 1YQ 0 8654 
5 1XK 0 BB 31 0 
BB47 3 BB40 1 
1ZM 1 1 UP 1 
6 8605 2 1XT 0 
8681 1 8667 1 
7 8602 2 
8 1 YE 1 C28 0 
1ZQ 1 1 ZF 0 
5 (300kV) 1 xs 0 
1ZG 0 
TBI FOLLOWED BY AUTOLOGOUS BM TRANSPLANTATION 
2x6 M 19 0 D29 0 
(6MV) 1 TZ 2 BB 33 1 
(+ABMT) 1 YN 2 BB 34 3 
K25 0 
1 WE 0 
1ZB 1 
Total 15 16 13 8 
* Axillary temperature> 40° C and positive blood culture. 
7 .6. Discussion. 
Treatment with 30 )lg/kg GM-CSF per day from day 1 to day 14 appeared to 
be highly effective to prevent leukopenia, induced by 5 Gy TBL Other schedules 
were less effective. 
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Treatment with GM-CSF before TBI resulted in a leukocytosis, but, as 
expected, not in a later onset of the leukopenia. The regeneration time of 
leukocytes was not earlier in the GM-CSF pretreated monkey than in the control 
monkeys, indicating, that treatment with GM-CSF did not result in a significant 
increase in HSC numbers. Thus, the mechanisms by which pretreatment with 
HGFs could mitigate pancytopenia, visualised in Figure 1.3, could not be 
demonstrated for GM-CSF: In the pretreated monkey, there was even a slightly 
delayed regeneration. Although only one monkey was studied, the absence of any 
beneficial effect contrasts strongly to the other treatment schedules. A negative 
eff~ct of pretreatment with GM-CSF can not be excluded. An unfavourable 
effect of GM-CSF might be due to a decrease in HSC numbers before TBI as a 
result of differentiation induced by GM-CSF. Such an unfavourable effect of 
GM-CSF has not been reported earlier. Additional experiments, involving a 
longer duration of the pretreatment might demonstrate this effect. 
Treatment with GM-CSF from day 1 to 7 after TBI results in a reduction of 
the leukopenia which is less pronounced than treatment from day 1 to 14. 
Although the duration of the leukopenia (defined as leukocyte counts <109/l) was 
similar for both schedules, ·the. monkeys treated for .1 week had lower the 
leukocyte counts than the monkeys treated for 2 weeks. 
'Treatment from day 7 to 21 results in a leukocytosis at the end of the treat-
ment, but occurred too late to reduce the leukopenia effectively. 
As expected, treatment with GM-CSF had the most pronounced effects on 
granulocytes, eosinophils· and monocytes, and minor effects on thrombocytes and 
reticulocytes. These effects are dependent on·the intensity ·of the cytoreductive 
treatment. This conclusion was quantified in relation to the dose of TBI, and· the 
effect on leukocytes appeared only significant (p < 0:05) at irradiation -doses 
lower than 8 Gy. The .doses of .TBI following which a, slight effect on 
thrombocytes andreticulocytes was observed were lower. This was linked to. the 
numbers of residual HSC, which could be calculated on the. basis of ;the 
relationship between the dose of- TBI and the su!Viving fraction of HSC as 
described in Chapter- IV. A s~gnificant effect of GM-CSF was only observed if 
the stem cell kill did not exceed 3 log for leukocytes and less for thrombocytes 
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and reticulocytes. In Chapter VI it was demonstrated that the reduction of BM 
transplantation related pancytopenia by treatment with GM-CSF was limited if 
low numbers of concentrated stem cells were transplanted. Other investigators 
described more pronounced effects of GM-CSF following transplantation of 
large numbers of unfractionated BM cellsl,2 
The hypothesis, that the difference between the results presented in Chapter VI 
and the data reported by the other investigators could be attributed to differences 
in graft size, was confirmed by the demonstration of a relationship between the 
effect of treatment with GM-CSF and the number of PHSC present at the start of 
this treatment. This does not necessarily mean that PHSC are GM-CSF 
responsive cells, since PHSC have the capacity to differentiate into GM-CSF 
responsive cells. 
The data described in this chapter permit an assessment of the therapeutic 
window of GM-CSF for mitigation of pancytopenia induced by acute cytotoxic 
insults to the hemopoietic system. The maximum effect of GM-CSF treatment is 
observed following an approximately 2 log stem cell kill, and the effect is only 
significant if the stem cell kill does not exceed 3 log. A response to GM-CSF is 
completely absent at more than 4 log stem cell kill, although the residual PHSC 
number is sufficient for endogenous regeneration. In clinical studies in which 
GM-CSF treatment significantly reduced chemotherapy induced neutropenia, the 
mean duration of neutropenia without GM-CSF was only 7.4 days, indicating 
that the chemotherapy did not kill more than 3 log of stem cells8. On the other 
hand, in 20 patients with solid tumors, transplanted with 2.8 to 7.9 x 107 
autologous BM cells/kg body weight, the reduction of leukopenia by treatment 
with GM-CSF was not significant. In those patients a leukocyte count> 109/l was 
achieved on day 15.0 ± 6.6 (mean± sd) in patients treated with GM-CSF and on 
day 16.7 ± 3.4 in historical controls9. Failure of GM-CSF to reduce cytotoxic 
treatment related pancytopenia of long duration is probably due to a lack of GM-
CSF sensitive cells in the early regeneration phase, as was the case in the 
transplanted monkeys in Chapter VI. 
Victims of a recent radiation accident have been treated with GM-CSF3. On 
the basis of the relationship between the number of surviving PHSC and the GM-
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CSF effect we may conclude that this approach can only be effective following 
relatively low doses of accidental irradiation. However, our doses of TBI can not 
be directly extrapolated to accidental irradiation, since the latter is, in general, 
inhomogeneous, resulting in an unpredictable surviving HSC fraction. 
The response to GM-CSF might also be used to estimate the number of 
residual HSC following cytotoxic treatment or accidental irradiation. The data 
presented in this chapter indicate, that GM-CSF can be used for such a purpose 
in the range between (the equivalent) of 4- 8 Gy TBI (6 MV X-rays). However, 
the 95 % confidence limits are wide, and at least 8 days of observation are 
required to obtain interpretable results. A longer observation period results only 
in a slight increase of the accuracy. However, the other methods of biological 
dosimetry are also not very accurate, especially in the high dose range4,10,11. 
Additional experiments including other HGFs, alone and in combination with 
GM-CSF, shall be performed and may result in a more useful in vivo assay for 
PHSC, i.e. a type of biological dosimetry, that estimates the radiation damage of 
the hemopoietic system. 
The reduction of leukopenia by treatment with HGFs is aimed at a reduction 
of infectious complications. In spite of the reduction of leukopenia by the GM-
CSF treatment there was a tendency of an increased frequency of sepsis in 
those animals as compared to the placebo treated or untreated controls. Although 
the incidence of sepsis was not significantly increased in this limited number of 
monkeys, it is unlikely, that a reduction of infectious complications will be found 
in a larger series. GM-CSF has been reported to stimulate the function of 
granulocytes in vivol2,13,14,15,16. A possible explanation for the increased 
frequency of infections could be a premature activation of granulocytes by 
pharmacological doses of GM-CSF, resulting in an exhaustion of granulocyte 
function. Alternatively, a reduced capacity of granulocytes to migrate to an 
inflammatory site, during treatment with GM-CSF has been described17. This 
could hamper the defense against bacterial invasion into tissues, and increase the 
risk of infections. 
The data presented lead to the f0llowing conclusions: 
In Chapter I, three possible mechanisms, by which treatment with HGFs could 
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mitigate the TBI induced leukopenia were postulated (figure 1.2 and 1.3): Only 
the first mechanism (stimulation of regeneration) could be confirmed for GM-
CSF, The other two mechanisms (pretreatment resulting in higher numbers of 
peripheral blood cells and a later onset of pancytopenia, and pretreatment 
resulting in an increase in numbers of PHSC and thereby in an earlier 
regeneration) could not be demonstrated for GM-CSF. 
Treatment with GM-CSF prevents the leukopenia induced by 5 Gy (6 MV X-
rays). This is mainly an effect on granulocytes, eosinophils and monocytes. 
The effectiveness of GM-CSF to mitigate leukopenia is dependent on the 
number of PHSC during the early regeneration phase. The maximum effects can 
be expected following 2 log stem cell kill, the effects were not significant 
following 3 log stem cell kill, and can be expected to be absent following 4 log 
stem cell kill. 
Surprisingly, mitigation of the leukopenia by treatment with GM-CSF did not 
result in a decreased incidence of infectious complications. This finding suggests 
additional studies concerning the influence of GM-CSF on the function of granu-
locytes in vivo. 
The quantitative and qualitative characterization of the effects of GM-CSF, as 
discussed above, establishing the therapeutic window of this HGF, should be simi-
larly done for all other HGFs. Furthermore, these data are a basis for studies on 
synergistic effects of hemopoietic growth factors in vivo. 
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CHAPTER VIIT 
GENERAL DISCUSSION 
The hemopoietic system is highly sensitive to cytotoxic insults such as those 
induced by chemotherapeutic drugs or total body irradiation (TBI). These agents 
result in a dose dependent kill of hemopoietic stem cells (HSC) and hemopoietic 
progenitor cells (HPC). As a consequence, a lack of peripheral blood cells, 
termed pancytopenia, may occur. Some of the more serious complications 
include an increased susceptibility to infections and bleeding. Surviving HSC 
have the capacity to proliferate and differentiate. This process eventually results 
in the reconstitution of the hemopoietic system. The duration of the pancytopenia 
is directly related to the available number of repopulating cells I. 
Blood cell production and, hence, also regeneration of blood cell production is 
controlled by a number of glycoproteins, termed hemopoietic growth factors 
(HGFs). Recombinant DNA technology allows for the production and purifi-
cation of these factors on a large scale, enabling in vivo manipulation of the 
hemopoietic system by administration of these compounds. Shortening of 
irradiation induced pancytopenia can be achieved by BM transplantation, and, in 
principle, also by in vivo manipulations of the hemopoietic system with HGFs. 
In humans, it is impossible to perform lethal experiments under standard 
conditions. This hampers the study of human hemopoiesis in vivo. For nearly 30 
years, the Rhesus monkey (Macaca mulatta) has been used as a model for human 
hemopoiesis and bone marrow transplantation. This model has been used 
successfully, to test many techniques in BM transplantation before its introduct-
ion into clinical practice2,3,4,5,6,7,8,9. 
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8.1. Characteristics of repopulating cells. 
The current concept of hemopoiesis includes the existence of PHSCs, which 
have the capacity of both self renewal and differentiation into specific lineages of 
committed hemopoietic progenitor cells, which eventually differentiate into 
mature blood cells. Consequently, a PHSC has the capacity to repopulate a 
lethally irradiated recipient, i.e. to grow out to a complete hemopoietic systemlO. 
In rodents, a quantitative functional assay, the spleen colony test can be used for 
HSC characterization II. In outbred species, such as rhesus monkeys and humans, 
the most immature cell detectable is CFU-mix12. Although CFU-S have been 
shown to be a heterogeneous group of cells13, not necessarily capable of 
repopulating a lethally irradiated recipient, the relationship between CFU -mix 
and PHSC is less well established than the relationship between CFU-S and 
PHSC. Studies on the nature of human PHSCs have been limited by the lack of a 
suitable assay and restricted by the impossibility of in vivo studies. Recently an 
in vivo HSC assay in rhesus monkeys has been developed in our laboratory. This 
autologous regeneration assay is based on the observation that the peripheral 
reticulocyte and leukocyte regeneration rates after autologous BM 
transplantation are directly related to graft sizel. The relationship between 
PHSCs and the early repopulating cells, which are measured by this assay has not 
been proved. In outbred species, it is impossible to study PHSC and early 
repopulating cells separately. The early repopulating cells have clinical import-
ance; since the complications of pancytopenia, can be largely prevented by early 
regeneration. 
Cell surface markers and light activated cell sorting have been used for 
characterization and purification of murine stem cells14,15. Among the cell 
surface markers available to isolate immature human hemopoietic cells, the 
CD34 antigen, identified by a number of monoclonal antibodies 
(MCAs)16,17,18,19 is of outstanding interest. It is mainly expressed on immature 
hemopoietic cells along various differentiation lineages, including hemopoietic 
progenitor cells such as CPU-blast, CFU-mix, CFU-GM, and BFU-E. Moreover, 
it is present only on 1-4% of human bone marrow cells. In CHAPTER III the 
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autologous regeneration assay was used to measure the HSC enrichment that 
could be obtained by selection of CD34 positive cells. For this purpose the anti-
CD34 MCA ICH320, was used. Isolation of ICH3 positive BM cells resulted in a 
80- 155 fold enrichment of colony forming units (CPU-C). The enrichment of 
HSC appeared to be in the same order of magnitude as the enrichment of CPU-C. 
The early repopulating capacity of CD34 positive cells was confirmed in RhLA 
identical, sex mismatched, sibling donor recipient combinations. The capacity of 
at least a subpopulation of these cells to sustain chimerism was demonstrated by 
using of the Y chromosome as a marker. However, only a minority of the 
progenitor cells were of donor origin. This mixed chimerism might indicate, 
that the PHSC are not sufficiently enriched by isolation of ICH3+ cells. Alter-
natively, immunological factors might result in the disappearance of donor 
derived cells. The immunological mechanisms and the cytokinetics involved in 
mixed chimerism are poorly understood. Further investigations, including a 
more intensive conditioning regimen are required for a more convincing proof 
of the capacity of CD34 positive cells to sustain long term chimerism. Such a 
conditioning might eradicate the recipient derived stem cells more effectively 
and suppress the possibly involved immunological reaction. This development 
brings positive selection of stem cells as a generally applicable method to 
eliminate T-lymphocytes and/or tumour cells from BM grafts, within the reach 
of clinical application. 
Characterization and purification of HSCs is further of importance for 
investigations on the influence of hemopoietic growth factors on self replication 
and/or differentiation of HSCs, and necessary for studies on the genetic control 
of stem cell differentiation, which needs to be elucidated to make gene therapy in 
hemopoietic stem cells feasible. Finally, specific cell surface markers could be 
used for the development of an in vitro HSC assay. However, the relatively weak 
fluorescence signal of ICH3 labelled cells, stained with anti lgG 2a/FITC, 
partially overlaps the aspecific signal of the negative cells. This hampers a 
quantitative detection of rare .events. Furthermore, the CD34 antigen is not 
exclusively expressed on HSC. Combination of ICH3 with other markers, such as 
lectins14 or antibodies directed against other surface antigens might solve both 
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problems21. However, whether the appropriate additional markers for the 
development of a specific in vitro HSC assay will be developed remains 
questionable in view of numerous unsuccessful attempts to fmd stem cell specific 
markers. Also growth factor receptors will probably not add to a solution, since 
these are not exclusively expressed on HSC. 
8.2. Effect of cytotoxic agents on the hemopoietic system. 
Radiation induced cell kill can be described by several mathematical models. As 
discussed in CHAPTER IV, in the higher dose ranges, the dose survival curves 
of highly radiosensitive cells described by different radiobiological models 
approach the curve described by the single hit model. Although the hemopoietic 
cells are more heterogeneous in their responses to cytotoxic drugs than to 
irradiation, dose-effect curves of many cytotoxic drugs can be described by 
similar mathematical models22,23. This heterogeneity is especially important for 
phase specific cytotoxic agents such as ARA-C and hydroxyurea. The effect of a 
cytotoxic drug is influenced by its distribution over the various body com-
partments, by protein binding, metabolism, and by the clearance of the drug 
from the body24. After a certain time the drug will be effectively cleared from 
the body and hemopoietic regeneration may occur. This is essentially similar to 
regeneration following TBL Therefore, radiation induced pancytopenia can be 
used as a simple, general model to study the prevention and treatment of these 
types of pancytopenia. Reliable information on the radiosensitivity of HSC is the 
starting-point for such studies. 
The autologous regeneration assay was used to measure the radiation sensitivity 
of Rhesus monkey HSC. In these experiments, described in CHAPTER IV, the 
Do value of HSC appeared to be 1.33 Gy for 6 MV and 1,16 for 300 kV X-rays. 
The method used does not allow for a highly accurate estimate of the Do value, 
which is reflected in wide confidence limits. Inclusion of an estimate of the total 
number of BM cells results in a somewhat lower Do value, but this value is 
significantly higher than the value that was assumed hitherto (0.6 Gy for 300 kV 
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X-rays). The measurements of the radiation sensitivity of hemopoietic stem cells 
have implications for the treatment of victims of radiation accidents. BM 
transplantation following doses of TBI larger than 10 Gy is useless, since such 
high doses frequently result in death due to irreversible gastrointestinal damage. 
Endogenous regeneration following 9.8 Gy TBI (300 kV) has been observed on 
day 30. On the basis of these data it was calculated, that the stem cell equivalent 
surviving 9.8 Gy TBI is in general sufficient for a complete hemopoietic reconsti-
tution within 6 weeks. Consequently, the aim of BM transplantation in the 
treatment of victims of irradiation accidents is shortening of the pancytopenic 
phase rather than replacement of destroyed BM. 
8.3. In vivo manipulation of the hemopoietic system with hemopoietic growth 
factors (HGFs ). 
In vivo manipulations of the hemopoietic system with HGFs could result in a 
shortening of the pancytopenic period, induced by cytotoxic damage to the 
hemopoietic system. This principle has been investigated for Granulocyte 
Macrophage Colony Stimulating Factor (GM-CSF) in the experiments described 
in CHAPTER V, Vl and VII. Three mechanisms were postulated: Firstly, the 
stimulation of hemopoietic regeneration by treatment with HGFs following the 
cytotoxic treatment. Secondly, treatment with HGFs before the cytotoxic treat-
ment could increase the number of mature blood cells, resulting in a later onset 
of the pancytopenia. Finally, treatment with HGFs before the cytotoxic treatment 
could 'increase the number HSC, resulting in the survival of a larger number of 
HSC and, consequently, in an earlier regeneration. The studies performed 
demonstrate that the latter two mechanisms do not apply to GM-CSF. The 
increased numbers of peripheral blood cells, induced by the treatment with GM-
CSF prior to TBI, subsequently rapidly decrease, due to a short survival time of 
these mature cells. Also, pretreatment with GM-CSF does not result in an earlier 
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regeneration following TBI, indicating, that G M -CSF does not induce a signifi-
cant increase of HSC numbers. Under certain conditions, the first mechanism, 
stimulation of hemopoietic regeneration, appeared to result in a significant reduc-
tion of leukopenia. It was possible to define these conditions: Following high 
doses of TBI the number of HSC available for repopulation appeared to be a 
limiting factor for the effectiveness of treatment with GM-CSF. If only small 
numbers of HSC are available, treatment with GM-CSF is apparently not additive 
to the endogenous production of HGFs. Therefore a significant effect on leuko-
cyte counts was only observed if the HSC kill did not exceed 3 log. 
As expected, GM-CSF mainly influences the numbers of granulocytes, eosino-
phils and monocytes. 
Surprisingly, mitigation of the leukopenia by treatment with GM-CSF did not 
result in a decreased incidence of infectious complications. This finding urges 
additional studies concerning the influence of GM-CSF on the function of granu-
locytes in vivo. 
The quantitative and qualitative characterization of the effects of GM-CSF, as 
discussed above, established the therapeutic window of this HGF. A similar analy-
sis is currently in progress for other HGFs, as well as for synergistic effects of 
different HGFs on hemopoietic regeneration. 
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SUMMARY 
Peripheral blood cells have a limited life span. Therefore, in humans a daily 
production of approximately 1011 blood cells is required to replace the lost cells. 
This process, termed hemopoiesis, is maintained from a small population of 
pluripotential hemopoietic stem cells (PHSC). PHSCs are primitive, archetypal 
round cells, which have the capacity of both self-renewal and differentiation into 
specific lineages of committed hemopoietic progenitor cells (HPC), which 
eventually differentiate into mature blood cells. 
Characterization and positive selection of HSC, is essential for the development 
of a generally applicable method to remove unwanted cells, such as T-
lymphocytes or malignant cells, from bone marrow grafts. Furthermore, charac-
terization of HSC could result in the development of a technique for HSC enumer-
ation. Among the cell surface markers available to isolate immature human 
hemopoietic cells, the CD34 antigen, identified by several monoclonal antibodies 
(MCAs) is of outstanding interest, since it is mainly expressed on immature 
hemopoietic cells, including hemopoietic progenitor cells such as CPU-mix, CFU-
GM, and BFU-E. Moreover, it is present only on 1-4% of human bone marrow 
(BM) cells and does not co-express with most differentiation antigens. ICH3, one 
of the anti CD34 MCAs was used for positive selection of HPCs and HSCs. These 
experiments have been described in CHAPTER III. Isolation of ICH3 positive 
BM cells resulted in a 80 - 155 fold enrichment of colony forming units (CPU-
C). A recently developed autologous repopulation assay for Rhesus monkey HSC 
was used to measure the repopulating capacity of autologous CD34 positive cells. 
The enrichment of repopulating cells appeared to be in the same order of 
magnitude as the enrichment of CPU-C. The repopulating capacity of CD34 
positive cells was confirmed in allogeneic transplantations, and mixed chimerism 
was found. Further investigations are required to confirm the capacity of CD34+ 
cells to grow out to a complete hemopoietic system. 
BM transplantation, therapeutic or accidental TBI, and chemotherapy are 
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associated with a lack of peripheral blood cells, termed pancytopenia. The 
duration of this pancytopenia is dependent on the number of HSC. Radiation in-
duced pancytopenia can be used as a simple, general model to study the preven-
tion and treatment of this type of pancytopenia. Therefore, reliable information 
on the radiosensitivity of HSC is essential. 
The autologous regeneration assay was used to measure the radiation sensitivity 
of Rhesus monkey HSC. In these experiments, described in CHAPTER IV, the 
Do value of HSC ,appeared to be 1.33 Gy for 6 MV and 1,16 for 300 kV X-rays. 
This is higher than the value that was assumed hitherto (0.6 Gy for 300 kV X-
rays). The measurements of the radiation sensitivity of hemopoietic stem cells 
have implications for the treatment of victims of radiation accidents. BM 
transplantation following doses of TBI larger than 10 Gy is useless, since such 
high doses frequently result in death due to irreversible gastrointestinal damage. 
Endogenous regeneration following 9.8 Gy TBI (300 kV X-rays) has been ob-
served on day 30. On the basis of these data it was calculated, that the number of 
stem cells surviving 9.8 Gy TBI is in general sufficient for a complete hemo-
poietic reconstitution within 6 weeks. Consequently, the aim of BM trans-
plantation in the treatment of victims of irradiation accidents can only be to 
shorten the pancytopenic phase rather than replacement of destroyed BM. 
' Hemopoiesis is tightly regulated by a number of glycoproteins, termed hem~-
poietic growth factors (HGFs). Recombinant DNA techniques allow for the 
production and purification of these factors on a large scale, enabling in vivo 
manipulation of the hemopoietic system by administration of these compounds. 
Shortening of irradiation induced pancytopenia can be achieved by BM trans-
plantation, and, in principle, also by in vivo manipulations of the hemopoietic 
system with HGFs. The influence of Granulocyte Macrophage Colony Stimulat-
ing Factor (GM-CSF), one of the HGFs, on the duration of the pancytopenic 
phase following different dpses of TBI, electively followed by BM 
transplantation have been described in CHAPTER V to VII. 
In CHAPTER V, a number of pilot experiments on the route of administration 
of GM-CSF have been described. Although intravenous administration of GM-
CSF resulted in higher leukocyte counts than subcutaneous administration, the 
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latter, also highly effective route of administration was chosen for the subsequent 
experiments. 
In CHAPTER VI, the influence of graded doses of GM-CSF on hemopoietic 
regeneration after autologous BM transplantation has been described. Treatment 
with GM-CSF from day 1 to 30 after autologous BM transplantation resulted in a 
marked leukocytosis, which reached a maximum in the fourth week of 
administration. Increasing the dose of GM-CSF up to 30 J.Lg/kg/day resulted in an 
increase of the observed leukocyte counts. Further dose escalation up to 100 
J.Lg/kg/day did not result in a further increase in leukocyte counts. In spite of the 
induction of leukocytosis, the shortening of leukopenic phase was limited to a 
few days to at maximum a week. The reduction of leukopenia after 
transplantation of larger numbers of (unfractionated) BM cells has been reported 
to be more pronounced. Therefore it was thought, that in the early exponential 
growth phase after BM transplantation, the number of GM-CSF sensitive cells 
was a limiting factor for the effectiveness of treatment with GM-CSF. 
This hypothesis was tested in CHAPTER VII. In this CHAPTER the 
experiments on the effects of GM-CSF after graded doses of TBI were 
described. Treatment with GM-CSF from day 1 to 14 after 5 Gy TBI almost 
completely prevented the radiation induced leukopenia. Increasing the dose of 
TBI resulted in a significant decrease in the effect of the G M-CSF 
administration. This observation was linked to the number of stem cells that 
survive the TBI. 
In spite of the observed reduction of leukopenia, the frequency of sepsis in the 
GM-CSF treated group, was not lower than in the placebo treated control group. 
There was even a tendency of a higher frequency of infections in the GM -CSF 
treated group. This phenomenon requires further investigation, since the 
prevention of infections is the ultimate aim of the mitigation of leukopenia by 
treatment with HGFs. 
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SAMENV ATTING 
Bloedcellen hebben een zeer beperkte levensduur. Daarom is het noodzakelijk 
dagelijks een groot aantal van deze cellen te produceren. Voor een volwassen 
mens komt dit neer op de aanmaak van ongeveer 1011 cellen per dag. Dit proces, 
hemopoiese genaamd, vindt plaats in het beenmerg (BM). Hierbij speelt de 
pluripotente hemopoietische stamcel (PHSC) een belangrijke roL Kenmerkende 
eigenschappen van de PHSC zijn "self-renewal", d.w.z. het vermogen zich te 
delen in twee dochtercellen die beide aile eigenschappen van de stamcel 
behouden, en het vermogen tot differentieren in de richting van een van de 
verschillende soorten bloedcellen. 
Onderzoek naar de eigenschappen van HSC en de zuivering van HSC zijn van 
be1ang voor de ontwikke1ing van een a1gemeen toepasbare methode voor het 
verwijderen van ongewenste cellen, zoa1s T-lymphocyten of kwaadaardige 
cellen, uit een BM transp1antaat. Verder zou meer informatie over stamcellen 
kunnen leiden tot de ontwikkeling van een techniek om stamcellen quantitatief te 
kunnen meten. 
Van de opperv lakte antigenen die hiervoor gebruikt kunnen worden is het 
CD34 antigen erg interessant, omdat het voorkomt op hemopoietische 
voorlopercellen, zoals de CPU-mix, de CPU-GM, en de BFU-E. Bovendien komt 
dit antigen s1echts op 1 - 4 % van alle BM cellen voor en is er geen co-expressie 
met de meeste differentiatie antigenen. Tegen dit antigen zijn verscheidene 
monoclona1e antilichamen (MCAs) geproduceerd. Een van de monoclonale anti1i-
chamen, gericht tegen CD34, het ICH3, werd gebruikt voor positieve se1ectie van 
hemopoietische progenitor cellen (HPCs) en HSCs. Deze experimenten zijn 
beschreven in HOOFDSTUK IlL Isolatie van ICH3 positieve BM cellen leidde tot 
een 80 tot 155 voudige verrijking van CPU-C. Een recent ontwikke1de, auto1oge 
repopulatie test voor Rhesus apen HSC werd gebruikt om te testen of deze CD34 
positieve cellen het vermogen hebben een bestraalde ontvanger te repopuleren. 
De verrijking van repopu1erende cellen b1eek van dezelfde orde van grootte te 
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zijn als de CFU-C verrijking. Het repopulerend verrnogen van CD34 positieve 
cellen werd bevestigd in allogene transplantaties, waarna gemengd chimerisme 
ontstond. Nader onderzoek is nodig om te bevestigen, dat CD34+ cellen het 
verrnogen hebben uit te groeien tot een compleet hemopoietisch systeem. 
Therapeutische of accidentele totale lichaamsbestraling (TBI) en 
chemotherapie, al dan niet gevolgd door BM transplantatie, veroorzaken een 
tekort aan periphere bloedcellen, pancytopenie genaamd. De duur van deze 
pancytopenie is afhankelijk van het aantal HSC. Door straling geinduceerde 
pancytopenie kan gebruikt worden als een algemeen model om bovengenoemde 
pancytopenieen te bestuderen. Hiervoor is betrouwbare inforrnatie over de 
stralingsgevoeligheid van HSC van belang. De autologe regeneratietest voor HSC 
werd gebruikt om de stralingsgevoeligheid van HSC te meten. In deze 
experimenten, beschreven in HOOFDSTUK IV, ble~k de Do waarde van HSC 
1.33 Gy te zijn voor 6 MV en 1.16 voor 300 kV rontgenstralen. Dit is hoger dan 
tot dusver werd aangenomen (0.6 Gy). Dit heeft consequenties voor de 
behandeling van slachtoffers van stralingsongevallen. BM transplantatie na TBI 
D.osis van meer dan 10 Gy is waarschijnlijk zinloos, omdat zulke hoge doses 
dikwijls dodelijk zijn door onherstelbare schade aan het maagdarrnkanaal. 
Endogene regeneratie na 9.8 Gy TBI (300 kV rontgenstraling) is waargenomen 
op dag 30. Op grond van deze gegevens werd uitgerekend, dat het aantal 
stamcellen dat een dosis van 9.8 Gy TBI overleeft in het algemeen voldoende is 
voor een herstel van de hemopoiese binnen 6 weken. Daarom is het doel van 
beenmergtransplantatie bij de behandeling van slachtoffers van stralingsonge-
vallen vooral verkorting van de duur van de pancytopenie in plaats van het 
vervangen van een vernietigd BM. 
Hemopoiese wordt gereguleerd door een aantal glycoprotelnes, hemopoietische 
groeifactoren (HGFs) genaamd. Recombinant DNA technieken maken het 
mogelijk deze factoren in zuivere vorrn te produceren op een schaal die groot 
genoeg is om er in vivo de hemopoiese mee te stimuleren. De door straling 
gelnduceerde pancytopenie kan bekort worden door BM transplantatie, en, in 
beginsel ook door behandeling met HGFs. De invloed van Granulocyte 
Macrophage colony stimulating factor, GM-CSF, een van die groeifactoren, op 
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de pancytopenie na verschillende doses TBI en na BM transplantatie wordt 
besproken in HOOFDSTUK V t/m VII. In HOOFDSTUK V worden een aantal 
pilot experimenten beschreven betreffende de wijze van toediening van GM-CSF. 
Hoewel continue intraveneuze toediening van GM-CSF tot hogere leukocyten 
aantallen in het perifere bloed leidde dan subcutane toediening, werd voor het 
laatste toedieningsschema gekozen voor de volgende experimenten. Immers, 
subcutane toediening 1 dd is ook zeer effectief en bovendien praktischer. 
In HOOFDSTUK VI is de invloed van verschillende doses GM-CSF op de 
hemopoietische regeneratie na BM transplantatie beschreven. Behandeling met 
GM-CSF van dag 1 tot 30 na autologe BM transplantatie leidde tot een forse 
leukocytose die een maximum bereikte in de vierde week van de behandeling. 
Hogere doses, tot 30 J...Lg/kg/dag leidden tot hogere aantallen leukocyten. Nog 
verdere dosisverhoging, tot 100 j...lg/kg/dag leidde niet tot een toename van het 
effect. Ondanks het optreden van die leukocytose, bleek de verkorting van de 
leukopenie slechts enkele dagen tot maximaal een week te zijn. Anderen hadden 
een sterkere verkorting van de leukopenie na autologe BM transplantatie 
beschreven; in die studies waren echter grotere transplantaten gebruikt. Daarom 
werd gepostuleerd, dat tijdens de exponentiele groei kort na een BM trans-
plantatie het aantal GM-CSF gevoelige cellen bepalend is voor het GM-CSF 
effect. 
Deze hypothese werd getoetst in HOOFDSTUK VII. In dit hoofdstuk zijn de 
experimenten beschreven betreffende de effecten van GM-CSF na verschillende 
stralingsdoses. Behandeling met GM-CSF van dag 1 tot 14 na 5 Gy TBI bleek de 
leukopenie vrijwel geheel te kunnen voorkomen. Na hogere stralingsdoses nam 
het GM-CSF effect sterk in betekenis af. Dit werd in verband gebracht met het 
aantal stamcellen, dat de bestraling overleeft. 
Ondanks het waargenomen gunstige effect op de aantallen leukocyten, was er, 
vergeleken met de placebo behandelde controle groep, in de met GM-CSF 
behandelde groep geen lagere frequentie van infectieuze complicaties. Er was 
zelfs. een tendens tot een hogere infectiefrequentie. Dit fenomeen dient nader 
onderzocht te worden, aangezien juist het voorkomen van infecties het uiteinde-
lijke doel is van de verkorting van de leukopenie door behandeling met HGFs. 
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